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Abstract
Abstract
In this study, I applied a range of techniques in an attempt to enhance our 
knowledge of the role that CD38 plays in the pathogenesis of CLL. Investigation 
of a number of techniques to genetically modify the CLL cells led to the 
development of a lentiviral transduction system that was able to induce a marked 
increase in the ectopic expression of CD38 on the CLL cell surface. Subsequent 
molecular analysis identified changes in gene expression which may enhance 
disease progression. The pro-angiogenic growth factor VEGF and the DNA 
mismatch repair protein Msh6 were both identified as candidates for further 
investigation. This work also highlighted the challenges and limitations involved 
in using a lentiviral knock-in system and led to the design of experiments 
utilising CD31 -expressing co-cultures to stimulate CD38 on the CLL cell 
surface. The CD31-expressing co-culture system induced survival within the 
CLL sample compared to cells incubated with the control, non-transfected co­
culture. Increased proliferation was illustrated through the incorporation of 
BrdU and induction of the cell cycle protein Ki-67. Multi-colour flow cytometry 
was employed to observe the expression of surface and intracellular molecules 
which may be involved in CLL cell activation and signalling. Changes in the 
phenotype of the CLL cells were consistently observed which support the notion 
that these cells can be activated in vitro and can thereby enhance B-cell receptor 
signalling. Specifically, CD 19, CD38 and the aberrantly expressed tyrosine 
kinase Zap-70 were all induced following incubation with CD31-expressing co­
culture. This is the first time that a lentiviral transduction system has been 
developed which efficiently expresses CD38 in a CLL cell population with little 
cell death. The work carried out in this project also highlights the importance of 
using co-culture to stimulate CD38 on the surface of the CLL cells in vitro. The 
novel findings within this project have given insight into some of the 
mechanisms of CD38 signalling, provided direction for future work and 
highlight the potential of CD38 as a therapeutic target in CLL.
XXI
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Chapter I Introduction
Chapter 1.0 Introduction
1.1 A brief history
With the development of novel cell staining techniques in the late 19th 
Century, Paul Ehrlich described the morphological differences between myeloid 
and lymphoid leucocytes which allowed a much stricter definition of leukaemia 
(Ehrlich, 1887). His work was in agreement with the interpretations of Neumann 
who had previously described lymphocytic leukaemia as a primary disease of the 
haematopoietic system (Seufert and Seufert, 1982). By the mid 20th century 
chemotherapy and radiotherapy had been in use for many decades as treatments 
for leukaemia and the results of long-term studies in patients with chronic 
lymphocytic leukaemia (CLL) were yielding some important findings. A report 
by Boggs et al. in 1966 described how intensive chemotherapy regimens were 
decreasing the mortality rates, but conversely a cohort of patients who remained 
untreated had better long-term survival (Boggs et al., 1966). At the same time, 
differences in the rate of proliferation of the leukaemic cells of individual 
patients were described, suggesting that the disease was able to manifest in two 
different forms: an indolent accumulation of lymphocytes or a more aggressive 
proliferation of cells (Galton, 1966). By the 1970s a large amount of clinical and 
laboratory data had accumulated for patients with CLL undergoing various 
treatment protocols (Hansen, 1973, Sawitsky et al., 1977). From this evidence 
came two simple, but very informative, classification systems for 
lymphoproliferative disease involving the clinical assessment of lymph nodes 
and spleen. These systems became the gold standard over the next decade and 
remain in use today (Binet et al., 1981, Binet et al., 1977, Rai et al., 1975). 
Revisions to the classification systems in the late 1980s along with new 
observations in the laboratory and clinic made the diagnosis, prognosis and the 
monitoring of patients with CLL much more comprehensive (Gale, 1987, Molica 
and Alberti, 1987, Montserrat et al., 1986).
The following decade saw great advances in the characterisation of cells 
through the staining of surface molecules and in 1994 Matutes et al. devised a 
scoring system to classify CLL into typical or atypical disease using a panel of 
antibodies (Matutes et al., 1994). This classification is still used in conjunction
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with the clinical staging systems defined by Rai and Binet and is the primary 
method of accurately diagnosing patients with CLL.
With the development of gene analysis techniques including fluorescence in 
situ hybridisation (FISH) and polymerase chain reaction (PCR) a patient’s 
prognosis following diagnosis can be more clearly defined and they can be 
monitored accordingly. These recent methods, along with novel markers of 
disease with prognostic significance, will be described in greater detail in the 
following sections.
1.2 Chronic lymphocytic leukaemia (CLL)
CLL remains the most common adult leukaemia in the Western world 
presenting at a median age of 65 years and accounting for around 30% of all 
leukaemias (Foon et al., 1990). Occurring predominantly in males (2:1 ratio) 
(Finch and Linet, 1992) CLL is characterised by the accumulation of immune- 
incompetent CD5 positive, mature-looking B-lymphocytes in the bone marrow, 
peripheral blood and lymphoid system (Montserrat and Rozman, 1995). The 
majority of the cells derived from the peripheral blood are arrested in the G0/G1 
phase of the cell cycle. However there is considerable evidence that these cells 
have undergone substantial cell division, most likely within in a lymphoid tissue 
proliferative compartment, to generate an expanding clone (Messmer et al., 
2005, Deaglio and Malavasi, 2009, Calissano et al., 2009).
The latest world health organization (WHO) classification scheme considers 
CLL as a mature B-cell neoplasm and does not distinguish it from small 
lymphocytic lymphoma (SLL) a disease that is comprised of the same cell 
phenotype, but which is usually confined to the lymph nodes (Jaffe, 2001). 
Accumulation of these mature lymphocytes eventually leads to bone marrow 
infiltration resulting in an impaired immune response (presumably due to a lack 
of normal B-cells), anaemia and thrombocytopenia. Around sixty percent of 
patients present with hypogammaglobulinaemia which becomes more prominent 
throughout the disease due to the inability of the CLL cells to express functional 
paraprotein (Dighiero, 1988).
Other clinical features including autoimmune manifestations and pathogenic 
autoantibodies have been detected in up to 30% of patients (Caligaris-Cappio,
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1996). They are usually polyclonal and are directed against haematopoietic 
antigens expressed on the surface of red blood cells and platelets. This may lead 
to severe autoimmune haemolytic anaemia and thrombocytopenia (Hamblin et 
al., 1986, Kipps and Carson, 1993).
1.2.1 Aetiology and epidemiology
The aetiology of CLL is unknown. Various studies have linked the 
development of CLL with exposure to occupational chemicals including 
benzene, radio-isotopes and pesticides (Schnatter et al., 2005, Pukkala et al., 
2009), though evidence to the contrary has also been presented (Linet, 2006). 
There is an established familial link in the development of CLL and individuals 
with first degree relatives suffering the disease possess a 2 to 7 fold increased 
chance of being diagnosed with CLL (Cuttner, 1992). This was confirmed by 
subsequent investigations using genome wide association analysis that identified 
a number of genetic loci that gave an accumulated risk of developing CLL (Di 
Bernardo et al., 2008, Crowther-Swanepoel et al., 2010). Other investigations 
have observed similar findings (Blattner et al., 1979, Neuland et al., 1983, Yuille 
et al., 2000, Capalbo et al., 2000), although studies involving twins have 
provided contrasting evidence as to whether there is an inherited genetic factor 
responsible for the development of CLL (Brok-Simoni et al., 1987, Chen et al., 
2002, Hakim et al., 1995). CLL is rarely seen in people of Asian origin and is 
not increased in multiple generations of Asian migrants who have settled in areas 
of high CLL prevalence (Pan et al., 2002). This again suggests that genetic 
factors are involved in the development of CLL.
1.2.2 Clinical presentation of CLL
Patients may present with asymptomatic disease and their elevated 
lymphocyte count identified through a routine blood test. This is rare though and 
most patients are investigated due to a persistent infection, general lethargy or 
malaise (due to an underlying anaemia) or increased tendency of bruising (due to 
a reduced platelet count). Upon examination the lymph nodes are often enlarged, 
though non-tender. Less visible is an enlarged spleen or liver occurring in around 
35% and 20% of patients respectively (Rai, 2003). Although CLL cells are able 
to accumulate in various lymphoid tissues, or organs, infiltration to the extent of
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enlargement of other sites, such as the tonsil or Waldeyer’s ring (at the rear of 
the pharynx), or as lesions in the skin are rare (Rai, 2003).
1.2.3 Clinical staging
A wealth of data collected throughout the mid twentieth century enabled Rai 
et al in 1975 and Binet et a l two years later to propose the criteria for a clinical 
staging strategy in CLL. Both classification systems are based on the clinical 
features observed upon examination and are still in use today as an accurate 
means of determining the prognosis for individual patients. Table 1.1 illustrates 
the Rai system. The individual stages range from 0 to IV and describe the 
symptoms according to the presence of lymphocytosis, lymphadenopathy, 
hepato/splenomegaly, anaemia and thrombocytopenia. Occurrence of the latter 
two anomalies is associated with advanced disease and an unfavourable 
outcome.
Low
0 Lymphocytosis only
Intermediate
I Lymphocytosis + lymphadenopathy
II Lymphocytosis + splenomegaly with/without lymphadenopathy or hepatomegaly
High
III Lymphocy tosis — anaemia, with or without organomegaly
IV Lymphocytosis + anaemia + thrombocytopenia, with or w ithout organomegaly
Table 1.1 Rai staging system (Adapted from Rai et al, 1975)
The Binet classification system is slightly simpler and is based on the 
presence or absence of anaemia or thrombocytopenia with lymphadenopathy at 
single or multiple sites (Table 1.2). Both systems are applicable to the CLL 
patient and determine the degree of B-cell infiltration into the lymphoid system, 
surrounding organs, and indirectly, the bone marrow.
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Stage A Patients have fewer than three areas of enlarged 
lymphoid tissue. Enlarged lymph nodes of the neck, 
underarms, and groin, as well as the spleen, are each 
considered "one group," whether unilateral (one-sided) 
or bilateral (on both sides).
Stage B Patients have more than three areas of enlarged 
lymphoid tissue
Stage C Patients have anaemia plus thrombocytopenia (platelets 
<100- 103/dL).
Table 1.2 Binet staging system (Adapted from Binet et al, 1981)
1.2.4 Laboratory diagnosis
In 1996 the National Cancer Institute set its criteria for the laboratory 
diagnosis of CLL and it was agreed that a lymphocyte count of 5xl09/litre was 
appropriate for the primary diagnosis of CLL (Cheson et al., 1996). Twelve 
years later the criteria were changed by the International Workshop for CLL 
(IWCLL) to differentiate sub CLL diseases, namely monoclonal B-cell 
lymphocytosis (MBL) and SLL, from the more classical form of the disease 
(Hallek et al., 2008). The amendment stipulated that a total B-cell count of 
5x109/1 should to be used to diagnose CLL. This amendment was met with some 
controversy (Hanson et al., 2009) and a consensus for the definitive diagnosis of 
this disease with regards to lymphocyte count still eludes the CLL community, 
as it has over decades of dispute (Cheson et al., 1996, Matutes and Polliack, 
2000). Fortunately with the use of immunophenotyping and cytogenetic analysis 
very few cases of CLL are misdiagnosed or incorrectly treated.
1.2.4.1 Morphology
Following the intense study of blood cell morphology an agreed CLL 
classification system was agreed upon in 1989 by a French, American and 
British (FAB) board to standardise the diagnosis of CLL using cell morphology 
(Bennett et al., 1989). Two main types of CLL may be primarily determined
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from blood film analysis. The first is typical CLL where the lymphocytes present 
are small (around 7.3pm in diameter (Kuse et al., 1985)) with a single lobed 
nucleus which occupies the majority of the cell volume leaving a thin layer of 
cytoplasm (Matutes and Polliack, 2000) (Figure 1.1). The nuclei encapsulate 
dark staining chromatin revealing very little nuclear detail (Hamblin, 2009). A 
few larger B-cells may be present which are twice the size of a typical CLL cell 
and portray a larger cytoplasmic region and a visible nucleolus. These cells are 
designated pro-lymphocytes (PL) and may be present in typical CLL when 
accounting for less than 10% of the total lymphocyte count (Frater et al., 2001).
CLL cell
Smudge cell
Figure 1.1 Blood film illustrating typical CLL cells and smudge cells
(Adapted from Brandon Guthery, M.D., and Nasir Bakshi, M.D. Department of 
Pathology, University of Oklahoma Health Sciences Center, Oklahoma City)
The second type of CLL, defined morphologically and by cell surface 
markers, is atypical CLL. It accounts for around 15% of all cases and can be 
divided into two sub-types (Criel et al., 1999, Matutes and Polliack, 2000); the 
first exhibits 10-55% prolymphocytes and is designated CLL/PL. The second 
sub type is known as “mixed cell-type” atypical CLL and plasmacytoid or 
cleaved B-cells are present. Both forms of atypical CLL are usually associated 
with poor risk cytogenetics and immunophenotype and therefore represent a 
more aggressive form of the disease.
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A regular feature of the CLL blood film are smudge cells which are CLL 
cells which have been smeared due to the increased fragility of the cell 
membrane. These smudge cells are an artefact of the slide preparation but are 
almost diagnostic for CLL (Simmonds et al., 1981) (Figure 1.1). In 2009 a report 
by Nowakowski et al. showed that the number of smudge cells observed on the 
blood film could predict survival in CLL patients (Nowakowski et al., 2009). 
Erythrocytes and platelets usually appear normal in typical CLL although in rare 
cases of hypergammaglobulinaemia the red cells stack in rouleaux formations 
(Hoffbrand AV, 2001).
1.2.4.2 Bone marrow and lymph node involvement
It has been reported that bone marrow examination upon presentation is an 
important determinant of patient outcome (Rozman et al., 1984), though 
evidence to the contrary exists (Mauro et al., 1994, Geisler et al., 1996). The 
presence of more than 30% lymphocytes in the bone marrow is indicative of 
CLL (Cheson et al., 1996). Four patterns of bone marrow histology have been 
described in CLL that are largely concerned with the degree of bone marrow 
infiltration. They are defined as interstitial, nodular, mixed (nodular plus 
interstitial) and diffuse. The most commonly observed is the mixed type with the 
diffuse pattern determining the worst prognosis (Rozman et al., 1984).
Proliferation centres have been described in the bone marrow and lymph 
nodes of CLL patients, which are constructed from large prolymphocytoid and 
paraimmunoblast cells surrounded by T-cells and small CLL lymphocytes 
(Matutes and Polliack, 2000, Wang et al., 2008). Identification of these 
structures during histological analysis is usually a determinant of progressive 
disease (Wang et al., 2008, Soma et al., 2006). However, lymph node biopsies 
are not routinely acquired from patients at diagnosis and are only obtained 
throughout the course of the disease if the nodes are enlarged due to suspected 
transformation.
1.2.4.3 Lymphocyte doubling time
The use of the lymphocyte doubling time (LDT) as a prognostic indicator 
was first described in the mid 1980s. Although the LDT correlates with other 
markers of disease, its use as a sole predictor of outcome in CLL patients was
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rapidly identified as an accurate and simple method of assessing disease 
progression (Montserrat et al., 1986). In 1986 Montserrat et al. proposed that an 
LDT greater than 12 months identified a patient cohort with a good prognosis, 
whereas an LDT of less than or equal to 12 months was associated with poorer 
survival (Montserrat et al., 1986, Vinolas et al., 1987). In addition they found 
that a short LDT predicted rapid progression for patients in the early stages of 
disease.
1.2.5 Immunophenotyping
To confirm the diagnosis of CLL, the presence of specific markers on the 
cell surface can be detected using flow cytometry. Dillman et al were one of the 
first groups to illustrate that monoclonal antibodies can be used to identify 
surface markers on lymphocytes and contribute to the identification of subsets of 
CLL with differing prognostic outcome (Dillman et al., 1983). Since then a 
plethora of cell-specific immunological markers have been identified on the 
surface of the aberrant cells to further define the type of leukaemia present and 
predict the course of the disease.
The Matutes score defines classical CLL as a CD 19+, CD20+, CD23+ and 
CD5+ monoclonal B-cell population, in the absence of other pan-T-cell markers 
(Matutes et al., 1994). The B-cells express either kappa (k) or lambda (2) light 
chains and surface immunoglobulin (slg) is of low density and is predominantly 
immunoglobulin-M (IgM) with or without IgD. Depending on the number of 
these cell markers expressed on a population of CLL cells (and morphological 
differences) the disease may be diagnosed as typical or atypical CLL. The 
absence of other specific markers is used to diagnose classical CLL from a 
multitude of other lymphoid malignancies. These include CD 10, CD 11c, cyclin 
D1 and CD 103 (Dillman, 2008). Many of the cell surface antigens used to 
diagnose CLL are markers of B-cell maturity (e.g. FMC7 and TdT). The stage at 
which the B-cell transforms may be crucial to the severity of the disease 
underlining the importance in identifying such molecules. CD79b and CD22 are 
either weakly expressed or absent from the B-cell surface in CLL. Both 
molecules are involved in cell signalling (CD79b is usually abundant as a 
component of the activated B-cell receptor) and their absence may account, in
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some part, for the anergic nature of the CLL cell (Caligaris-Cappio et al., 1993, 
Payelle-Brogard et al., 2006).
The identification of numerous antigens specific for the individual B-cell 
disorders is important in the accurate diagnosis of the disease and provides 
prognostic value beyond the realms of cell morphology alone. A summary of 
surface and intracellular markers, used to identify the various B-lineage 
malignancies, are shown in Table 1.3.
Marker Follicular CLL Mantle MZL/MALT PLL’ DLBClI I  HCL BL/BLL LPL
Sig + dim ♦ ♦/+ + ♦ + +
Cig - -/♦ -1* - - - +
CD5 - ♦ + -/- -/+ - - - -
CD10 + - V- - -1+ - + -
CD20 + dim ♦/+ + t + t +
CD23 ./+ ♦ +/- - • - ■
CD43 • t  + •1* - -/+ + - H-
CD103 - - ♦/- - NA + NA •
Cyclin D1 - - - - -/+ - ■
+, >90% positive; +/-, >50% positive; -/+, <50% positive; <10% positive; CLL = chronic 
lymphocytic leukaemia; MZL/MALT = splenic marginal zone/mucosa-associated lymphoid 
tissue; PLL = prolymphocytic leukaemia; DLBCL = diffuse large B-cell lymphoma; HCL =  
hairy cell leukaemia; BL/BLL = Burkitt lymphoma/Burkitt-like lymphoma; LPL =  
lymphoplasmacytoid lymphoma; SIg = surface immunoglobulin; C lg = cytoplasmic 
immunoglobulin.* A T-cell variant is present in approximately 20 to 30% o f  PLL cases. NA = 
Not applicable for diagnosis o f  this disease.
Table 1.3 Surface and intracellular markers of B-lineage malignancies
(Adapted from Finak et al, 2009)
1.2.6 Cytogenetics
The analysis of chromosomes, using metaphase banding techniques and the 
development of interphase FISH, have allowed the identification of genetic 
aberrations with diagnostic and prognostic significance in CLL. Clonal 
cytogenetic aberrations can be identified in 50% of CLL cases using 
chromosome banding and an additional 30% more subtle rearrangements and
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mutations can be identified using interphase FISH (Mossafa H, 1997, Reedy,
2005).
Sub-clones may be found in some patients, which exhibit complex 
cytogenetic karyotypes. The most common aberrations identified upon 
presentation, or as the disease develops, are 13q deletion, trisomy 12, 17p 
deletion, and l lq  deletion. Many of the biological mechanisms altered by such 
genetic mutations are well described and have provided rationale for the 
observed disease progression and insight into the generation of tailored 
treatments for each sub-set of disease. There have been many studies carried out 
correlating these cytogenetic abnormalities with the clinical outcome of patients 
(Garcia-Marco et al., 1997, Mayr et al., 2006).
1.2.6.1 17p deletion
Monoallelic deletion of various sized portions of the short arm of 
chromosome 17 are observed in 7-8% of CLL cases and are associated with a 
poor prognosis (Amiel et al., 1997). The inferior outcome of CLL patients whose 
cells harbour the 17pl 3 deletion is thought to be due to the loss of genetic 
material encoding the p53 gene. The p53 protein plays a major role in cell 
development and is responsible for regulating progression through the cell cycle 
during mitosis. In response to an array of insults, including DNA damage, 
functional p53 is able to arrest the cell cycle in the Gl/S phase and allow the 
repair of genetic material before cell division. If the damage is irreparable then 
p53 promptly induces apoptotic signals resulting in deletion of the cell (Jacks 
and Weinberg, 1996). Many of the chemotherapeutic agents used to treat CLL do 
so by inducing DNA damage thereby promoting apoptotic cell death. Clones 
accommodating the p53 deletion are particularly resistant to these agents and 
remission is short-lived following the treatment of such patients (Wattel et al.,
1994). Novel therapeutic regimens include combination chemotherapy, high 
dose steroids and immunotherapy using monoclonal antibodies such as 
Alemtuzumab (anti-CD52) (Zenz et al., 2009). Initial studies have shown that 
these drugs improve the outcome in this poor prognostic group of patients 
(Lozanski et al., 2004). Additionally mutations in the p53 gene have been 
described in CLL (Gaidano et a l , 1991). Such mutations may occur in the
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absence of p53 deletion and are also associated with a poor outcome in CLL 
(Zenz et al., 2009).
1.2.6.2 13ql4.3 deletion
Deletion of a region within 13ql4.3 is the most common genomic aberration 
in CLL and occurs in more than 50% of patients (Stilgenbauer et al., 1998). Two 
functional genes present within this region are the deleted in lymphocytic 
leukaemia genes 1 and 2 (DLEU1 and DLEU2). Recent evidence suggests that 
these genes transcribe proteins which are involved in the regulation of tumour 
suppressor micro-RNA molecules miR-15a and miR-16-1 (Mertens et al., 2009). 
Deregulation of these recently described micro-RNA molecules in CLL results in 
an indolent disease with a favourable outcome. In a recent report the 
DLEU2/miR-15a/16-l gene cluster was shown to control B-cell proliferation and 
its deletion led to CLL like disease in mice (Klein et al., 2010).
1.2.6.3 Trisomy 12
In 15-25% of CLL cases, sub-clones exist which harbour three copies of 
chromosome 12. This genetic aberration is associated with an atypical CLL cell 
phenotype with increased surface immunoglobulin and FMC7 (Matutes et al., 
1996). Although associated with other poor prognostic indicators such as CD38 
and unmutated immunoglobulin genes (Athanasiadou et al., 2006), a direct 
correlation between trisomy 12 and a poor prognosis has not been established. 
The presence of trisomy 12 was shown to correlate with a reduced survival time 
only in the presence of a second chromosomal aberration when compared with 
patients with 13q abnormalities or a normal karyotype (Juliusson et al., 1990).
1.2.6.4 Ilq22-q23 deletion
Deletion of a segment of the long arm of chromosome 11 is seen in 
approximately 14% of patients with CLL (Bullrich et al., 1999). The portion of 
the chromosome affected encodes the ataxia telangiectasia mutated (ATM) 
protein which is a key player in the recruitment of tumour suppressor proteins to 
sites of DNA damage and cell cycle regulation. Patients with the deleted ATM 
gene are therefore often resistant to conventional chemotherapy which induces 
DNA damage. llq22-23 deletion in CLL is associated with increased
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lymphadenopathy and poor survival, particularly in younger patients (Dohner et 
al., 1997). Interesingly the loss of this potent mechanism of apoptosis induction 
has been exploited in the treatment of CLL. Inhibition of Poly (ADP-ribose) 
polymerase (PARP) imposes the requirement for DNA double strand break 
repair. ATM is essential for this function and in its absence the cell undergoes 
mitotic catastrophe (Kurz and Lees-Miller, 2004). This method of synthetic 
lethality has been found to be very successful in killing CLL cells in vitro and in 
vivo and PARP inhibitors such as Olaparib are being assessed for use in CLL 
patients with the 1 lq22-23 deletion (Weston et al., 2010).
1.2.6.5 Additional cytogenetic abnormalities
Various other genetic aberrations have been observed in CLL that are known 
to have prognostic significance. Translocations involving the immunoglobulin 
heavy chain locus on chromosome 14 may be detected although such anomalies 
are much more common in the solid tumours (t(14;18) in follicular lymphoma 
and t( 11; 14) in mantle cell lymphoma). Other genetic abnormalities include 
deletion of chromosome arm 6q, acquisition of a portion of chromosome 8 
(8q24), trisomy 3 and trisomy 18.
1.2.7 CLL transformation (Richter’s Syndrome)
First described by Maurice Richter in 1928, Richter’s syndrome is the 
transformation of CLL to an aggressive diffuse large B-cell lymphoma 
(DLBCL). More recently Richter’s transformation has been found to represent 
two biologically different conditions. The first is the transformation of CLL into 
a DLBCL that has arisen from the original CLL clone. The second represents a 
similar DLBCL that originates from a different clone to that of the original CLL 
(Rossi and Gaidano, 2009). CLL transforms to Richter’s syndrome in around 
five to twenty percent of cases (Tsimberidou and Keating, 2005). Until recently 
the biological and clinical characteristics of CLL and their relation to 
transformation to Richter’s was unclear. A study by Rossi et al. in 2008 
identified the variables in CLL which may be used to predict the onset of 
Richter’s (Rossi et al., 2008). Table 1.4.a and b summarise the biological and 
clinical variables respectively.
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Biological
Variable
Events
(n)
Log-rank. Risk of 
mortality within § 
years (%) P HR
Cox
95%CI P
IgHV <98% 6/114 7 0.006 0.11
IgHV >98% 11/64 28.3 3.65 1.34-9.35
No IGHV 4-39 13/170 11.1 <0.001 0.002
IgVH 4-39 4/8 56.2 6 1.95-18.43
Del 13q 14 3/95 3.8 0.004 0.009
No Del 13q 14 13/78 25.4 5.27 1.5-18.5
CD38 <30% 4/123 4.7 <0.001 0.002
CD38 >30% 11/60 35.4 6.01 1.91-18.89
Zap70 <20% 1/77 1.9 0.004 0.003
Zap70 >70% 7/50 21 11.24 1.38-91.55
HR, hazard ratio; Cl, confidence interval; P, P value calculated by both log-rank and Cox 
univariate analysis; BM, bone marrow; LDH, lactate dehydrogenase; ULN, upper limit of 
normal.
Table 1.4.a Biological risk factors of CLL transformation to Richter’s 
syndrome identified by univariate analysis at CLL diagnosis (Adapted from 
Rossi et al., 2008)
Clinical Variable
Events
(n)
Log-rank. Risk of 
mortality within 
5 years (%) P HR
Cox
95%CI P
Lymph node <3 cm 7/158 6.1 <0.001 <0.001
Lymph node >3cm 10/26 49.9 9.99 3.7-26.96
Nodal areas involved <3 8/151 8.3 <0.001 0.001
Nodal areas involved >3 8/33 31.8 5.51 2.66-14.72
LDH <1 ULN 9/167 8.6 <0.001 0.001
LDH >1 ULN 6/17 42.3 5.89 2.14-16.21
Binet Stage A 7/135 7.1 0.002 0.004
Binet Stage B-C 10/50 29.6 4.18 1.59-11.01
No diffuse BM 8/138 8.4 0.017 0.024
Diffuse BM 8/46 22.9 3.1 1.16-8.27
HR, hazard ratio; Cl, confidence interval; P, P value calculated by both log-rank and Cox 
univariate analysis; BM, bone marrow; LDH, lactate dehydrogenase; ULN, upper limit of 
normal.
Table 1.4.b Clinical risk factors of CLL transformation to Richter’s 
syndrome identified by univariate analysis at CLL diagnosis (Adapted from 
Rossi et al., 2008)
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1.2.8 Treatment of CLL
CLL patients may present with very high lymphocyte counts (sometimes in 
excess of 500xl09/L), but with good prognosis CLL cell phenotype, normal 
cytogenetics and a long LDT. This suggests that the disease has manifested over 
a period of many years or even decades and that aggressive treatment with 
cytotoxic drugs is not required for this indolent accumulation of lymphocytes. 
The use of first-line lymphocyte depleting drugs may be enough to control the 
lymphocyte count sufficiently so that patients remain well enough to live with 
the disease for many years. However, regular assessment of the lymphocyte 
count is required to ensure that the CLL clone does not transform into aggressive 
disease. Patients with a less favourable prognosis following clinical staging, cell 
phenotyping and genetic investigations, are candidates for more aggressive 
therapy usually involving an intensive combined chemotherapy regimen. Early 
strategies for the treatment of CLL included the use of standard chemotherapy 
alkylating agents like chlorambucil that induced a complete remission in around 
5% of patients (Figure 1.2) (Kay, 2006). The purine nucleoside analogues (which 
prevent elongation of DNA strands through direct incorporation into DNA and 
also inhibit RNA polymerase II) were introduced in the 1980s. These molecules, 
when used in combination with the original alkylating agents, induced a much 
improved response in patients with CLL (Kay, 2006). Various combinations of 
these drugs have been used in clinical trials yielding similar outcomes in 
patients. The use of fludarabine as a single agent or in combination with 
cyclophosphamide resulted in more patients entering complete remission and 
this drug remains an important chemotherapeutic option for CLL patients with 
advanced disease (Eichhorst et al., 2006).
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Figure 1.2 The development of CLL therapy throughout the 20th century
and patient outcome (Adapted from Kay, 2006a)
Advances in immunotherapy have seen the introduction of monoclonal 
antibodies that target the CLL B-cells (rituximab (anti-CD20)) or mature B and 
T-cells (alemtuzumab (anti-CD52)) within the patient. Although more target 
specific, they are known to cause substantial immune suppression and are used 
with care as treated patients are susceptible to infection (Peleg et al., 2007). A 
recent summary of first and second line treatment for advanced CLL was 
published by Eichhorst et al. in 2009 for the European Society for Medical 
Oncology (Eichhorst et al., 2009). They determined that only those patients with 
advanced stage disease with anaemia and/or thrombocytopenia, who do not 
respond to treatment with corticosteroids, should receive chemotherapy. First 
line regimens should consist of fludarabine, cyclophosphomide with rituximab 
(FCR) in younger (or fitter) patients, or chlorambucil in those with co­
morbidities. The results from this study agreed with data published by Tam et al. 
in 2008, which highlighted the use of rituximab as a first line therapy in CLL 
(Tam et al., 2008). More recently, data from the CLL8 German study confirmed 
that the use of rituximab in combination with FC results in an increased
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progression-free and overall survival in CLL patients (Hallek et al., 2010). In 
addition, bendamustine has been reported to be more effective as a first line 
therapy for advanced stage CLL when compared to chlorambucil (Knauf et al.,
2009).
It has been widely established that patients with a deleted p53 gene respond 
poorly to DNA damaging agents and as such these individuals have benefited 
from first line alemtuzumab monotherapy or alemtuzumab in combination with 
high dose steroids such as dexamethazone and methylprednisolone (Hillmen et 
al, 2007, Dungarwalla et al., 2008, Pettitt et al., 2006). Novel drug therapy in 
CLL includes the use of the immunomodulatory drug lenalidomide and the 
monoclonal antibody lumiliximab. Lenolidamide was reported to re-establish the 
humoral immune recognition of malignant CLL cells through increased 
expression of the CD 154 antigen on the cell surface (Lapalombella et al., 2009). 
In the same report Lapalombella et a l described TNF-related apoptosis-inducing 
ligand (TRAIL) mediated apoptosis and the generation of antibodies by normal 
B-cells following treatment with lenalidomide. Lumiliximab is an anti-CD23 
monoclonal antibody that was shown to be beneficial in combination with 
fludarabine, cyclophosphomide and rituximab in CLL (Byrd et al., 2010). A 
second generation of fully humanised anti-CD20 monoclonal antibodies 
(Ofatumumab and GA-101) are currently being trialled in CLL. These antibodies 
have shown enhanced complement-dependent cytotoxicity and antibody- 
dependent cellular cytotoxicity compared with rituximab (Cheson, 2010, 
Bologna et al., 2011).
17p deleted patients are candidates for bone marrow transplant, though this 
is usually a last resort due to the high rate of mortality associated with 
myeloablative stem cell transplantation in older patients. (Michallet et al., 1996). 
Reduced intensity (non-myeloablative) and autologous transplantation may be 
considered though there is little data to suggest that these options offer a survival 
advantage over current therapies (Gribben, 2008).
1.2.9 The origin of the CLL cell
The origin of the CLL cell is a topic which has been widely debated and 
various hypotheses have been proposed and reviewed over the years in light of 
novel findings. Initial studies describe CLL B-cells as closely resembling CD5
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positive lymphocytes in the mantle zone of the secondary lymphoid follicle (Rai, 
2003). The CLL cells express low levels of surface immunoglobulin and are 
predominantly anergic. These features are characteristic of normal B- 
lymphocytes that have been exposed to self antigen and are candidates for 
deletion (Damle et al., 2002). CLL cells have also been shown to display some 
biological features of T-cells (Majolini et al., 1998, Wiestner et al., 2003). This 
led Caligaris-Cappio and Ghia to surmise that the transformation event in CLL 
may occur at an early stage of maturation when the B-cell was less distinct from 
its immunoregulatory partner, the T-cell (Caligaris-Cappio and Ghia, 2004).
The discovery that the immunoglobulin genes in CLL can be either mutated 
(suggesting that the cells had experienced antigen) or unmutated (suggesting a 
naive B-cell phenotype) confounded initial hypotheses and the idea arose that 
CLL was in fact two separate diseases; the first originating from a naive B-cell 
and the second from an antigen experienced, post germinal centre B-cell 
(Hamblin, 2002, Dighiero, 2002, Fegan, 2002). Gene expression analysis has 
identified specific genes differentially expressed between the two groups, which 
supports this theory (Ferrer et al., 2004). Evidence to the contrary exists however 
and additional gene expression studies have illustrated that CLL cells exhibiting 
unmutated IGHV genes have profiles very similar to that of antigen experienced 
memory B-cells (Klein et al., 2001, Rosenwald et al., 2001). An interesting 
study by Herve et al. induced auto and polyreactivity of mutated CLL antibodies 
by reverting them to the germ line sequence in vitro. They concluded that both 
mutated and unmutated CLL were derived from a self-reactive B-cell precursor 
and that somatic hypermutation has an important role in the development of CLL 
by altering the BCR autoreactivity (Herve et al., 2005). Current thinking is from 
an immunobiological approach with an emphasis on the possibility that CLL is 
an antigen driven disease. The identification of stereotyped IGHV 
rearrangements in mutated and unmutated CLL, together with gene array 
analysis, suggest that the CLL cell is an antigen experienced B-cell (Stevenson 
and Caligaris-Cappio, 2004). The progression of this B-cell is determined by a 
host of other molecular and biochemical events occurring within the cell and 
with its surrounding microenvironment (Ghia and Caligaris-Cappio, 2006).
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1.2.10 Antigen driven disease/autoimmunity
The fact that the VH gene rearrangements utilised by CLL B-cells from 
individual patients show a great deal of parity supports the hypothesis that a 
common antigen, or antigens, may be present in vivo and play a role in B-cell 
transformation or disease progression. Messmer et al. described a high degree of 
IGHV restriction in 452 patient sequences broken down into 5 distinct groups 
with regard to gene segment usage (Messmer et al., 2004). More recently, 
investigations by Stamatopoulos’ group compared the distribution of IGHV gene 
usage and somatic hypermutation in normal B-cells to a large cohort of CLL 
patients. They described the use of restricted IGHV segments in CLL and 
correlated specific rearrangements (including IGHV 3-21 and 4-34), along with 
stereotyped CDR3 regions and mutational load, with aggressive disease (Murray 
et al., 2008). The group followed up this work by looking at intraclonal diversity 
within the immunoglobulin light chains. They illustrated restricted gene usage 
and stereotyped light chains, especially within the IGHV 4-34 subset (Kostareli 
et al., 2010). This evidence strongly implies that specific antigenic stimuli are 
involved in the selection of the malignant B-cell clone or that CLL derives from 
a specific progenitor B-cell with a limited ability to select alternative IGHV 
rearrangements. Two recent reports describe the source of possible antigens that 
may stimulate the CLL cells to proliferate. Interestingly the antigens identified 
were derived from the surface of apoptotic cells generated by oxidation during 
the apoptotic process (Lanemo Myhrinder et al., 2008, Catera et al., 2008). 
These autoantigens are known to contain epitopes similar to those on bacteria 
and other microbes. A possible hypothesis therefore would be that the CLL clone 
is derived from a population of B-cells whose role is to target apoptotic cells and 
facilitate their clearance. In the presence of infection, bacterial antigens may 
stimulate these cells to proliferate uncontrollably. A review by Ghia et al. 
suggests that the CLL cell is most likely derived from an anergic CD5+ B-cell 
that is auto/poly reactive. Whether the autoantigen present is the cause of the 
transformation event is highly debatable, but it is likely that it is involved in 
maintaining the clone (Ghia et al., 2007).
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1.3 Molecular characteristics of CLL
A multitude of genetic anomalies occur in individual patients with CLL that 
make it an extremely complex and heterogeneous disease. The presence or 
abscence of somatic hypermutations in the IGHV genes that encode the B-cell 
receptor (BCR) determine a good or poor prognosis in CLL patients respectively. 
Over-expression of certain genes in the CLL cell results in the production of 
intracellular and surface proteins giving rise to an aggressive disease. The 
biology of many of these molecules is known and their presence in the CLL cell 
is undesirable if the normal processes of cell differentiation or programmed cell 
death are to take place. CD38 is an example of a cell surface glycoprotein which 
may be over-expressed on the surface of CLL cells. A second molecule 
expressed in many cases of aggressive disease is the ^-associated protein Zap-70. 
This intracellular tyrosine kinase has signalling properties that may enhance the 
proliferative potential of the CLL clone (Deaglio and Malavasi, 2009). CD38 and 
Zap-70 confer a poor prognosis when over-expressed in CLL and both have been 
widely investigated as markers of aggressive disease. Although an association 
exists between the increased expression of CD38, Zap-70 and the presence of 
unmutated IGHV genes, many conflicting reports have been published. (Hamblin 
et al., 2002, Cruse et al., 2007, Rassenti et al., 2008, Crespo et al., 2003, 
Rassenti et al., 2004, Wiestner et al., 2003). Other molecules that may be 
aberrantly expressed in CLL patients include CD23, CD49d, P2-microglobulin, 
vascular endothelial growth factor (VEGF) and the Bcl-2 family proteins 
(Fournier et al., 1992, Schimmer et al., 2003, Veronese et al., 2009, Rossi et al., 
2008, Packham and Stevenson, 2005).
1.3.1 Immunoglobulin genes and the B-cell receptor
1.3.1.1 Immunoglobulin gene diversity in B-cells
The primary events that allow the expression of a diverse number of antigen 
recognition epitopes on the surface of the B-cell occur at an early stage of B-cell 
development through rearrangement of the variable (V), diverse (D) and Joining 
(J) segments of the B-cell receptor. Following antigen recognition the B-cell 
migrates to the lymph node germinal centre where it is genetically modified to
19
Chapter 1 Introduction
obtain a second level of antibody diversification so that a B-cell, highly specific 
to the foreign antigen, may be selected for clonal expansion (Li et al., 2004).
Within the germinal centre of the lymph node two main processes occur to 
enhance antibody diversity. The first of these is class switch recombination 
which involves rearrangement of the IGHV chain gene to incorporate one of the 
constant (C) regions (Chaudhuri and Alt, 2004). Known to be induced by IL-4 
derived from T-cells, the different classes of antibody generated may be released 
into the peripheral circulation to act as soluble mediators of immune surveillance 
with different properties depending on the C region usage (Janice Kuby, 1997). 
The second process employed, in order to introduce further antibody diversity, is 
that of somatic hypermutation. Point mutations (or less frequently insertions or 
deletions) are introduced into a 1.5kb region of the IGHV gene 150-200 base 
pairs down-stream of the promoter region (Li et al., 2004). This mechanism 
generates very subtle alterations to the B-cell antigen receptor expressed on the 
surface resulting in an extremely high specificity for the antigen. These complex 
processes require the participation of T-helper cells and dendritic cells and are 
characterised by the over-expression and down regulation of a multitude of genes 
within the B-cell (Li et al., 2004). The proteins expressed facilitate entry into the 
germinal centre, association with the exponent cells, genetic diversification, 
clonal expansion (or deletion) and differentiation.
1.3.1.2 IGHV gene usage in CLL
Investigations have been carried out to identify the IGHV gene usage of the 
malignant B-cell population in patients with CLL. Initial studies found that the 
IGHV gene usage of the CLL cells from different patients is not random (Fais et 
al., 1998). Later studies observed the gene usage in large patient cohorts and 
identified the most common recombinations. Specific BCR sub-types correlate 
with disease outcome and patients with VH3-21 recombinations were reported to 
have a shorter survival in CLL patients with mutated IGHV genes (Tobin et al., 
2002, Thorselius et al., 2006). Investigations have also been carried out which 
highlight the association of VH3-23 rearrangement as a marker of poor prognosis 
within the mutated IGHV gene cohort (Gerard Tobin, 2004, Bomben et al.,
2010). Additional studies have illustrated that the VHl-69 recombination is
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associated with the presence of unmutated immunoglobulin genes and aggressive 
disease (Potter et al., 2003, Forconi et al., 2009).
1.3.2.3 Somatic hypermutation in CLL
Early investigations looked at the mutation status of the CLL cell IGHV 
genes to observe whether the B-cell had encountered antigen and undergone 
somatic hypermutation in the germinal centre (Cai et al., 1992, Hashimoto et al.,
1995). Surprisingly the mutation status of individual patients varied from 
unmutated to highly polymorphic (Oscier et al., 1997). Analysis of the 
unmutated and mutated subgroups (defined as a IGHV sequence containing more 
or less than 98% homology to the corresponding germ line region respectively) 
revealed that patients with CLL B-cells harbouring unmutated genes had a 
significantly worse prognosis (Hamblin et al., 1999, Damle et al., 1999) (Figure
1.3).
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Figure 1.3 Correlation between IGHV  status and survival. Sampled from a 
cohort of 321 mutated and 100 unmutated patients from Cardiff University, 
Hospital of Wales. (Log rank survival p=<0.001; Hazard ratio=2.538)
Finally proteomic analysis of mutated versus unmutated CLL samples has 
illustrated differences in protein expression between the two groups (Cochran et 
al., 2003). Among the proteins identified nucleophosmin, which is involved in
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the regulation of murine double minute 2 (Mdm2) protein during p53 initiated 
programmed cell death, was absent in the unmutated group, but present in 
mutated cases in multiple-post-translationally modified forms.
1.3.1.4 Complementarity determining region 3 (CDR3)
Complementarity determining regions form specific epitopes involved in 
antigen recognition and are generated by the recombination of the VDJ genes 
(Murray et al., 2008). In a recent analysis of 916 CLL patients 22% exhibited 
CDR3 homology even though they comprised different VDJ rearrangements 
(Stamatopoulos et al., 2007). In a second study the CDR3 region was associated 
with specific IGHV gene usage and somatic hypermutation in CLL patients 
(Murray et al., 2008). This data provides additional evidence for the role of a 
specific antigen in the progression of CLL (Tobin et al., 2003, Caligaris-Cappio, 
2009).
1.3.1.5 Immunoglobulin light chains
Recent analysis of immunoglobulin light chains in CLL has illustrated that 
patterns of restricted gene selection and somatic hypermutation exist which 
mirror that of the IGHV genes (Hadzidimitriou et al., 2009). This presents 
convincing evidence that the entire BCR antigen recognition site utilises a 
restricted set of immunoglobulin genes (including heavy and light chain genes) 
and adds credence to the hypothesis that the CLL clone is selected or driven by 
specific antigen or autoantigen.
1.3.2 The BCR and signalling
The BCR comprises two main functional domains bound to the B-cell 
membrane. IgM or IgD ligand binding domains constitute the first and are 
predominantly extracellular. Disulphide bond links to Ig-a and Ig-P 
heterodimers, containing 48-61 amino acid cytoplasmic tails, make up the 
intracellular portion of the BCR and allow signalling (Janice Kuby, 1997). A raft 
of membrane bound molecules and intracellular substrates and kinases are 
recruited to the BCR following antigen binding. Phosphorylation of down-stream 
kinases results in calcium mobilisation and changes in gene transcription (Figure
1.4).
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Figure 1.4 BCR signalling pathways (Adapted from David Fruman, UCLA) 
http://mbb.bio.uci.edu/frumanyindex.htm
1.3.2.1 BCR signalling in normal B-cells
One of the primary roles of the BCR, following stimulation, is to mediate 
signals which promote migration and entry of the B-cell to the lymph node. Here 
the cell undergoes genetic diversification to allow selection of a mature cell, 
highly specific for the encountered antigen (Agenes et al., 2000). The cell then 
differentiates to form an antibody secreting plasmacytoid cell, or is retained in 
the periphery as a mature memory B-cell. During these processes the BCR 
responds to external stimuli to promote the survival and development of the cell, 
or if required, programmed cell death (Agenes et al., 2000).
BCR ligation is thought to be rapidly followed by the formation of clusters 
or raft complexes on the cell surface that are comprised of molecules which aid 
in BCR signalling (Weintraub et al., 2000). They include CD 19, CD21, CD81 
and CD38 (Fujimoto et al., 1998, Deaglio et al., 2003). Other surface proteins 
may be recruited which inhibit BCR signalling including CD5, CD22, CD72 and 
Fey receptor lib (Bikah et al., 1996, Walker and Smith, 2008, Adachi et al., 
2000, Koncz et al., 1998). Activation of Srk family kinases Lyn, Syk, Lck and
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Btk as well as mitogen activated protein-K (MAPK) and Ras pathways result in 
the translocation of nuclear factors (including the nuclear factor NFk-B) and 
increased calcium flux (Zipfel et al., 2000, Meinhardt et al., 1999). Protein 
kinase C-P (PKC-p) phosphatidylinositol-3-kinase (PI3-K) Erk and Akt all play a 
role in BCR signalling and have all been implicated in the development of CLL 
(Barragan et al, 2003, de Frias et al., 2009).
1.3.2.2 BCR signalling in CLL
In CLL, aberrant BCR signalling is thought to contribute to the maintenance 
and progression of the disease and many of the intracellular molecules active 
during normal signalling processes are thought to be atypically expressed.
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Figure 1.5 Role of P13K in the signalosome model of BCR signalling
(Adapted from D.Fruman, UCLA), http://mbb.bio.uci.edu/fruman/index.htm
Figure 1.5 illustrates the various pathways involved in BCR signalling. BCR 
induced activation of Syk has been illustrated in CLL resulting in up-regulation 
of the anti-apoptotic protein Mcl-1 (Gobessi et al., 2009). Indeed this 
intracellular protein has been shown to be over-expressed in CLL, predominantly
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in poor risk groups (Pepper et al., 2008, Petlickovski et al., 2005). Activation of 
the PI3K/Akt pathway is thought to be essential to CLL cell survival (Barragan 
et al., 2003). A recent in vitro study by de Frias et a l illustrated that the use of 
Akt inhibitors in CLL led to rapid apoptosis of the clone, an effect not as potent 
in normal B or T-cells and one which could not be reversed by the addition of 
the potent survival mediators stromal derived factor-1 (SDF-1) and IL-4 (de 
Frias et al., 2009). In a previous study Akt was shown to be activated in CLL via 
two distinct pathways involving PI3K and PKC-P (Barragan et al., 2006). 
Activation of the MAPK pathway has also been described in CLL (Sainz-Perez 
et al., 2006). BCR stimulation results in phosphorylation of Mek-1 and Mek-2 
which in turn activate Erk, a mediator of normal B-cell development (Chang et 
al., 2003). In a study by Richards et al. the inhibition of Mek signalling blocked 
a subset of B-cell functions including proliferation but did not induce growth 
arrest or apoptosis in these cells (Richards et al., 2001). Further studies using the 
Epstein-Barr virus transformed CLL cell line EHEB showed increased 
sensitivity to purine analogue-induced apoptosis following inhibition of the 
MAPK/ERK pathway using two novel compounds (Smal et al., 2007). A third 
group of intracellular signalling molecules may be activated following 
stimulation of the BCR. The pathway is initiated by PKC-P that regulates the 
activity of I-kB a potent inhibitor of NF-kB. Over expression of the PKC-pII 
protein has also been described in CLL. This molecule increases the nuclear 
translocation and survival effects of NF-kB induced transcription (Abrams et al.,
2007).
The CD38 receptor is thought to associate with the BCR to enhance 
signalling on the surface of CLL cells. A report by Lanham et al. correlated 
increased CD38 expression and the presence of unmutated IGHV genes with an 
increase in BCR signalling (Lanham et al., 2003). In a series of experiments, 
Lund et al. illustrated that (unlike in normal B-cells) B-cells unresponsive to 
BCR stimulation did not proliferate when stimulated with an anti-CD38 antibody 
(Lund et al., 1996). They then showed that CD38 lowered the threshold for BCR 
signalling in murine B-cells responsive to BCR stimulation. Removal of surface 
immunoglobulin negated any CD38 response following stimulation using the 
anti-CD38 antibody. With the use of mutants expressing specific portions of the 
BCR they showed that signalling could be rescued by the expression of the
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cytoplasmic tail of Iga or IgP- Utilising vectors expressing CD38 mutants, Lund 
et al. then illustrated that the cytoplasmic tail of CD38 was not required for 
CD38 mediated signalling (Lund et al., 1996). These results suggest that the 
BCR and CD38 are closely associated on the cell surface during CD38 signalling 
and that CD38 utilises the cytoplasmic domain of the BCR during this process. 
Interestingly the effects of CD38 ligation included an increased calcium flux in 
the absence of any intra-cellular tyrosine phosphorylation. This work highlights 
the association between the BCR and CD38 during signalling and raises the 
question whether these molecules are working in synergy to promote the survival 
and proliferation of CLL B-cells.
1.3.2.3 Zap-70 and BCR signalling in CLL
As well as the aberrant expression of B-cell signalling proteins seen in CLL, 
the T-cell signalling molecule Zap-70 is expressed in a subset of patients. 
Although essential for pre B-cell development Zap-70 is not usually present in 
mature B-lymphocytes (Schweighoffer et al., 2003). The presence of the tyrosine 
kinase was shown to increase BCR signalling in CLL cells, particularly those 
expressing unmutated IGHV genes (Chen et al., 2002, Chen et al., 2005). 
Subsequent investigations of Zap-70 illustrated that it was able to act as an 
adapter protein during BCR signalling as it does not require kinase domain 
activation in order to enhance signalling (Chen et al., 2008).
1.3.2.4 Zap-70 as a marker of prognosis
The presence of Zap-70 has been associated with poor prognosis in CLL 
(Durig et al., 2003). Because of its role in promoting BCR signalling, initial 
clinical studies proposed that it could act as a surrogate for IGHV mutation status 
in CLL (Rassenti et al., 2004, Del Principe et al., 2006). Figure 1.6 illustrates the 
survival of patients according to their Zap-70 status. A clear relationship 
between the Zap-70 status and survival can be observed using a 20% cut-off 
point.
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Figure 1.6 Correlation between Zap-70 status and survival. Sampled from a 
cohort of 262 Zap-70 negative and 189 Zap-70 positive patients from Cardiff 
University, Hospital of Wales. (Log rank, p=<0.001; Hazard ratio=1.744)
1.3.3 CLL cell signalling and migration
Stromal derived nurse like cells have been described in CLL. These cells 
have been shown to enhance CLL cell survival through the release of stromal 
derived factor-la (SDF-la) (Burger et al., 2000). The CXCR4 receptor that 
binds the SDF-la chemokine can be detected on the surface of CLL cells. In 
vitro experiments have shown that CXCR4 promotes the migration of CLL cells 
through a stromal cell layer in the presence of SDF-1 (Burger et al., 1999). The 
tyrosine kinase Zap-70 is known to up-regulate CXCR4 in the process of T-cell 
transendothelial migration (Ticchioni et al., 2002) and Deaglio et al. showed that 
CD38 and Zap-70 expressing CLL cells illustrate enhanced migration in 
response to SDF-la (Deaglio et al., 2007a). They also showed that ligation of 
CD38 with an agonistic antibody induced Zap-70 phosphorylation. In a similar 
study Quiroga et a l showed that CLL cell migration could be blocked by 
treating the cells with an inhibitor of the Syk tyrosine kinase which is involved in 
BCR signalling (Quiroga et al., 2009).
CD49d is a member of the integrin superfamily that has attracted recent 
attention in CLL. Also known as a4 integrin it makes up half of the cell surface 
a4pl lymphocyte homing receptor and is known to regulate adhesion of the cells
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to the extracellular matrix by binding fibronectin, or to other cells via the 
VCAM-1 receptor (Rose et al., 2002). In a study of 303 patients with CLL, high 
CD49d expression significantly correlated with CD38, Zap-70 and 
immunoglobulin gene mutation status. It was also shown to be an independent 
prognostic marker for overall survival and time to first treatment (Rossi et al., 
2008, Majid et al., 2010).
Engagement of CXCR4 up-regulates matrix metalloproteinase-9 (MMP-9), 
a gelatinase effective in the breakdown of intercellular matrices and which is 
integral to the process of transendothelial migration (Redondo-Munoz et al.,
2006). CD49d has been shown to induce the expression of CXCR4 in CLL cells 
(Redondo-Munoz et al., 2006). The integrin was also reported to be involved in 
the transendothelial migration of CLL cells in a separate process involving the 
pro-angiogenic mediator VEGF (Till et al., 2005). In this recent report Till et al. 
showed that blocking VEGF (using a monoclonal antibody or an inhibitor of the 
VEGF receptor) resulted in a marked reduction in the transendothelial migration 
of CLL cells. This effect was not seen in normal B-cells. A recent gene 
expression study illustrated the increased expression of mRNA coding for 
molecules that induce adhesion and migration (including the integrin CD49d). 
These genes were only over-expressed in Zap-70 positive cells that also 
displayed increased in vitro survival (Stamatopoulos et al., 2009).
There is substantial evidence to suggest that a raft of surface and 
intracellular molecules are involved in promoting the migratory potential of CLL 
cells. CD38, present on the surface of CLL cells, has the potential to bind CD31 
on endothelial cells and facilitate the process of migration through the induction 
of such molecules. Whether Zap-70, VEGF, CD49d and the chemokines and 
their receptors are induced or activated following stimulation of CD38 is a 
question that remains to be answered in CLL.
1.4 CD38 in CLL
CD38 was first described on the surface of lymphocytes in 1980 by 
Reinherz et al. who were looking at antigens on the surface of T-cells (Reinherz 
et al., 1980). Since then an array of work has identified the various roles of 
CD38 in multiple cell types and uncovered intriguing evidence illustrating that
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ADP-Ribosyl cyclase (ADPRc), a homologue of CD38, was present in primitive 
organisms over 700 million years ago (Malavasi et al., 2008).
1.4.1 Phylogeny of CD38
Evolution of the CD38 molecule has been eloquently described in a series of 
reports by Malavasi and Deaglio whose laboratories have been studying CD38 
and its homologues for many years. (Deaglio and Malavasi, 2006, Malavasi et 
al., 2006). Through analysis of the genetics of various species they postulated 
that the 7kb gene found in Aplysia, which translates to the soluble ADPRc 
enzyme, developed to become the 90kb gene expressing the membrane bound 
CD38 multifunctional glycoprotein found on many cell types in higher animals 
including human beings. Its homologue CD 157 evolved in parallel with CD38 as 
a glycosylphosphatidylinositol (GPI) membrane-anchored protein with similar 
calcium mobilising properties.
1.4.2 Genetics
The CD38 and CD 157 genes are found on the short arm of chromosome 4 
and are arranged in a head-to-tail manner (telomere —►CD 157 —►CD38 
—►centromere) implying that CD38 and CD 157 are derived by gene duplication 
(Malavasi et al., 2006). The CD38 gene consists of 8 exons that make up 98% of 
the 80kb fragment. Expression of the gene is controlled by regulatory elements 
on exon 1 and multiple binding sites exist for transcription regulatory molecules 
such as NF-kB, Spl, T-cell transcription factor-la (TCF-1), nuclear factor for 
IL-6 (NF-IL-6), interferon-responsive factor-1 (IRF-1) and glucocorticoid 
hormones (Tirumurugaan et al., 2008, Buggins et al., 2010). There is also a 
retinoic acid response element site located at the 5' end of exon 1 on 
chromosome 4 known to induce the transcription of CD38 in myeloid cells 
(Kishimoto et al., 1998). A single nucleotide polymorphism (SNP) has been 
characterised within the 5' region that incorporates a Pvu II  restriction site into 
the gene (Ferrero et al., 1999). The C to G mutation has been studied in various 
cohorts and the literature suggests that the presence of the polymorphism, in its 
homo or heterozygous form, results in susceptibility to CLL (Jamroziak et al.,
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2009), disease progression and transformation to Richter’s syndrome (Aydin et 
al., 2008).
1.4.3 Structure of CD38
CD38 is a type II trans-membrane glycoprotein with a small cytoplasmic 
region (21 amino acids), a single chain transmembrane region (23 amino acids) 
and 256 amino acid extracellular domain that can be loosely divided into two 
regions. The extracellular NH2 portion consists of 156 amino acids that make up 
5 a-helices. This region is adjacent to the COOH domain (amino acids 200-300) 
that contains four parallel P-sheets surrounded by two long and two short a- 
helices. The two regions are joined at multiple positions along the amino acid 
sequence (namely residues 118-119, 143-144, and 200-201; (Malavasi et al.,
2008). These bridges act as a hinge, allowing the structure to open and close 
depending on the binding of relevant molecules (Liu et al., 2005) (Figure 1.7).
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Figure 1.7 Crystal structure of CD38 (Adapted from Liu et al,. 2005)
CD38 is generally reported as a 45KDa molecule, although treatment with 
different reagents and the use of various technical approaches has yielded 
proteins varying between 34 and 45KDa (Ferrero and Malavasi, 1997). Jackson 
et al. calculated that the molecular weight of the CD38 protein is approximately
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34KDa and suggested that 25% of the isolated complex was made up of 
carbohydrate (Jackson and Bell, 1990). A soluble form of the molecule has been 
described which is present at high levels in the serum of patients with various 
conditions including multiple myeloma and HIV infection (Funaro et al., 1996).
1.4.4 Functions of CD38
By the time CD38 was recognised as a cell surface molecule possessing 
enzymatic properties similar to that of ADPRc, a wealth of knowledge had been 
obtained on the biochemical properties of this calcium mobilising enzyme. 
Additionally, the CD 157 ectoenzyme was found to induce calcium mobilisation 
on the surface and within the cell. Interestingly, recent evidence has illustrated 
that CD38 also acts as a multi-functional molecule harbouring receptor- 
signalling capabilities (Ferrero and Malavasi, 1997).
1.4.5 Calcium mobilisation by ADPRc and CD38
Derived from nicotinamide adenine dinucleotide (NAD) and nicotinamide 
adenine dinucleotide phosphate (NADP) respectively, cADPR and nicotinic acid 
adenine dinucleotide phosphate (NAADP) are potent mediators of calcium 
release from intracellular stores (Chini et al., 1995). Both molecules and their 
precursors have very different structures which makes it surprising that they are 
both synthesised by ADPRc, CD38 and CD157. This mechanism of intracellular 
calcium release is known to be involved in the initiation of many cellular 
functions in plants and animals including proliferation, activation, gene 
expression, fertilisation and neurotransmitter release (Lee, 2001).
The production of cADPR or NAADP was initially thought to be dependent 
upon the levels of substrate available to the enzyme. It was later discovered that 
the catalytic pathway chosen is dependent upon the pH of the surrounding 
environment (Aarhus et al., 1995). In acidic conditions NAADP is generated 
where as in alkaline pH cADPR is produced. Acidic organelles such as 
endosomes participate in the endocytic pathway which is thought to be mediated 
by calcium release induced by the NAADP generated in such an acidic 
environment (Lee, 2001). On the extracellular membrane cADPR is thought to 
target the ryanodine receptor in a complex series of interactions involving 
calmodulin and other accessory proteins (Lee et al., 1995). In an experiment by
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Guse et al. the binding of ryanodine increased in a concentration dependent 
manner following the addition of cADPR (Guse et al., 1999). A number of other 
investigations have supported this theory and highlighted the role of cADPR in 
ryanodine receptor mediated calcium flux (Prosser et al., 2010). Following the 
conversion of NADP to cADPR, CD38 has the ability to hydrolyse cADPR to 
ADP-ribose in a secondary reaction. In a series of experiments, Howard et al. 
showed that purified cADPR augmented the proliferative response of activated 
murine B-cells (Howard et al., 1993). This suggests that the enzymatic functions 
of CD38 are able to deplete this molecule at the lymphocyte surface and allow 
proliferation of the cell.
Site-directed mutagenesis has allowed the identification of the specific 
nucleotides within the CD38 molecule that are required for cADPR synthesis 
and hydrolysis into ADPR. In a seminal study by Tohgo et al cysteine residues 
119 and 201 were identified as essential for both the synthesis and hydrolysis of 
cADPR (Tohgo et al., 1994). A later study by Graeff et al. identified the Glu-146 
site as being crucial in determining whether the synthesis or hydrolysis function 
be performed by the CD38 enzyme (Graeff et al., 2001). Much of this work has 
been carried out in lower organisms such as yeast and Aplysia, with the focus 
being solely on analysis of the regions of CD38 responsible for the generation of 
cADPR, ADPR and NAADP. Such investigations are imperative in translational 
research when looking for specific drug target sites to treat disease.
1.4.6 Receptor functions of CD38
Almost two decades after the CD38 antigen was described on the surface of 
lymphocytes it was suggested that the molecule was not just an ecto-enzyme 
involved in the control of intra-cellular calcium, but in addition possessed a 
receptor-signalling capacity in these cells (Deaglio et al., 2003). In the late 1990s 
Malavasi and his group generated a non-substrate, agonistic antibody for CD38 
which had the ability to stimulate intracellular signals resulting in the 
transcription and secretion of an array of biologically relevant molecules 
(Ausiello et al., 2000). It was promptly noted that some of the molecules 
activated following CD38 ligation were similar to those induced following 
stimulation of the T-cell receptor (TCR).
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1.4.7 CD38 signalling in T-cells
Much of the early work on CD38 signalling was carried out in T-cells. 
Ligating CD38 with the agonistic monoclonal antibody IB4 led to both early and 
late signalling events involving the T-cell receptor (Zubiaur et al., 1997). 
Zubiaur et al. illustrated that following CD38 stimulation, phosphorylation of 
protein tyrosine kinases phospholipase C-yl (PLC- yl), c-Cbl, Zap-70 and She 
occurred in Jurkat cells. Down-stream activation of the MAPK Erk-2 was 
abrogated in Lck kinase-deficient mutants indicating an essential role for this 
molecule in CD38 signalling. The results of this extensive study concluded that 
both Raf-l/MAPK and CD3-£/Zap-70/PLC-yl pathways are triggered following 
the ligation of CD38 (Zubiaur et al., 1997). In a later study by the same group it 
was shown that ligation of CD38 led to tyrosine phosphorylation of both the 
CD3-£ and CD3-e portions of the TCR. They subsequently developed a mutant 
CD3-£ expressing TCR that exhibited defective binding to CD38. Following 
ligation, this unit was not phosphorylated but the down-stream effects of CD38 
stimulation were the same. This suggests that the CD3-e subunit is sufficient for 
CD38 activation of MAPK and PKC signalling cascades, though it is still likely 
that the CD3-£ sub unit plays a synergistic role in signalling as it is known to 
effectively recruit Zap-70 to the TCR (Zubiaur et al., 1999).
CD38 is abundant in lipid rafts on the surface of T-lymphocytes (Deaglio et 
al., 2006). Experiments depleting the cholesterol within these rafts resulted in 
abrogated CD38 signalling (Zubiaur et al., 2002). The recruitment of co­
signalling molecules, including Src family kinases, to the lipid rafts suggested 
that this is a site where the CD38 molecule can exhibit enhanced signalling 
(Munoz et al., 2003). In a study by Cho et al. Lck was one of the molecules 
found in abundance in the CD38/TCR lipid raft domain and the same group duly 
illustrated that the Src homology-2 (SH2) region of Lck binds to the cytoplasmic 
tail of CD38 causing phosphorylation of the molecule (Cho et al., 2000). This 
work confirms that Lck has a definitive role in CD38 signalling and the 
activation of T-cells.
1.4.8 CD38 in normal B-cell development
CD38 is expressed on the surface of lymphoid and myeloid cells at various 
stages of cell maturation. It is present on progenitor B-lymphocytes in the bone
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marrow where it has a role in lymphopoiesis. Within the bone marrow 
microenvironment, interaction of B-cells with stromal cells in the presence of 
cytokines such as IL-2 and IL-4 stimulates the cells to mature and divide 
(Kumagai et al., 1995). The use of monoclonal antibodies to block the actions of 
CD38, prior to stimulation by cytokines and co-culture with stromal cells, was 
found to suppress B-cell lymphopoiesis (Kumagai et al., 1995).
Subsequent investigations have identified CD 19 as a mediator of CD38 
signalling. In normal B-cell progenitors, CD 19 has the ability to recruit specific 
kinases to the inner membrane (including syk and c-cbl) allowing CD38 to signal 
via PI3-K pathways (Kitanaka et al., 1996, Kitanaka et al., 1997). More recently 
the non-receptor tyrosine kinase Btk has been implicated in a novel signalling 
cascade leading to PKC, phosphatidylcholine, phospholipase C and 
phospholipase D-dependent B-lymphocyte activation. In a study by Moreno- 
Garcia et al. stimulation of CD38 resulted in the proliferation of splenic B-cells 
through phosphorylation of Btk in an alternative mode of CD38 signalling which 
was completely independent of phospholipase C-y2 in the canonical pathway 
(Moreno-Garcia et al., 2005).
Mature B-cells found in the periphery do not exhibit the CD38 antigen and 
only re-express the molecule following antigen stimulation or differentiation into 
antibody-secreting plasmacytoid B-cells (Deterre et al., 2000, Campana et al., 
2000).
1.4.9 CD38 as a marker of poor prognosis in CLL
CD38 was first described as a poor prognostic marker in CLL by Damle et 
al in 1999 who observed the outcome of 47 patients phenotyped for CD38 
expression and genotyped for IGHV mutation status (Damle et al., 1999). Both 
the presence of surface CD38 (>30% cells) and unmutated immunoglobulin 
genes correlated strongly with survival and CD38 was proposed as a novel and 
more simple means of predicting outcome in newly diagnosed CLL patients. In 
2001, Ibrahim et al. studied a larger cohort of patients and strongly correlated the 
presence of CD38 on the cell surface with a poor prognosis (Ibrahim et al., 
2001). In 96 out of 218 patients more than 20% of the CLL clones expressed the 
CD38 antigen and this cohort were found to have increased lymph node 
involvement, lower haemoglobin levels, high serum p2-microglobulin and
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shorter survival times. These observations were confirmed in subsequent studies 
where the expression of CD38 correlated with disease progression and treatment 
free survival in patients with CLL (Ghia et al., 2003, Durig et al., 2002). In a 
more recent study CD38 was shown to retain its prognostic significant in a 
cohort of patients with stage A disease (Letestu et al., 2010). Interestingly, a 
number of patients present with two distinct CLL cell populations; one CD38 
negative and the other CD38 positive. This bimodal phenotype was shown to 
correlate with unmutated immunoglobulin genes and an unfavourable outcome in 
CLL patients (Ghia et al., 2003). Using a 20% cut off point, CD38 positivity 
correlated with overall survival in a cohort of 485 patients from Cardiff 
University Hospital of Wales (figure 1.8).
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Figure 1.8 Correlation between CD38 status and survival. Data from a cohort 
of 269 CD38 negative and 216 CD38 positive patients from Cardiff University, 
Hospital of Wales. (Log rank, p=<0.001; Hazard ratio=2.3)
1.4.10 The role of CD38 in the pathogenesis of CLL
Following the identification of CD38 as a marker of poor outcome, various 
groups have investigated whether the molecule has a role in enhancing the 
survival or proliferation of the CLL clone. In 2005, Pittner et al. described the 
increased expression of activation markers including CD 18, CD49d and CD20 in 
CD38 positive CLL cells and also showed that the CD38 expressing cells were
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more receptive to additional activation through interferon simulation (Pittner et 
al., 2005). Expression analysis within bi-modal patients illustrated that the CD38 
positive sub-clone had a distinct gene expression profile compared to the CD38 
negative sub-clone (Pepper et al., 2007). Comparing CD38 positive and negative 
CLL cells from independent patients Damle et a l then illustrated that the former 
appear as a phenotypically activated subset (Damle et al., 2007). In the same 
report, they illustrated additional markers of activation including Zap-70, CD27, 
CD62L and CD69. Staining for the cell cycle entry protein Ki-67, Damle et al. 
illustrated increased proliferation within the CD38 positive clone and identified 
the presence of enhanced telomerase activity. They also illustrated that there was 
no difference in the telomere lengths between the CLL cells taken from CD38 
positive and negative patients (Damle et al., 2007). The latter phenomenon was 
complemented by Lin et a l who carried out genetic analysis on monoclonal 
CD38 positive and negative CLL subclones isolated from the same patient and 
illustrated no difference between the telomere lengths or the clonal evolution of 
the cell subsets according to their CD38 status (Lin et al., 2008). In 2009 
Calissano et a l carried out similar experiments and highlighted that there was no 
difference in the telomere lengths of CD38 positive and negative CLL B-cells. 
These investigations have led to the intriguing supposition that CD38 expression 
is transient on the surface of CLL cells.
With a wealth of knowledge obtained from studying the functions of CD38 
in T-cells, Malavasi and colleagues were in a prime position to investigate its 
role on the B-cell surface in CLL. A report by Deaglio et al in 2003 illustrated 
the signalling capacity of CD38 in CLL (Deaglio et al., 2003) and a second 
manuscript three years later summarised a comprehensive body of work which 
strengthened the hypothesis that CD38 is not just a marker of activation in this 
disease (Deaglio et al., 2006). Investigations by the same group, on the short 
term affects of CD38 ligation using an agonistic antibody, revealed increased 
calcium flux following cross-linking. However, this effect was not observed in 
all of the CD38 positive patient samples investigated and the increases in 
intracellular calcium were small. The addition of IL-2, which is known to up 
regulate CD38 on the surface of cells already expressing CD38, resulted in 
increased calcium flux in previously unresponsive CLL samples. This suggested 
that a minimum threshold was necessary for signalling or that IL-2 was able to
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modify the arrangement of CD38 with accessory molecules on the cell surface to 
allow signalling (Deaglio et al., 2006). Due to its small cytoplasmic domain (21 
amino acids) it is not unreasonable to postulate that other molecules may be 
required for CD38 signalling to take place within the cell. With the use of co­
capping experiments Deaglio et a l described how CD 19 and the BCR were 
recruited alongside CD38 in lipid raft formations and highlighted the similarity 
between the synergy of these molecules in B-cell signalling (Deaglio et al., 
2007b). Overall these experiments illustrated that CD38 had the capability to 
signal in the presence of co-accessory molecules and that this signal results in the 
prolonged survival of the CLL cell. The necessity for accessory molecules and 
cytokines to enhance cell signalling reinforced the idea that the tissue 
microenvironment was an ideal location for CLL cell activation and clonal 
expansion (Deaglio et al., 2006).
1.5 In vivo survival and proliferation of the CLL Cell
1.5.1 Proliferation centres and the microenvironment
Removal of CLL cells from the body results in the rapid onset of apoptosis 
(Collins et al., 1989). This suggests the presence of in vivo stimuli which 
enhance the survival and proliferation of the cells. This process is thought to take 
place in proliferation centres in the lymph nodes and bone marrow where the 
CLL cells are in contact with other cells such as T-cells and stromal cells. (Munk 
Pedersen and Reed, 2004). These sites are also a prime location for antigen 
presentation and immunological activation of the CLL cell (Ghia et al., 2008).
Proliferation centres, or pseudofollicles, have been described in the bone 
marrow and lymph nodes of CLL patients that are rich in pro-lymphocytes and 
paraimmunoblasts (Schmid and Isaacson, 1994). Staining tissue biopsies has 
illustrated that CLL cells reside in large numbers in these sites together with T- 
cells. Whether the CLL cells actively recruit the T-cells through the use of 
chemokines, or alternatively “attract their attention” through autoimmune 
responses (as described in other diseases such as rheumatoid arthritis (Takemura 
et al., 2001)) is a matter for debate. The survival of the CLL cells is promoted 
within these regions through stimulation of surface receptors and the presence of
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survival factors such as IL-2. One of the mechanisms which enhances CLL 
survival within the microenvironment was highlighted in a recent a study by 
Patten et al., who illustrated that through close interactions with T-cells in the 
pseudofollicles, the CLL cells express higher levels of CD38 which signifies an 
activated subset of cells (Patten et al., 2008).
1.5.2 CD31
CD31 (PECAM-1) is a member of the immunoglobulin super family 
expressed on endothelial cells and is the only known non-substrate ligand for 
CD38 (Deaglio et al., 1996, Deaglio et al., 1998). In a study by Deaglio et al 
ligation of CD38 by CD31 resulted in CLL cell activation and the induction of 
anti-apoptotic mechanisms that promoted cell survival. Following re-modelling 
on the cell surface and recruitment of the BCR and CD 19, the interaction 
between CD31 and CD38 was shown to illicit up-regulation of CD 100 in CLL 
cells (Deaglio et al., 2005). CD 100 is a survival receptor that binds to plexin-Bl. 
Plexin-Bl is found on nurse-like stromal cells present in the bone marrow and 
lymph nodes of CLL patients along with CD31. The multiple interactions of 
CD38 with its ligand CD31 and accessory molecules the BCR and CD 19, 
together with co-receptor signalling via CDlOO/plexin-Bl all occur on the 
surface of the CLL cell to enhance cell survival and proliferation (Deaglio et al., 
2006, Granziero et al., 2003).
Investigations have been carried out to determine whether the expression of 
CD31 on the surface of CLL cells correlates with outcome in CLL. Ibrahim et al 
illustrated that in a cohort of 120 patients, those expressing low levels of CD38 
and CD31 had a favourable outcome compared to the rest of the group. They 
also showed that patients with a high CD31 expression, but low CD38, exhibited 
a poor outcome not significantly different to that of the CD38 positive group 
(Ibrahim et al., 2003). Poggi et a l illustrated that anti-apoptotic mediators of the 
Bcl-2 family were up regulated in a cohort of patients whose clone expressed 
high levels of CD31 on the cell surface. They studied the effects of CD31 
ligation and observed increased activation of the PI3K/Akt pathway as well as 
nuclear localisation of the NF-kB sub units p65 and p52. (Poggi et al., 2010). 
Conversely Mainou-Fowler et a l showed that low levels of CD31 on the cell 
surface correlated with aggressive disease in CLL (Mainou-Fowler et al., 2008).
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1.6 Objectives
The multiple roles of the transmembrane glycoprotein CD38 have been 
widely studied in both T- and B-lymphocytes in health and disease. Although 
present on the surface of immature B-cells and abundant on antigen experienced 
plasma cells, CD38 is not present at high levels on the surface of healthy mature 
B-cells within the peripheral blood. In around 30% of CLL cases CD38 is highly 
expressed on the surface of the cell and has been shown to be a marker of 
aggressive disease. A relatively small group of researchers have carried out a 
wealth of investigations to determine whether CD38 is involved in the 
pathogenesis of CLL or whether it is merely a marker of an activated clonal B- 
cell. Work thus far has clearly identified CD38 as having signalling properties 
and it has also been reported to interact with other surface and intracellular 
signalling molecules such as the BCR and Zap-70.
The central hypothesis of this project was that CD38 has distinct signalling 
capabilities which contribute to the aggressive nature of CD38 positive CLL. 
Four principle objectives were devised to test this hypothesis:
1) To optimise a gene delivery technique to express CD38 on the surface of 
CD38 negative CLL cells. Using this approach I aimed to determine the direct 
effects of CD38 expression on the cell surface of CLL cells by comparison with 
genetically unmodified cells derived from the same patient.
2) To utilise this model along with native CD38 expressing CLL cells to assess 
•the in vitro survival and proliferation of CLL cells in liquid culture and under co­
culture conditions.
3) To observe changes in the genotype of the CLL cells following the expression 
of CD38 on the surface of the cells.
4) To observe changes in the phenotype of the CLL cells following the 
expression of CD38 on the surface of the cells.
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Chapter 2. Materials and Methods
2.1 List of Materials and laboratory equipment 
(See Appendix 1)
2.2 Preparation of general reagents
2.2.1 Phosphate buffered saline (PBS)
IX Phosphate Buffered Saline (PBS) was made up by dissolving 5 PBS 
tablets in 0.5 litres of distilled water. The PBS was sterilised by autoclaving at 
121°C, 151b/ins2 for 20 minutes and then stored at room temperature.
2.2.2 Preparation of LB media for bacterial cell culture
Luria-Bertani (LB) media was made up by adding lOg of tryptone (1%), 5g 
of yeast extract (0.5%) and lOg of NaCl (0.17M) to 950ml of de-ionised water. 
The mixture was autoclaved as described. LB-agar, for making plates, was made 
from the same mixture adding 15g/l agar before autoclaving. For experiments 
requiring selective media, 200pl ampicillin (50pg/ml) was added following 
cooling of the media to approximately 50°C prior to pouring the LB-agar plates.
2.2.3 Preparation of eukaryotic cell culture media
2.2.3.1 Culture media for non-adherent cells
For cells cultured in suspension, media was made up in 500ml of Roswell 
Park Memorial Institute (RPMI) media. 50ml of fetal calf serum (FCS) (final 
concentration 10%) was added followed by 10ml Penicillin plus Streptomycin 
(2X), 5ml L-glutamine (IX) and 5ml Sodium Pyruvate (IX). The media was 
mixed well and left at room temperature to cool for an hour before storing at 4°C. 
All work was carried out using careful cell culture techniques in a Class II safety 
cabinet.
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2.2.3.2 Culture media for adherent cells
Culture media for adherent cells contains the Dulbecco’s Modified Eagle’s 
Media (DMEM) additive rather than RPMI. The media was made up following 
the same protocol as above without the requirement for the addition of L- 
glutamine as this is already contained in DMEM.
2.2.4 Paraformaldehyde
1% Paraformaldehyde (Sigma) was prepared by dissolving lg of 
paraformaldehyde in 100ml PBS. To dissolve the paraformaldehyde the solution 
was heated to 70°C and once dissolved was left to cool and then stored at 4°C in 
the dark to prevent depolymerisation and subsequent release of the carcinogen 
formaldehyde. The preparation of paraformaldehyde was carried out in a fume 
hood for safety purposes.
2.2.5 Waste disposal
As the work contained in this project required the use of primary human 
tissue, bacteria and attenuated lentivirus it was important to adhere to strict health 
and safety regulations within the laboratory and decontaminate and dispose of 
waste in the appropriate manner. Gloves and lab coats were worn at all times and 
contaminated waste was placed into a solution containing 2,500ppm chlorine 
over night before disposal.
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2.3 Methods
2.3.1 Primary cell isolation
2.3.1.1 Density centrifugation of peripheral blood to obtain patient CLL cells
Mononuclear cells from CLL patients were isolated from peripheral blood 
samples collected in EDTA. Ficoll reagent (Histopaque) was used to isolate the 
low-density layer of mononuclear cells containing CLL B-cells. 2.5ml of blood 
was mixed with 2.5ml of sterile PBS in a 15ml tube. 7ml of Ficoll reagent was 
carefully transferred to the bottom of the tube using a syringe and the sample was 
centrifuged at 756 x g for 20 minutes with no brake. The monolayer of low 
density cells was removed using a pastette and washed in 10ml sterile PBS. 
Following centrifugation at 272 x g for 5 minutes the cells were re-suspended in 
3ml of sterile H20  for 5 seconds to lyse any contaminating red cells. 10ml of 
sterile PBS was then added to restore the isotonic solution. The cells were 
pelleted and washed once more in sterile PBS before re-suspending in 1-10ml 
sterile PBS (depending on the size of the pellet).
2.3.1.2 Cell counting on the Beckman Coulter Vi-cell
Cell counting was performed using a Vi-cell analyser (Beckman Coulter). 
Briefly, 50pl of each sample was added to 450pl PBS in a cell counting tube and 
placed into the cell counting carousel. The cell type and dilution factor were 
entered into the Vi-cell and it was set to run. The number of viable cells per ml 
was ascertained within each sample using trypan blue exclusion.
2.3.1.3 Cell counting using the Neubauer Haemocytometer
lOpl of the cells in suspension were mixed with lOpl of trypan blue 
exclusion dye (to stain dead cells) and 40pl of PBS to give a 1 in 6 dilution. lOpl 
was pipetted onto the grid of a disposable Neubauer haemocytometer and placed 
under the microscope. The number of unstained cells in 9 small squares was 
added together and multiplied by 60,000 to give the number of cells per ml.
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2.3.1.4 Purifying CLL cells
The majority of patient samples derived from Ficoll separation of 
mononuclear cells consisted of over 95% CLL B-cells following density 
centrifugation. In those cases where there was less than 95% B-cells the T-cells 
were removed with the use of magnetic beads. CD 19 positive CLL cells were 
isolated by negative selection using CD3-expressing Dynabeads. 20pl of beads 
labelled with anti-CD3 antibody were used per lxlO6 CLL cells. The beads were 
washed once in PBS and incubated with the CLL cells in 2ml of PBS at 4°C. The 
sample was incubated for 20 minutes and mixed at regular intervals. The sample 
was then made up to 5ml with PBS and placed into the Dynal rack containing the 
magnet. After 5 minutes the sample was decanted into a fresh tube whilst 
maintained within the magnetic field. This CD3 depleted sample was spun at 272 
x g for 5 minutes and re-suspended in 500pl of PBS. The purity of the sample 
was assessed by flow cytometry for CD 19+ cells (Figure 2.1).
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Figure 2.1 Percentage CD19 positive cells in a CLL sample pre (a) and post 
(b) depletion of CD3-expressing T-cells
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2.3.2 Eukaryotic cell culture
2.3.2.1 Thawing cells from liquid nitrogen stores and transferring to liquid 
culture
The standard precautionary methods were used when dealing with liquid 
nitrogen (use of face masks and gloves). Following recovery from the nitrogen 
store, the cells were placed in a water bath at 37°C for 5 minutes. In order to 
remove the dimethyl sulphoxide (DMSO) storage reagent the cells were 
transferred to a 15ml tube containing 5ml of pre-warmed culture medium (RPMI 
and DMEM for non-adherent and adherent cells respectively) and gently mixed 
to give a homogeneous suspension. This suspension was centrifuged at 272 x g 
for 5 minutes to pellet the cells and the supernatant was carefully removed. The 
cells were then re-suspended in 8ml of fresh media, transferred to a small culture 
flask and incubated in a humidified atmosphere maintained at 37°C, 5% C 02.
2.3.2.2 Sub-culture of non-adherent cells
The confluence of non-adherent cells was determined by the turbidity and 
the colour of the RPMI media within the T175 flask. When appropriate, the cells 
were aspirated from the flask and centrifuged at 272 x g for 5 minutes. After re- 
suspending in 20ml, an aliquot of 1-5 ml was placed in to a fresh flask containing 
30ml of fresh media. The remaining cells were used in experiments or discarded. 
Smaller cell preparations were performed in T75 flasks in 15ml of media.
2.3.2.3 Sub-culture of adherent eukaryotic cells
Aspirating the media from the adherent cells left them bound to the bottom 
of the T175 flask. They were then washed in 10ml PBS to remove residual FCS 
in the DMEM media as this is known to inhibit the effects of trypsin. Following 
aspiration of the PBS, 5ml of trypsin was added and the cells were incubated for 
5 minutes at 37°C, 5% C 02. 8ml of DMEM media was washed over the bottom 
of the flask to ensure all cells were re-suspended. After centrifuging at 272 x g 
for 5 minutes the supernatant was discarded and the cells were re-suspended in 
10ml DMEM media. 0.5 to 5ml was replaced into the original small flask 
depending on the demand for cells. 25ml of DMEM media was added to 
supplement the cells for up to 5 days in culture. The cells were cultured at 37°C,
44
Chapter 2 Materials and Methods
5% C 02. Smaller cell preparations were performed in T75 flasks in 15ml of 
media.
2.3.2.4 Freezing down eukaryotic cell lines for long term liquid nitrogen 
storage
The storage media was made up of:
50% FCS
40% DMEM plus additives 
10% DMSO
8xl06 Cells were re-suspended in 4ml of storage media and 500pi was 
aliquoted into 8 cryo-storage tubes. The samples were placed into a freeze 
container submersed in isopropanol and placed into the -80°C freezer. After 24 
hours the samples were transferred to the liquid nitrogen store.
2.3.2.5 Preparation of co-culture
Adherent fibroblasts were utilised as in vitro co-cultures to simulate the in 
vivo microenvironment. Genetically modified sub-sets expressing the human 
CD31 or the human CD 154 antigen were employed to stimulate CD38 or CD40 
on the surface of CLL cells respectively. The fibroblast cells were first irradiated 
to prohibit their growth within the co-culture environment. (Details of co-culture 
cells and their origin can be seen in appendix 2.1.3).
23.2.5.1 Irradiation
5xl06 co-culture cells were re-suspended in 25ml DMEM with additives and 
irradiated at 75 Grays (27 minutes in the presence of Caesium-137, y emission). 
The volume was then made up to 50ml and 2ml was plated out into the wells of a 
6-well plate. Prior to irradiation, 1ml of the trypsinised co-culture cells were 
washed and placed into a fresh culture flask for future experiments.
23.2.5.2 Co-culture conditions
Following irradiation 1ml of fresh DMEM plus additives was aliquoted into 
each well (of a 6-well plate) and the cells were left at 37°C, 5% CO2 over night to
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adhere. After at least 12 hours the CLL cells were added to the co-culture and the 
media was changed every 3-4 days depending on its colour.
2.3.3 Generation of lentiviral plasmids
The SxW and EGFP plasmids are illustrated in Figures 2.2 and 2.3 
respectively. The CD38 expressing lentivirus was generated by excising CD38 
from the expression of green fluorescent protein plasmid (pEGFP-1) and 
incorporating it into the SxW lentiviral backbone (Figure 2.5).
WPRE 
3’HR'SIN seq primer
A£nl(8257)
X7io 1(8241)
5'HR'SIN seq primer 
3' SFFV LTR 
cPPT
RRE-Rev responsive element
LTR-HIVdelU3
Lenti-SxW
9064 bp
Amp. Res.
LTR HIV-1
Figure 2.2 SxW plasmid, highlighting the Kpnl and Xhol within the 
multiple cloning region
46
Chapter 2 Materials and Methods
pEGFP-1 (Incorporating CD38)
Xhol (1 3 4 4 )
Kan/Neo
Kpnl (2276)
SV40 Poly A
Figure 2.3 pEGFP-1 plasmid, highlighting CD38 and the Kpnl and Xhol 
restriction sites
2.3.3.1 Digestion of pEGFP-1 and SxW plasmids
Both the CD38-containing pEGFP-1 modified plasmid and the Lenti-SxW 
plasmid were digested using the Xho-1 and Kpn-1 enzymes. The reaction 
mixture consisted of 20pl of 10X buffer, lOpl of BSA, lOpl of Kpn-1 
(10,000U/pl), lOpl of Xho-1 (10,000U/pl), 40pl of SXW plasmid (50ng/pl) and 
20pl sterile water. The reaction was placed at 37°C on an orbital shaker for 2 
hours. The 927bp CD38 fragment and the 4700kb linear pEGFP fragment were 
then run on an agarose gel to assess the efficiency of the digestion (Figure 2.4).
2.3.3.2 Agarose gel electrophoresis
A 1% agarose gel was prepared by dissolving lg agarose in 100ml IX TBE 
(microwave at full power for 2 min). 4pl of Ethidium Bromide was then added 
and the gel was left to set in the gel plate containing a 10 well comb. After 
cooling the entire digest was run on the gel using IX running dye. 0.2pg lkb 
ladder was loaded alongside the product and the gel was run for lhour at 
120 Volts.
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1kb pEGFP-1 Neg 1kb
ladder digest control ladder
12000bp 
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4700kb
pEGFPlin
927kb 
CD38 lin
Figure 2.4 Agarose gel showing the K pnl, Xhol digested pEGFP plasmid
2.3.3.3 Extracting DNA from the gel using the QIAquick Gel Extraction kit 
(QIAGEN)
The DNA fragment was carefully, but rapidly excised from the gel whilst 
under the ultra violet light. The fragment was weighed and 3 volumes of buffer 
QG were added per lOOmg of gel. The sample was incubated for 10 minutes at 
50°C and 1ml of isopropanol was added to the dissolved gel solution. This 
solution was then pipetted into a QIAquick column and spun at 16,000 x g for 1 
minute. The sample was then washed by adding 75ml of Buffer PE and the 
sample was again spun for 1 minute at 16,000 x g. Eventually the DNA was 
eluted by adding 50pl of elution buffer to the column, letting it sit for 5 minutes 
at room temperature and then centrifugation at 16,000 x g for 5 minutes.
2.3.3.4 Shrimp Alkaline Phosphatase (SAP) treatment of excised fragments
This method is used to dephosphorylate the sticky ends of the cleaved 
plasmid fragments. The restricted SxW plasmid was treated by mixing 12.5pi 
10X buffer, 56pl of water, 50pl of SxW plasmid (20ng/pl) and 1.5pi of SAP 
enzyme. The reaction was placed at 37°C on the orbital shaker for 2 hours and 
then at 65°C for 15 minutes to inactivate the enzyme. Following the SAP
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treatment the QIAGEN QIAquick purification protocol was utilised to purify the 
plasmid DNA.
2.3.3.5 Clean up of PCR products using the QIAGEN QIAquick PCR 
purification kit
Five volumes of Buffer PB were added to one volume of PCR product. The 
sample was then centrifuged at 16,000 x g for 1 minute to bind the DNA. The 
sample was then washed by adding 750pl of Buffer PE and the sample was again 
spun for 1 minute at 16,000 x g. 50pi of elution buffer was added and the sample 
was centrifuged at 16,000 x g for 1 minute.
2.3.3.6 Ligation
The CD38 fragment was ligated into the SAP treated SXW vector by mixing 
2pl 10X buffer, lp l T4 DNA ligase, 2pl Sterile water, 5pl SXW plasmid 
(20ng/pl) and lOpl CD38 insert (40ng/pl) (Figure 2.5). The reaction was left over 
night at 16°C and then transformed into the DH5a E.coli bacteria.
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WPRE 
3'HR'SIN seq primer
1(9191) 
A pnl(9 l82)
CD38
Xho 1(8241)
5'HR'SIN seq primer 
3' SFFV LTR 
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Not K6651)
LTR-HIVdelU3
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9989 bp
“ " R“
LTR HIV-1
Figure 2.5 S38W plasmid, illustrating the incorporation of the human CD38 
gene and Not 1, Kpnl and Xhol restriction sites
2.3.3.7 Digestion of the CD38 plasmid
The S38W plasmid was digested using Notl enzyme to observe whether the 
CD38 fragment had incorporated into the SXW plasmid. lOng of CD38 plasmid 
was added to 1 pi of New England Buffer 3 (NEB) and 0.25 pi BSA in a 500pl 
eppendorf tube. 0.5pl Notl enzyme (10,000U/pl) was added and the solution was 
incubated at 37°C for 1 hour. The plasmid incorporates two Notl restriction sites 
and when digested effectively generates two products of 2540bp and 7449bp in 
length (Figure 2.6).
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Figure 2.6 Agarose gel illustrating Notl digested Lenti-CD38 Plasmid
2.3.4 Prokaryotic cell culture and plasmid amplification
2.3.4.1 Transformation of competent E.coli DH5a bacteria
In preparation, the LB media was warmed to 37°C in a water bath and the 
plasmids, and the DH5a cells, were thawed on ice. The DH5a cells were gently 
mixed and 50pl was placed into three separate 1.5ml eppendorf tubes. The tubes 
were labelled and 2pl of the respective plasmid DNA was added. Each cocktail 
was mixed gently and placed on ice for 30 minutes. The cells were subjected to 
heat shock by placing them into a 42°C water bath for 20 seconds. They were 
then placed on ice for a subsequent 2 minutes. 950pl of pre-warmed LB was 
added to the bacteria/plasmid transformation reactions and the tubes were 
incubated for 1 hour on the orbital mixer at 37°C, 225rpm.
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2.3.4.2 Plating the bacteria
Two plates containing LB-agar with ampicillin (50pg/ml) were prepared for 
each sample. On the first, a sample of the bacteria was streaked out onto the 
media and on the second the remaining mixture was poured out onto the plate. 
This made it more probable that a single colony would be retrieved from at least 
one of the plates. The plates were then incubated over night at 37°C, 5% C 02.
2.3.4.3 Picking single colonies and growing the transformed bacteria
From the plates containing the best spread of single bacterial colonies two 
single colonies were picked for each of the plasmid transformed bacterial 
preparations and transferred to a 15ml Falcon tube containing 5ml LB with 
ampicillin (50pg/ml). This was incubated for 6 hours on the orbital mixer at 
37°C, 225rpm. Following incubation the sample with the greatest number of 
bacteria (deduced by turbidity) was selected and transferred into a conical flask 
with 250ml LB including ampicillin (50pg/ml). The flask was then incubated 
overnight on the orbital mixer at 37°C, 225rpm to allow the transfected bacteria 
to multiply. The bacterial plates were wrapped in clingfilm and stored at 4°C.
2.3.4.4 Storage of transformed bacteria in glycerol
Before carrying out the plasmid DNA extraction, an aliquot of each of the 
transformed bacteria was stored in sterile glycerol. 850pl of the transformed 
bacteria in LB containing ampicillin (50pg/ml) was transferred to a 1.5ml 
Eppendorf tube. 150pl of sterile glycerol was added and the sample was snap 
frozen on dry ice. The samples were stored at -80°C.
2.3.4.5 Isolation of plasmid DNA using the QIAGEN Plasmid Maxi kit
All reagents were included in the QIAGEN Plasmid Maxi Kit (QIAGEN). In 
preparation, the Sorvall large centrifuge and the swing out rotor centrifuge were 
set to 4°C and the buffers were made up according to the manufacturer’s 
instructions. Conforming to the “overnight culture” protocol, 500ml of the 
transformed bacterial culture was centrifuged at 6000 x g for 15 minutes at 4°C 
to pellet the cells. The supernatant was then poured off and the bacterial cell 
pellet was homogeneously re-suspended in 10ml Buffer PI. 10ml of Buffer P2 
was then added and the container was mixed thoroughly through inversion and
52
Chapter 2 Materials and Methods
maintained at room temperature for 5 minutes. Following the addition of 10ml of 
Buffer 3 the sample was again mixed thoroughly and incubated on ice for 20 
minutes. The sample was centrifuged at 756 x g for 30 minutes at 4°C to pellet 
the cell lysate. The supernatant retrieved at this stage was subsequently re­
centrifuged at 756 x g for 15 minutes at 4°C to remove any residual bacterial cell 
debris. The QIAGEN columns were placed into 50ml collection tubes and the 
binding filter was equilibrated by applying 10ml of Buffer QBT. The solution 
was allowed to pass through the column under gravity flow. The plasmid DNA 
(contained in the lysate supernatant (around 30ml)) was then transferred to the 
column and allowed to pass through the filter under gravity flow. The plasmid 
DNA, now bound to the column, was subsequently subjected to two consecutive 
wash stages using 30ml of Buffer QC. Again the liquid was allowed to pass 
through the column under gravity flow. When the last of the QC Buffer had 
passed through the column 15ml of Elution Buffer was added and the plasmid 
DNA was collected into a fresh 50ml Falcon tube. The Plasmid DNA was 
precipitated by adding 10.7ml (0.7 vol) room temperature isopropanol. The 
sample was then centrifuged for 30 minutes at 3000 x g 4°C to pellet the DNA. 
The supernatant was carefully decanted leaving a plasmid DNA pellet at the 
bottom of the 50ml tube. Sterile 70% ethanol was then added to re-suspend and 
wash the pellet. The sample was again centrifuged for 15 minutes at 3000 x g at 
4°C, and the ethanol was decanted. Inverting the sample onto a tissue allowed the 
remaining ethanol to evaporate and the DNA pellet was re-suspended in 0.5ml 
TE buffer, and stored at -20°C.
2.3.4.6 Quantification of plasmid DNA
lOpl of each plasmid DNA prep was diluted 1/50 in sterile water and 
analysed on the spectrophotometer to quantify the yield of DNA. The absorbance 
at 260nm was measured and the amount of DNA calculated taking into account 
the dilution factor and the knowledge that a 50pg/ml plasmid DNA solution has 
A260nm o f  1 .
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2.3.5 Generation of lentivirus
The plasmids generated were used alongside helper plasmids pA8.91 (gag, 
pol) and MD2G (envelope) (See Appendix 2) in a third generation lentivirus 
production procedure adapted from Dull et al (1998).
2.3.5.1 Calcium phosphate transfection of 293T Cells
Calcium phosphate bound to DNA facilitates its passage through the 
eukaryotic cell membrane and into the cytoplasm. This method has been used 
effectively to allow the genetic modification of eukaryotic cells through 
transfection with plasmid vectors. 75pi of calcium chloride was added to a sterile 
10ml tube. To this lOpg of the lentiviral plasmid, 7.5fig of the pA8.91 plasmid 
and 5 fig of the pMD2G plasmid were added (final concentration: 13ng, lOng and 
6.6ng respectively). The volume was made up to 750pl using molecular grade 
water and the solution was mixed thoroughly. In a second sterile 10ml tube 750pl 
4-(2-hydroxyethyl)-1 -piperazineethanesulfonic acid (HEPES) was bubbled using 
a sterile pastette and a media dispenser gun. The pDNA calcium chloride mix 
was added by dripping slowly through a 1ml pipette. The mixture was vortexed 
for 2-4 seconds and left at room temp for 20 minutes to allow pDNA/calcium 
phosphate precipitates to form. The precipitate was then distributed evenly over 
the adhered 293T cells prepared in fresh suspension media, and gently mixed. 
This preparation produced enough precipitate to transfect one medium flask of 
70% confluent 293T cells which was incubated for 48 hours at 37°C, 5% C 02.
2.3.5.2 Harvesting and concentrating the virus
9ml of the supernatant was carefully aspirated from each of the 4 medium 
flasks containing the 293T cells and transferred to a 50ml Falcon tube. The 
Falcon tube was centrifuged at 1700 x g for 10 minutes to pellet any cell debris 
and 11.5ml of the supernatant was transferred to three 12ml ultra centrifuge (UC) 
tubes (Beckman). These tubes were placed into the UC holders (stored at -4°C) 
that were then sealed and balanced to within O.lg. Ultracentrifugation was 
carried out at 121,603 x g for 2 hours at 4°C in a vacuum to pellet the viral 
particles. After 2 hours the supernatant was carefully removed and the pellet re­
suspended in 250pl RPMI (room temperature) containing no additives. 50pi 
aliquots of the concentrated virus were stored at -80°C in sterile 500pl tubes.
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2.3.5.3 Quantification of viral particles using the Retrotek p24 Enzyme 
linked immunosorbent assay (ELISA)
The HIV-1 p24 antigen ELISA from Retro-tek (Zeptometrix corp.) was used 
to quantify the virus. 1:500, 1:1000, 1:2500, 1:5000 dilutions of the CD38 and 
GFP virus were prepared using DMEM. The control standards were also 
prepared as described by the protocol to give 125, 62.5, 31.3, 15.6, 7.8 and 0 
pg/ml concentrations. Wash buffer was made up by adding 15ml of 10X wash 
buffer with 135ml of autoclaved water. The wells of the ELISA kit were pre­
washed 5 times using 300pl of IX wash buffer. 1.5 pi of each sample dilution 
was added to 268.5pl of DMEM plus 30pl of lysis buffer. 200pl of this sample 
was then added to the antibody coated wells supplied with the kit alongside the 
standards. The plate was incubated overnight at 37°C. The next day the plate was 
washed 5 times with IX wash buffer and 100pi of reconstituted HIV-1 p24 
detector antibody bound to biotin was added to each well. The sample was left 
for 1 hour at 37°C. The plate was again washed 5 times and lOOpl of streptavidin 
peroxidase working solution was added to each well. The wells were then sealed 
using the coating sticky plastic sheets supplied with the kit and left for 30 
minutes at 37°C. Following 5 washes with the IX wash buffer, lOOpl of substrate 
working solution (containing tetramethylbenzidine and DMSO) was added to 
each well and the uncovered plate was incubated at 37°C. At this stage the blue 
colour developed and was stopped after 30 minutes by adding lOOpl stop 
solution (proprietary formulation) to each well. The plate was immediately 
placed into the plate reader and the fluorescence measured at 450nm.
2.3.6 Transduction and transfection of lymphocytes
2.3.6.1 Infection of Jurkat cells with viral supernatant
A Neubauer chamber was used to determine the number of Jurkat cells in 
culture and lx l0 6 cells were transferred to each dish of a 6-well plate. Viral 
supernatant was added in the following amounts: 0, lOpl, 50pl, lOOpl, 250pl, 
and 500pl. The plates were stirred gently and incubated for 48 hours at 37°C, 
5%C02 before carrying out flow cytometry to identify cells expressing the gene 
of interest (GFP was primarily observed using a laser microscope). (Details of 
cell lines and their origin can be seen in appendix 2.1.3).
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2.3.6.2 Infection of primary CLL cells with concentrated virus
The cell samples were centrifuged at 272 x g for 5 minutes and the pellet 
was re-suspended in 3ml RPMI plus supplements, lx l0 6 CLL cells were used in 
each well and concentrated virus was added. The plates were stirred gently and 
incubated for 48-72 hours at 37°C, 5% CO2 before carrying out flow cytometry 
to identify the percentage of CLL cells expressing GFP.
2.3.6.3 Nucleofection
Nucleofection of primary CLL cells was carried out using the AMAXA B- 
cell Nucleofection kit. In preparation, 500pl of supplement solution was added to 
2.25ml of nucleofection solution to make up the nucleofection buffer. 5xl06 CLL 
cells were re-suspended in lOOpl of nucleofection buffer and the plasmid DNA 
was added to the sample (1-5 fig of GFP-CD38 or AMAXA GFP control 
plasmid). This sample was then aliquoted into the nucleofection chamber and the 
U-15 programme was initiated. The sample was immediately collected and 
placed into a 6-well plate containing 3ml of DMEM plus supplements. A sample 
that did not undergo nucleofection was included as a control in these 
experiments. The plate was incubated at 37°C and 5% CO2 for 24 hours to allow 
for gene expression.
2.3.6.4 Cell sorting on the MoFlo
5xl06 nucleofected CLL cells were washed in PBS and re-suspended in 3ml 
PBS. The sample was then sorted on the MoFlo cell sorter (Dako Cytomation) 
and GFP positive and negative fractions were collected. The fractionated 
populations were immediately placed back into culture in 3ml DMEM plus 
additives at 37°C 5% CO2 .
2.3.6.5 Electroporation of in vitro transcribed RNA
2.3.6.5.1 Generation o f in vitro transcribed mRNA
The GFP-expressing pGEM4Z-EGFP-A64bis plasmid was a kind donation 
of F. Van Bockstaele and B. Verhasselt. Following transformation of the plasmid 
into DH5a E.coli bacteria and expansion of the cells, the plasmid DNA was 
harvested. The plasmid was then linearized using 3 pi of the Spel restriction
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enzyme in a reaction containing lOpl NEB buffer 2, lp l BSA and 77pi of 
nuclease-free water. The digest was set up for 12 hours at 37°C on the orbital 
shaker at 225rpm. Following linearization the digest was run on a gel to check its 
purity. Due to a small amount of circular plasmid remaining, the entire sample 
was separated on an agarose gel and the linear fragment was isolated using the 
QIAGEN QIAQuick gel clean up protocol. The sample was then quantified using 
1 pi on the Nanodrop spectrophotometer.
For in vitro transcription, the T7 mMESSAGE mMachine kit was used, lpg 
of linear plasmid DNA containing the genetic code for GFP was added to a 
master mix containing lOpl 2X NTP/CAP reagent, 2pl of 10X buffer and 2pl of 
RNA polymerase enzyme. The mix was incubated for 2 hours and 30 minutes at 
37°C on the orbital shaker at 225 rpm. The sample was then heated to 70°C for 5 
minutes to inactivate the enzyme, lp l of Turbo DNase was added and the sample 
was left at 37°C for 15 minutes to degrade any contaminating DNA. 30pl of 
nuclease-free water and 30pl of lithium chloride were added and the sample was 
stored over night at -20°C. In order to precipitate the RNA, the sample was 
pelleted at 16,000 x g for 30 minutes at 4°C and the supernatant was removed, 
lml of 70% ethanol was then added and the sample was again spun at 16,000 x g 
for 10 minutes to pellet the sample. The pellet was subsequently air dried, re­
suspended in nuclease-free water, quantified and stored at -80°C.
2.3.6.5.2 Electroporation
lxlO7 CLL cells were washed twice in DMEM containing no additives and 
then in 10ml Optimix wash buffer. The sample was then re-suspended in lml of 
Optimix Electroporation buffer and the IVT mRNA was added (0, 20 and 40pg). 
The cell solution was added to the electroporation chamber and electroporated at 
500 Volts and 150 Farads for 2 seconds. The sample was immediately removed 
using a pipette and placed into a 6-well plate containing 3ml DMEM plus 
supplements for 24 hours at 37°C, 5% C 02. Following this period, expression of 
GFP was assessed by flow cytometry.
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2.3.7 Primary CLL cell molecular biology and gene expression assays
2.3.7.1 RNA isolation
Up to lxlO7 CLL cells were re-suspended in lml of Trizol, mixed well and 
stored at -80C. Samples were thawed at room temperature and 200pl of 
chloroform was added. Following vortexing, the sample was left at room 
temperature for 5 minutes and then centrifuged at 16,000 x g for 15 minutes at 
4°C. The aqueous layer on the surface containing the RNA was then carefully 
removed and placed into a fresh tube. 500pl of isopropanol was added and the 
sample was mixed well by vortexing. Following 10 minutes at room temperature, 
centrifugation of the sample was carried out at 16,000 x g for 10 minutes at 4°C. 
The supernatant was then poured off and the pellet was washed in 500pl of 70% 
ethanol. Centrifugation at 16,000 x g for 10 minutes at 4°C allowed the sample to 
pellet on the bottom of the tube and the supernatant was carefully removed and 
the RNA left for approximately 10 minutes to air dry. 20-60pl of RNase-free 
water was used to re-suspend the pellet depending on its size and the sample was 
quantified using the Nanodrop spectrophotometer.
2.3.7.2 NanoDrop quantification of RNA
The NanoDrop stage was wiped clean and lpl of RNase-free water was 
added to zero the reading. 1 pi of each sample was added in turn, and RNA was 
quantified by the NanoDrop machine. The purity of the RNA was assessed by 
calculating the ratio of the absorbance at 230nm and 260nm.
2.3.7.3 Reverse Transcription
1 pg of RNA was used in each RT reaction in a volume of 3 pi of RNase-free 
water. This was added to 4pl MgCL, 2pi of 10X RT buffer, 2pi of each dNTP 
(CGA and T, lOpM each), lpl of RNase inhibitor, lp l of 50pM random 
hexamers and 1 pi 50U/pl reverse transcriptase enzyme. The sample was placed 
into the thermal cycler and incubated at 25°C for 10 minutes, 42°C for 30 
minutes and finally 95°C for 5 minutes to inactivate the enzyme. The temperature 
was then maintained at 4°C until the cDNA samples were removed and stored at 
-20°C.
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2.3.7.4 QPCR on the Roche Light Cycler
In preparation the Sybr green reagent was thawed and 10pl of DNA 
polymerase enzyme from vial la  was added. 5.4pl of pure water, 1.6pl MgCh, 
lpl of Sybr green working reagent and 0.5pi of the respective forward and 
reverse primer (lOpM) were made up per sample. This mixture was carefully 
pipetted into a lightcycler capillary and 2pl of cDNA was added. The samples 
were briefly centrifuged at 379 x g and placed into the Light cycler instrument. 
Following a ‘pre-heat’ at 95°C for 1 minute the cycling conditions were 95°C for 
3 seconds, 60°C for 5 seconds and 72°C for 12 seconds for 45 cycles. In a final 
step, the sample was denatured by heating to 95°C over a period of 10 minutes. 
The single peak observed in Figure 2.7 illustrated that the PCR product was of a 
single length and that no non-specific amplification had occurred.
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Figure 2.7 Melting curve of the 259 base pair MCL-1 PCR product
2.3.7.5 Affymetrix Microarray
The standard Affymetrix protocol was carried out for the labelling and 
detection of RNA from untreated CD38 virus treated and GFP treated RNA 
samples. The central biotechnology service (CBS) at Cardiff University was
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utilised for this technique and the Affymetrix protocol was kindly carried out by 
Mrs Megan Musson.
Step 1. Total RNA clean up after extraction
As RNA quality is possibly the most crucial factor for the success of the 
experiment, the RNA samples were purified using the QIAGEN RNeasy columns 
before proceeding to sample labelling (see above).
Step 2. Spectrophotometric QC
A quality assessment was necessary to verify that the samples were of 
sufficient molecular weight and purity to proceed with full labelling and 
hybridization. The samples were therefore run on the Agilent Bioanalyzer to 
ensure that the RNA was of sufficient quality. All samples met the following 
requirements for acceptance:
• Concentration > 0.5mg/ml
• A260/A280 >1.7
• Minimum yield per sample of 3pg
Step 3. Bioanalyzer QC
Each RNA sample was run on the Bioanalyser 2100 QC device to observe 
any RNA degradation.
Step 4. Sample Labeling
(i) First strand synthesis
5pg of total RNA was mixed with 0.5plT7-(T)24 primer (lOOpM) and 5.5pl 
of DEPC-treated water. The reagents were mixed and incubated at 70°C for 10 
minutes. The sample was then chilled on ice and pelleted. In a separate tube the 
2pl of 5X first strand buffer was mixed with lp l of 0.1 M DTT and 0.5pi dNTP 
blend (lOmM). 3.5pl of 1st strand premix was added to each annealed primer- 
RNA mix and incubated at 37°C for 2 minutes. 0.5pl of Superscript II RT was 
then added to each target and the samples were incubated at 42 °C for 1 hour. 
They were then placed into a water bath at 16°C ready for 2nd strand synthesis.
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(ii) Second strand synthesis
The samples were placed on ice to cool for 5 minutes. Meanwhile 45.5pi of 
DEPC-treated water was mixed with 15pl 5X second strand buffer, 1.5 pi dNTP 
blend (lOpM) 0.5pl E.coli DNA ligase (lOU/pl), 2pl E.coli DNA Pol 1 (lOU/pl) 
and 0.5pl RNaseH (2U/pl). The 2nd strand master mix was added to each 1st 
strand reaction, mixed well, spun and incubated at 16°C for 2 hours. Following 
incubation lpl of T4 DNA Polymerase [lOU/pl] was added and the sample was 
lightly vortexed, spun and incubated at 16°C for 5 minutes. 5pl of 0.5M EDTA 
was then added to each sample.
(iii) Clean-up of double stranded cDNA
80 pi of Phenol: chloroform: isoamyl alcohol [48:1:1] (saturated with lOmM 
Tris pH8) was added to each ds cDNA sample and vortexed. A 1.5 ml Phase 
Lock Gel Light (PLG) tube was prepared for each sample by pelleting the gel in 
a microcentrifuge at 16,000 x g for 20-30 seconds. The entire cDNA-PCI mixture 
was transferred to the PLG tube and centrifuged for 2 minutes at top speed. The 
aqueous phase was then transferred to a fresh tube and precipitated by adding 2 
pi Glycogen, 80 pi NFLjOAc 5M and 400pl ethanol 100%. The sample was then 
stored at -80°C for 60 minutes to increase the cDNA recovery. Following 
thawing each sample was centrifuged at 4°C for 30 minutes and washed with 
70% ethanol. The samples were then centrifuged at 4°C for 10 minutes and the 
pellet was air dried for 10 minutes. The pellet was re-suspended in 1.5pl DEPC- 
treated water.
(iv) In vitro transcription reaction (using biotin-NTPs)
The IX NTP labelling cocktail was prepared by mixing 2pl 10X ATP 
(75mM), 2pl 10X GTP (75mM), 1.5pl 10X CTP (75mM), 1.5pl 10X UTP 
(75mM), 3.75pl Bio-11-CTP (10 mM), and 3.75pl Bio-11-UTP (10 mM). 14.5pl 
of this mix was added to the 1.5 pi cDNA along with 2pl 10X T7 transcription 
buffer and 2pl 10X T7 enzyme mix. The sample was run in a thermocycler for 6 
hours at 37°C and then left on hold at 4°C.
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(v) Clean-up of labelled cRNA
The sample volume was adjusted to lOOpl with RNase-free water. 350pl 
Buffer RTL was added and mixed thoroughly. This was followed by the addition 
of 250pl absolute ethanol and the sample was mixed well by pipetting. The entire 
sample (700pl) was applied to an RNeasy mini spin column sitting in a collection 
tube and centrifuged for 15 seconds at 16,000 x g. The RNeasy column was 
transferred into a new 2ml collection tube and 500pi Buffer RPE was added. The 
sample was then centrifuged for 15 seconds at 16,000 x g and the flow-through 
was discarded. 500pi Buffer RPE was pipetted onto an RNeasy column and 
centrifuged for 2 minutes at 16,000 x g to dry the membrane. The flow-through 
was discarded and spun at 16,000 x g for 2 minutes to dry the pellet. The RNeasy 
column was transferred into a new 1.5ml collection tube and 50pl RNase-free 
water was placed directly on the membrane. The sample was left for 1 minute 
and then centrifuged for 1 minute at 16,000 x g to elute. This step was repeated. 
The cRNA was quantitated using the Nanodrop spectrophotometer.
Fragmentation o f  cRNA for target preparation
(i) Fragmentation reaction
15pg of fragmented cRNA was used in 300pl of hybridization mix. The 
sample was incubated for 35 minutes at 94°C and then stored at -20°C until ready 
to perform hybridization.
(ii) Preparing the hybridization target
Before preparing the pre-mix, the 20X GeneChip Eukaryotic Hybridization 
Control cocktail was heated for 5 minutes at 65°C. The premix was made up by 
mixing 4.15pl control B2 oligonucleotide, 12.5pl 20X Eukaryotic Hybridization 
controls, 2.5pi Herring Sperm DNA (lOmg/ml), 2.5pi acetylated BSA 
(50mg/ml), 125pl 2x Hybridization buffer and 12.5g fragmented cRNA in water.
(iii) Targeting hybridization to GeneChip array
The hybridization cocktail was heated to 95 °C for 5 minutes and spun in the 
microfuge at 16,000 for 5 minutes to remove any insoluble material. The 
GeneChip probe array was then prepared for sample loading. The probe arrays
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were equilibrated to room temperature before use. The array was filled with IX 
Hybridization buffer (200pl) and incubated at 45°C for 10 minutes with the 
rotation at 60rpm. The buffer was then removed and replaced with the 
appropriate volume of clarified hybridization cocktail. The probe array was 
replaced into the rotisserie oven and hybridized for 16 hours at 45°C, with a 
rotation of 60 rpm.
In the microarray experiments three untreated and virus treated samples were 
run on Affymetrix U133A GeneChips that contain 23,500 sequences derived 
from the Genebank database. All of the data obtained from the gene array study 
were analysed using Genespring 7.0 analysis software.
2.3.7.6 Sequencing
PCR products were extracted from the gel and cleaned using the QIAGEN 
clean-up protocol described. The samples were quantified on the Nanodrop 
spectrophotometer and the ABI Big Dye 3.1 kit was used to amplify the 
fragments.
2.3.7.6.1 Sequencing PCR
The reaction mixture consisted of 4pl Terminator Ready Reaction mix, lpg 
template, lpl primer (3.2pM) and 4pl sterile water. The thermocycler was 
programmed to carry out 25 cycles of [96°C for 10 seconds, 50°C for 10 seconds, 
60°C for 4 minutes] and then hold at 4°C.
2.3.7.6.2 Purifying sequencing products by isopropanol precipitation
The sequencing reaction was transferred into a 1.5 ml microcentrifuge tube. 
40 ml of 75% isopropanol was added and the sample was mixed. The sample was 
then placed at -20°C for 30 minutes to precipitate the products. Following 
thawing the sample was spun for 20 minutes at 16,000 x g in a microcentrifuge. 
The supernatant was aspirated leaving the pellet at the bottom of the tube. 250 ml 
of 75% isopropanol was added to the tubes and the pellet was re-suspended. The 
sample was then centrifuged at 16,000 x g for 5 minutes at maximum speed and 
the supernatant removed. The sample was air dried on the bench for 10 minutes 
then stored at -20°C until ready for electrophoresis.
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2.3.7.6.3 Preparation o f sequencing products fo r electrophoresis
Electrophoresis was carried out by the CBS service at Cardiff University. 
Each sample was re-dissolved in 3ml loading buffer (deionized formamide/25 
mM EDTA (pH 8.0) with blue dextran (50 mg/ml) at a 5:1 ratio) immediately 
before use. The sample was then heated to 95°C for 2 minutes and immediately 
placed on ice. 2pi of each sample was loaded into the 96-well plate for 
sequencing. Sequencing was performed on the ABI 3700 16 capillary genetic 
analyser.
2.3.8 Cell biology and biochemical assays
2.3.8.1 Flow cytometry
Flow cytometry was employed to assess viability, proliferation and the 
expression of surface and intracellular molecules.
2.3.8.2 Preparation of Jurkat cells for flow cytometry
lml of the Jurkat cells were removed from each well and transferred to a 
FACS tube. The tubes were centrifuged at 272 x g for 5 minutes to pellet the 
cells. After pouring off the supernatant 500pl of 1% paraformaldehyde was 
added to each tube and the cell pellet was re-suspended by mixing. Incubation for 
15 minutes at 4°C was sufficient to fix the cells and they were washed twice in 
3ml before re-suspending in 500pl PBS.
2.3.8.3 Preparation of primary CLL cells for flow cytometry
250 or 500pl of the cell suspension was pelleted by centrifugation at 272 x g 
for 5 minutes. The pellet was re-suspended in lOOpl PBS and the relevant 
antibody was added (4pl/lx l06 Cells) (see table 2.1.5 in Appendix 1 for list of 
antibodies). All CLL samples were stained with anti-CD 19 to identify the CLL 
B-cell population. Following incubation at room temperature for 15 minutes in 
the dark, the cells were washed once in lml PBS, pelleted and fixed in 250pl 1% 
Paraformaldehyde.
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2.3.8.4 Fix and perm of CLL cells for intracellular staining
To quantify intracellular proteins by flow cytometry the cells were fixed and 
permeabilised to allow entry of fluorescent antibodies into the cell. Intracellular 
staining for Zap-70 and Ki-67 was carried out using this method. The cells were 
washed and stained for CLL B-cell specific extracellular antigens CD5 and 
CD 19. The sample was washed in lml PBS and 50pl of Fixing reagent A was 
added (Caltag). Following 10 minutes in the dark the cells were again washed 
and 50pl of permeabilisation reagent B containing 0.1% Nonidet-P40 was added 
together with the desired antibody. Following 15 minutes incubation in the dark, 
the sample was washed in lml PBS and the cells re-suspended in 500pl of 1% 
paraformaldehyde. The sample was then stored at 4°C before being run on the 
flow cytometer.
2.3.8.5 Annexin V/PI staining for apoptosis
As the cell enters the process of apoptosis ATP in the cell is depleted and 
phosphatidylserine is expressed on the external leaflet of the cell membrane. 
Annexin V is a natural ligand that binds phosphatidylserine and can therefore be 
used to detect this early marker of programmed cell death. Cells were washed 
twice in PBS and re-suspended in 200pl of IX calcium containing binding 
buffer. 5 pi of annexin V- fluorescein isothiocyanate (FITC) reagent was added 
and the sample was incubated for 10 minutes in the dark. lOpl of propidium 
iodide (20pg/ml) was added and the cells were run on the flow cytometer. 
Annexin V-FITC staining was detected in FL1 and PI in FL3.
2.3.8.6 Assessment of proliferation through incorporation of 
Bromodeoxy-uridine (BrdU)
Cell division is pre-empted by the replication of DNA. BrdU is able to 
replace thymidine during this process and antibodies to BrdU therefore allow the 
detection of dividing cells. Proliferation was assessed in CLL cells incubated in 
CD31 -expressing and untransduced fibroblast co-cultures. lxlO6 CLL cells were 
incubated for 32 hours in co-culture. BrdU was added to give a final 
concentration of lOpM. The cells were incubated for a further 16 hours to allow 
BrdU integration. The CLL cells were then removed from the co-culture layer 
with a pipette and washed in lml staining buffer (Bender Medsystems). After
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pelleting, the cells were fixed using lOOpl cytofix/cytoperm reagent and left for 
20 minutes at 4°C. The cells were then washed using lOOpl cytoperm/wash 
buffer and pelleted. lOOpl cytoperm buffer was added to permeabilise the cells 
and the sample was placed on ice for 10 minutes. The cells were washed and 
lOOpl of DNase (300pg/ml) was added. The sample was then incubated at 37°C 
for 1 hour. After this time, the cells were resuspended in 50pl of anti BrdU-FITC 
antibody and incubated for 20 minutes at room temperature. The sample was then 
washed in lml of cytoperm/cytowash buffer pelleted and resuspended in 200pl 
of IX PI solution (final concentration lpg/pl). Flow cytometry was used to 
detect BrdU-FITC in FL1 and PI in FL3.
2.3.8.7 Measurement of VEGF in the CLL supernatant by ELISA
Levels of the VEGF protein released by the CLL cells into the supernatant 
were quantified using the VEGF-A ELISA kit (Bender Medsystems). A positive 
control sample was included in the kit and dilutions were prepared which ranged 
from 31 to 2000 picomoles. The required number of wells was prepared by 
washing twice with 300pi of well wash buffer. lOOpl of the control and the 
samples were added to the pre-coated wells and incubated in the dark at room 
temperature for 2 hours. The wells were aspirated and washed 5 times with 300pi 
of well wash buffer. lOOpl of the detection antibody was added to each well and 
the plate was incubated in the dark at room temperature for 1 hour. After this 
period the wells were again washed 5 times using the well wash buffer. lOOpl of 
Avidin-HRP solution was added and the plate was left in the dark at room 
temperature for 20 minutes. Following washing 5 times lOOpl of Avidin-HRP 
was again added to each well and the sample incubated in the dark at room 
temperature for 3 minutes. Again the wells were washed 5 times and lOOpl of 
TMB substrate was added to each well. The plate was then incubated in the dark 
at room temperature for 15 minutes to allow the reaction to occur. 50 pi of stop 
solution was added and the plate was read on the plate reader at 450nm.
2.3.8.8 Cytospin slide preparation and staining CLL cells with Giemsa for 
morphological analysis
Isolated CLL lymphocytes were washed in PBS and re-suspended at a 
concentration of 2xl06/ml. 50pl was placed into the cartridge of the assembled
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cytospin slide apparatus containing an absorbent filter card with a window for the 
cells to come into contact with the slide. The slides were spun at 188 x g for 6 
minutes and then removed from the holders. The cells were fixed in 70% ethanol 
for 5 minutes and 5% Giemsa solution was added (enough to cover the surface of 
the cells (100-150|nl)). The samples were left at room temperature for 30 minutes 
and the excess dye was washed off using PBS. The samples were placed under a 
Zeiss Axio microscope for analysis and digital images were recorded at x40 and 
xlOO.
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2.3.9 Statistical analysis
The paired /-test was used to determine differences in protein expression 
from paired samples under varying conditions. The Mann-Whitney test was 
employed to analyse non-parametric un-paired data when comparing different 
patient samples. When correlating gene or protein expression in a cohort of 
patients the Spearman test was used. GraphPad Prism 4.0 was used to carry out 
the statistical analysis. All of the data obtained from the gene array study were 
analysed using Genespring 7.0 analysis software (Agilent Technologies, UK 
Ltd).
2.3.10 Patient samples and ethical approval
Primary CLL cells were collected from CLL patients from the University 
Hospital of Wales Cardiff and Birmingham Heartlands hospital. The patients' 
informed consent was obtained in accordance with the ethical approval granted 
by the South East Wales Research Ethics Committee in accordance with the 
Declaration of Helsinki. Patients presented with Binet stage A-C disease and 
were selected for use according to surface CD38 expression.
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Chapter 3. Genetic modification of primary CLL 
Cells
3.1 Introduction
The objective in this chapter was to develop a method of gene delivery to 
increase the expression of the CD38 glycoprotein on the surface of CD38 
negative primary CLL cells. This would allow the characterisation of the 
effects of CD38 on a homogeneous genetic background. It has been postulated 
that in certain cases, CLL cells are able to rapidly divide in so called 
proliferation centres in the lymph nodes of the host (Schmid and Isaacson, 
1994, Lampert et al., 1999). Even though this may be the case, the majority of 
the tumour cells in the peripheral blood remain in a quiescent state in G0/G1 
of the cell cycle and appear resistant to apoptosis. In vitro these cells are 
notoriously difficult to genetically modify with the use of retroviral vectors, 
which have become an established means of gene transduction in dividing 
cells (Muhlebach et al., 2005, Wolfrum et al., 2007). In this chapter, three 
different methods of gene transfection were evaluated in an attempt to 
increase the expression of CD38 on the surface of primary CLL cells; 
nucleofection, electroporation of in vitro transcribed messenger RNA and a 
lentiviral vector system.
3.2 Nucleofection of plasmid vectors
The nucleofection method involves pulsing an electric current through the 
CLL cell sample in the presence of a plasmid vector. Pores are created in the 
cell membrane enabling the plasmid to enter the cell and express the gene of 
interest. The nucleofection procedure can cause substantial cell death of CLL 
cells (Van Bockstaele et al., 2008) and the introduction of circular plasmid 
DNA (rather than linear DNA) into the cell has been shown to induce cell 
death in various cell types including B-cells, dendritic cells and macrophage 
(Seiffert et al., 2007, Shimokawa et al., 2000). This phenomenon is thought to 
occur due to the induction of an intrinsic defence mechanism against invading 
bacterial pathogens which causes apoptosis (Weinrauch and Zychlinsky, 
1999). Furthermore lipopolysaccharide (LPS), carried over from plasmid
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preparations, is a potent mediator of cell death (Boyle et al., 1998, Gordillo et 
al., 1999). Due to the anticipated cell death associated with nucleofection, 
large numbers of CLL cells (2.5x107) were used in each experiment and 
following nucleofection, a CD40 ligand bearing 3T3 cell co-culture was 
employed to prolong the survival of the CLL cells in vitro. The pEGFP-1 
plasmid used in these experiments (Figure 2.3) expressed a CD38-GFP fusion 
gene. Following nucleofection (of a CD38 negative sample) the successfully 
transfected cells expressed the CD38-GFP fusion protein that was readily 
detected using flow cytometry. GFP was detected in 34.5% of the CLL 
sample nucleofected using the CD38-GFP plasmid (Figure 3.1.a). A control 
GFP expressing plasmid (Amaxa) was run in parallel and following 
nucleofection, 27% of the cells expressed the fluorescent product (Figure 
3.1.b). Control samples were run which excluded the nucleofection process 
(Figure 3.1.c) and omitted the plasmid from the nucleofected CLL sample 
(Figure 3.1.d). From these latter samples the threshold was set for GFP 
detection.
The post nucleofection sample consisted of a mixed population of 
genetically modified and non-genetically modified CLL cells. To analyse the 
role of CD38 a pure CD38 positive population was required and therefore the 
cells were sorted using a MoFlo high-speed cell sorter. The cells were sorted 
into GFP positive and GFP negative fractions and rapidly returned to co­
culture to minimise cellular stress and subsequent cell death. Figure 3.2.a 
illustrates the gating strategy used to separate the cells on the cell sorter. A 
total of 2xl06 GFP negative cells and 4xl05 GFP positive cells were isolated 
following nucleofection of an initial 2.5x10 CD38 negative CLL cells.
To assess whether the CD38 fusion protein was being expressed on the 
cell surface, a sample of both the GFP positive and GFP negative fractions 
was stained with anti-CD38 (R-phycoerythrin) and run on the flow cytometer. 
Figure 3.2.b illustrates that the GFP positive fraction also expressed the CD38 
fragment on the surface. As expected, the GFP negative CLL cells did not 
express the CD38 antigen. To enable the differential analysis of gene 
expression between the genetically modified and unmodified cells both the 
untransfected and GFP-expressing samples were pelleted and re-suspended in
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Fig 3.1 G F P  w as expressed in C L L  cells follow ing 
nucleofection o f G FP-C D 38 and  contro l G F P  plasm ids.
5xl06 CLL cells were placed into the nucleofection chamber. The 
first sample was nucleofected in the absence of plasmid (a) the 
second control sample was mixed with 5pg of the GFP-CD38 
plasmid in the chamber, without the nucleofection process taking 
place (b) the GFP expression within the CLL cells was measured by 
flow cytometry following nucleofection in the presence of 5pg of 
(c) GFP-CD38 plasmid and (d) 2pg of the GFP plasmid in the 
control sample .
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Figure 3.2 Isolation o f G F P  positive cells using the M oflo 
cell so rter.
The gating strategy employed on the cell sorter separated the GFP 
positive from the GFP negative cells (a) following cell sorting the 
samples were placed into cell culture media at 37°C for 24 hours after 
which a sample of each fraction was run on the flow cytometer to 
observe GFP and CD38 expression. The overlays illustrate (b) GFP 
and (c) CD38 expression in the isolated CLL cell populations.
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Trizol reagent (containing guanidinium thiocyanate) for subsequent RNA 
isolation.
3.3 Electroporation of in vitro transcribed messenger RNA (IVTmRNA)
An alternative means of transfecting cells, similar to the nucleofection 
technique, is to generate a pulse of electricity in the presence of mRNA 
encoding the gene of interest. The pulse renders the cells porous for a suitable 
amount of time for the small mRNA molecules to enter the cell. Unlike the 
nucleofection procedure, the absence of the circular bacterial plasmid in this 
method should eliminate cell death due to DNA cytotoxicity and 
contaminating bacterial LPS. This technique has recently been successful in 
the transfection of CLL cells with a GFP-ZAP-70 fusion gene, with very little 
cell death reported during the electroporation procedure (Van Bockstaele et 
al., 2008). Drawbacks of the technique include the lengthy preparation of 
IVTmRNA, which takes three days to obtain a relatively small amount of 
template (around 60pg). Furthermore, this technique requires electroporation 
which is known to cause increased cell death (Seiffert et al., 2007).
Following transcription of mRNA encoding GFP in the laboratory, the 
CLL cells were electroporated and flow cytometry was utilised to detect the 
GFP protein. Increasing amounts of IVTmRNA, ranging from 0 to 40pg, were 
placed into solution with CLL cells and electroporated at 500 Volts, 150p 
Farads (As optimised in the procedure by Van Bockstaele et al, 2008). Figure 
3.3.C and 3.3.d illustrate that following electroporation, there was no increase 
in the expression of the GFP protein in the CLL cells regardless of the amount 
of mRNA added. The figure is representative of experiments carried out on 
three separate CLL samples. Due to the lack of gene expression, this approach 
was not pursued further.
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Figure 3.3 No G F P  expression w as observed following 
electroporation  o f IV Tm R N A .
5xl06 CLL cells were resuspended in the electroporation buffer (a) 
the first sample was electroporated at 500V 150F with no in vitro 
transcribed messenger RNA (IVT mRNA). In the second sample (b) 
20pg of IVT mRNA encoding GFP was added prior to electroporation, 
(c) 20pg IVT mRNA was added to the third sample and (d) 40pg to 
the final CLL sample before electroporation.
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3.4 Lentiviral gene transduction
3.4.1 Introduction
In nature the virus gains entry into the cell through specific surface 
interactions and utilises the genetic machinery of the cell to incorporate its 
own genetic material into the host genome within the nucleus (Kay et al., 
2001). Unaware of the presence of the foreign gene the cell unwittingly 
transcribes the hybrid genome and generates the proteins required for viral 
replication. This mechanism has been exploited by scientists who have 
genetically modified the viral genes to introduce a gene of interest into the 
host cell.
Stable transduction o f human cells through viral gene delivery
The first type of viral gene transfer was carried out using murine derived 
oncogenic retroviruses (Miller, 1992). These structures contain the basic 
genetic elements required for viral entry into dividing human cells, integration 
of the viral cDNA into the host genome and the expression of regulatory 
proteins, enzymes and the viral envelope glycoprotein which encapsulates the 
replicated virus as it leaves the host cell.
Retroviruses
The retroviral genome consists of two identical copies of a single 
stranded nucleic acid RNA molecule bound by hydrogen bonds to form a 
dimer (Coffin et a l , 1997). The genome, along with virus replication 
enzymes, are housed within the protein core of the virus which is in-tum 
encapsulated in a glycoprotein containing phospholipid envelope. It is the 
outer glycoprotein envelope which interacts with specific host cell membrane 
receptors to allow entry of the viral core into the cell cytoplasm through direct 
fusion or endocytosis (Coffin et al., 1997). In the cytoplasm reverse 
transcription enzymes, transferred in the viral core particle, produce a cDNA 
fragment from the viral RNA. Following entry into the nucleus the viral 
genome is permanently integrated into the host DNA where it is referred to as 
the provirus (Buchschacher and Wong-Staal, 2000). During host cell 
replication the proviral DNA is transcribed into mRNA and the genes required
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for construction of the virus are translated into functional precursor structural 
proteins, replication enzymes and envelope glycoproteins (Buchschacher and 
Wong-Staal, 2000).
Genetics and post-translational modifications
The retroviral genome encodes three genes essential for replication. The 
first two genes are gag and pol which are transcribed into a single mRNA 
precursor coding for the viral core proteins and the viral replication enzymes 
respectively (Buchschacher and Wong-Staal, 2000). The translated chimeric 
protein is self-cleaved through its own protease activity which subsequently 
causes degradation of the pol product into separate enzymes with protease, 
reverse transcriptase and integrase activity (Fields et al., 1996). Matrix, capsid 
and nucleo-capsid proteins are core molecules that are all formed through 
additional protease cleavage of the Gag protein (Fields et a l , 1996). The third 
gene (env) codes for the proteins contained within the envelope structure. 
Cellular proteases are responsible for the cleavage of the envelope 
glycoprotein into the external envelope glycoprotein and the transmembrane 
protein, two molecules which instigate cell membrane interactions as a 
prelude to viral infection (Buchschacher and Wong-Staal, 2000).
Reduction o f viral pathogenesis through genetic modification
Through in vitro manipulation, the retrovirus can be utilised as an 
effective means of gene transfer. The use of such a system, where a virus is 
introduced into host cells, raises serious issues with regard to safety, 
especially in cases where the virus has the potential to operate as a vector for a 
therapeutic gene in the treatment of human disease (Kay et a l , 2001). With 
this in mind, together with the safety issues involved in working with such 
molecules, various molecular modifications have been made to viral vectors to 
increase their safety and reduce their potential to replicate (Delenda, 2004). 
Primarily the vector is stripped of its viral genes from the genome and left 
with the minimum structural protein and enzyme coding regions necessary for 
viral production and infection. The virus is also rendered replication defective 
meaning that following infection of the target cell, the virus is no longer able 
to replicate and cause further infection (Delenda, 2004). This is achieved by
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removing cis-acting sequences from the genes encoding the viral proteins 
required for replication. These sequences allow propagation of a number of 
replication events including reverse transcription of viral RNA (pbs), 
continued DNA synthesis (ppt), incorporation (att) and transcription of the 
provirus and packaging of the viral genome (Delenda, 2004). A promoter 
gene inserted up-stream of the gene of interest allows this fragment to be the 
only one transcribed following infection into the host genome.
Additional measures, taken to reduce the pathogenic potential of the 
virus, include the integration of the required genes into target or packaging 
cells in trans. The gene of interest together with its promoter is incorporated 
into an initial plasmid vector. The viral genes gag and pol are cloned into a 
second plasmid and the env gene, coding the envelope protein, is cloned into a 
tertiary plasmid vector. Only following transfection of the packaging cell line 
are these plasmid vectors expressed together to allow production of the virus 
(Buchschacher and Wong-Staal, 2000) (Figure 3.4). With each of these 
modifications in place the potential of the viral system to cause pathogenesis 
through genetic recombination is low (Buchschacher and Wong-Staal, 2000).
Lentiviral Vectors
The application of lentiviruses in gene delivery has been widely studied, 
predominantly using the Human immunodeficiency virus-1 (HIV1) (Naldini 
et al., 1996). Replication of these types of virus requires additional genes 
which have to be present in the lentiviral vector system if successful gene 
transfer is to be carried out in vitro. The nine genes which encode the genome 
of the HIV virus are the structural genes gag, pol and env which have already 
been discussed, two additional genes tat and rev, which are essential for 
replication and regulate the levels of HIV gene expression at transcriptional 
and post transcriptional levels respectively and four accessory genes v if vpr, 
vpu and nef which are involved during in vivo replication and pathogenesis 
(Buchschacher and Wong-Staal, 2000). Elimination of the accessory genes in 
the lentiviral vector allows transfection and viral production whilst 
eliminating much of the pathogenic potential of the virus.
The Tat protein is involved in enhancing the transcriptional activity of the 
long terminal repeat (LTR) promoter, dramatically increasing transcription of
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Figure 3.4 G enera tion  o f len tiv irus (Adapted from 
Buchschacher and Wong-Staal, 2000).
The plasmid vector construct incorporating the gene of interest within 
the LTR regions of the lentivirus back bone are introduced to the 
packaging cell along with the helper plasmids encoding gag and pol 
and the envelope gene (env). Translation of all three genes results in 
the accumulation of viral proteins and the RNA transcript of the gene 
of interest. Due to the lack of cis acting sequences the gag, pol and env 
genes are not packaged within the newly generated lentivirus. Further 
propagation of the virus is therefore not permitted. The virus is 
released from the packaging cell and infected target cells express the 
gene of interest.
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the rev gene. Rev promotes the accumulation of viral transcripts in the 
cytoplasm through its interaction with the rev-responsive element (rre) on the 
viral genome (Malim et al., 1990). This mechanism allows the production of 
late viral proteins. Up-regulation of rev can be achieved in the lentiviral vector 
by introducing a constitutively active promoter gene into the LTR region, 
negating the requirement for the tat gene (Kim et a l , 1998). The elimination 
of tat leaves only the gag, pol and rev genes from the original HIV genome, 
increasing the biosafety of the vector system even further.
The retrovirus is only effective in transducing dividing cells (Lewis and 
Emerman, 1994). During cell division the nuclear envelope breaks down 
allowing the virus to access the genomic DNA. In non-dividing cells the 
retrovirus is unable to transit the nuclear envelope and therefore there is no 
formation of the provirus. In contrast lentiviral vectors produce integrase and 
matrix proteins which enhance nuclear localisation (Gallay et al., 1995). The 
accessory protein Vpr binds directly to the nuclear pore complex allowing 
entry of the virus into the nucleus. The exact mechanism of this process is 
poorly understood and investigations have shown that formation of the 
provirus can occur in the absence of the vpr gene (Yamashita and Emerman, 
2005). To increase biosafety vpr is left out of the lentiviral construct used to 
infect target cells in vitro.
In summary, genetic engineering of lentiviruses has allowed the 
generation of a safe and effective means of genetically modifying primary 
quiescent cells in the laboratory. Lentiviruses have been successfully 
employed in the genetic modification of a number of different cell types and 
there are many factors integral to the success of the lentiviral system. Such 
factors include the promoter used and the type of envelope which coats the 
virus. The pHR' SINcPPT SFFV-WPRE, third generation lentivirus developed 
in this project integrated the Spleen focus forming virus promoter up-stream 
of the gene of interest. The CD4 T-cell targeting envelope construction 
protein in HIV-1 is encoded by the HIV-1 env gene which was removed from 
the attenuated lentiviral backbone. In the generation of the lentivirus used in 
this work, the VSVG encoding envelope gene was utilised in trans (within the 
MD2G helper plasmid) to allow viral entry into a range of cells via binding to 
surface phospholipid.
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3.4.2 GFP lentivirus on Jurkat cells
Jurkat cells were infected with a GFP expressing lentivirus. Details of the 
generation of plasmids and the lentivirus can be found in the materials and 
methods section (2.3.3 - 2.3.5). The addition of increasing amounts of virus (0 
to 32pi) resulted in a dose dependent increase in the expression of GFP in 
Jurkat cells (Figure 3.5.a).
CLL cells are notoriously difficult to transduce with lentivirus. The virus 
was therefore concentrated by ultracentrifugation prior to infection of CLL 
cells and re-suspended in DMEM media without supplements. Initially the 
concentrated virus was compared to the crude viral supernatant by infecting 
Jurkat cells. This allowed the assessment of whether a significant amount of 
viral particles were lost during the ultracentrifugation step. The concentrated 
GFP virus was diluted 1 in 46 with DMEM (as 34.5ml of supernatant was 
ultracentrifuged and resuspended in 750pl DMEM (see materials and methods
2.3.5.2)) and increasing volumes were added to Jurkat cells. The transduction 
of the Jurkat cells was compared using the same volumes of crude supernatant 
added to CLL cells. Figures 3.5.b and 3.5.C illustrate the transduction 
efficiency of crude viral supernatant and diluted viral concentrate respectively. 
The transduction of Jurkat cells using increased volumes of both crude 
supernatant and concentrated GFP virus resulted in a linear increase in GFP 
expression. An increased amount of transduction was seen using lower 
volumes of crude supernatant suggesting that there were approximately twice 
as many viral particles present in the crude supernatant compared to the 
diluted concentrated virus. This experiment was designed to assess the loss of 
viral particles when concentrating the crude supernatant. When the amount of 
particles in the concentrated preparation was calculated, allowing for the 
dilution factor, there was a 20 fold increase in the viral yield when 
concentrating the virus by ultracentrifugation. This meant that it was worth 
while carrying out the concentration procedure to obtain more virus/ml.
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Figure 3.5 G F P  w as expressed in J u r k a t  cells trea ted  
w ith increasing  am oun ts o f len tiv irus.
lx l0 6 Jurkat cells were treated with increasing amounts of 
concentrated GFP lentivirus and incubated at 37°C for 48 hours. 
Figures a (i-iv) illustrate the GFP expression in samples treated with 
0, 2, 8 and 32pl of lentivirus respectively. The increase in GFP 
expression is illustrated following the use of viral supernatant (b) and 
concentrated lentivirus (diluted 1/40) (c).
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3.4.3 Treating Primary CLL cells with GFP virus
Adding increasing amounts of GFP virus to the CLL cells saw a dose- 
dependent increase in the amount of GFP expressed (Figure 3.6.a). In the 
titration experiment a maximum of 35% of the CLL cells were transduced by 
adding 64pl of the GFP virus (Figure 3.6.a). Addition of more virus did not 
result in an increase in GFP expression in this sample. An estimation of the 
number of infectious viral particles present in 1 pi of virus was then made and 
the multiplicity of infection (MOI), which is a measure of the number of viral 
particles required to infect one cell, was determined and applied to all 
subsequent experiments (using this particular batch of virus). The maximum 
amount of transduction was 35% GFP expression using 64pl of concentrated 
virus, lx l0 6 CLL cells were used in the experiment which meant that 350,000 
cells were GFP positive following the addition of 64pl of virus. Taking this 
number (which was the maximum amount of cells transduced) as 100% 
transduction, a figure was generated illustrating the expression of GFP as a 
percentage of the maximum expression (Figure 3.6.b). Using values of the 
number of cells transduced as a percentage of the maximum, the MOI was 
calculated for the GFP virus (Figure 3.6.c). Table 3.1 shows the number of 
CLL cells transduced using increasing amounts of GFP lentivirus. Assuming 
that one viral particle infects one cell, and taking a mean of the three values 
obtained from the linear range (illustrating a linear increase on the graph in 
Figure 3.6.a), the number of particles per microlitre was estimated to be 
82,341 (Table 3.1). From figure 3.6.a it can be seen that 64pl of virus was 
required to transduce the maximum number of CLL cells.
From the equation:
Number of Viral particles/ul x Volume of Virus (ul) = 82341 x 64 = 5.3 
Number of cells being transduced 1000000
an MOI of 5.3 was required to transduce the maximum number of CLL cells.
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Figure  3.6 M ultip licity  o f infection (M O I) calculated 
from  G F P  v iru s  trea ted  C L L  cells.
Increasing amounts of GFP lentivirus were added to lx l0 6CLL cells. 
Following 48 hours incubation GFP expression was determined by 
flow cytometry. The increase in GFP expression in was calculated as 
the percentage GFP expression (a), the percentage of the maximum 
expression (b) and subsequently the multiplicity of infection (c).
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Microlitres of 
virus
% GFP 
expressing cells
Number of cells 
transduced
Infectious 
particles per 
microlitre
2 20.7 207261 103,631
4 35.2 352118 88,030
8 44.3 442889 55,361
Mean 82,341
St Dev 24,633
T able 3.1 T itra tio n  o f G F P  len tiv iru s on C L L  cells.
There was a mean of 82,341 infectious virus particles per 
microlitre of concentrated GFP virus.
Microlitres of 
virus
% CD38 
expressing cells
Number of cells 
transduced
Infectious 
particles per 
microlitre
2 23.0 230321 115,161
4 22.9 228802 57,201
8 47.0 470007 58,751
Mean 77,037
St Dev 33,025
Table 3.2 T itra tio n  o f CD 38 len tiv irus on C L L  cells.
There was a mean of 77,037 infectious virus particles per 
microlitre of concentrated CD38 virus.
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3.4.4 CD38 virus on CLL cells
Following expression of GFP in Jurkat and primary CLL cells, a plasmid 
containing the same HIV 1-derived backbone was generated containing the 
gene encoding CD38. The same helper plasmids were utilised, (namely A8.91 
and MD2G) and the lentivirus was again generated using the 293T packaging 
cell line, under the same conditions as used for the GFP virus including 
concentration using ultracentrifugation.
Primary CLL cells were treated with the concentrated CD38 virus. A dose 
dependent increase in CD38 expression was seen in the CLL cells following 
infection with the CD38 virus with a maximum transduction of 93% in the 
titration experiments (Figure 3.7.a). The optimum amount of CD38 virus 
required to infect the largest percentage of the CLL cells without using excess 
virus was estimated at 40pl of concentrated virus for lx l 06 CLL cells (Figure 
3.7.a). Again the amount of virus present was estimated using the linear slope 
of the graph and a mean of 77,037 infectious particles per microlitre was 
calculated for the CD38 virus (Table 3.2). From the equation (above) 40pl of 
CD38 lentivirus corresponded to an MOI of 3.2. Figure 3.8 illustrates the 
CD38 expression in a single CLL sample before (Figure 3.8.a) and following 
the addition of CD38 virus (MOI 3.2) (Figure 3.8.b). CD38 was not expressed 
at high levels in cells from the same patient treated with GFP virus at an MOI 
of 3.2 (Figure 3.8.c). A CD38 positive patient was run in parallel as a positive 
control for the experiment (Figure 3.8.d). Figure 3.8.e illustrates the increase 
in CD38 expression using an overlay of the histograms for untreated and 
CD38 virus treated samples.
3.4.5 Summary of MOI
Titrating the virus on CLL cells illustrated that the number of infectious 
viral particles contained within lp l of both the GFP and the CD38 virus was 
comparable (82,341 and 77,037 infectious particles per microlitre for the GFP 
virus and CD38 virus respectively). Thus, using an equal volume of GFP virus 
(compared to CD38 virus) in subsequent experiments constituted an 
appropriate control which would distinguish the effects of CD38 expression 
from the effects of generic viral infection.
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F igure  3.7 High levels o f CD38 expression w ere observed 
following the add ition  o f increasing  am ounts o f 
len tiv irus.
lxlO6 CLL cells from a CD38 negative patient were treated with 
increasing amounts of CD38 virus and the expression of CD38 on the 
surface was measured by the percentage of cells expressing the antigen 
(a) and by the MFI (b). Following calculation of the number of viral 
particles per microlitre, the multiplicity of infection was determined 
for each amount of virus added. This is illustrated in (c) where an MOI 
of 3.2 is sufficient to transduce more than 80% of the CLL cells.
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Figure 3.8 An M O I o f 3.2 tran sd u ced  over 90%  o f C L L  
cells in a single p a tien t sam ple.
Primary CLL cells were isolated from a fresh patient sample and lx l0 6 
cells were treated with lentivirus. In the untreated control sample 5% 
of the CLL cells expressed CD38 on the surface (a). Following the 
addition of 128pl of CD38 virus 94% of the cells expressed the CD38 
antigen (b). Addition of GFP virus induced an increase in CD38 
expression in a small percentage of the cells (10%) (c). Figure 3.8d 
illustrates the native CD38 expression of a CD38 positive patient. The 
increase in CD38 expression in the CD38 virus treated CLL sample 
compared to the negative control is illustrated in (e).
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3.4.6 Quantification of lentivirus using the Retro-tek p24 ELISA
Calculating the number of viral particles by titrating the CD38 and GFP 
virus to CLL cells illustrated that similar amounts of virus were being 
generated within the individual preparations. To support these findings the 
virus was quantified using a p24 ELISA. Figure 3.9 illustrates that a 
comparable amount of the p24 gag gene product was present in both CD38 
and GFP virus preparations with values of 77,790,698 particles/pi 
(±16,190,667±SD) and 78,468,992 particles/pl (±14,430,044±SD) 
respectively.
3.4.7 CD38 expression in CLL cells treated with CD38 and GFP 
virus
CD38 is a marker of activation in many different cell types. The infection 
of CLL cells with concentrated lentivirus may have the potential to activate 
the cells and induce the expression of CD38 on the surface. It was therefore 
important to determine the expression of CD38 on CLL cells following 
treatment with the control GFP virus. CLL cells were treated with equal 
amounts of both GFP and CD38 virus. Figure 3.10.a illustrates the CD38 
expression in cells infected by each virus. There was no dose related increase 
in the number of cells expressing CD38 or in the MFI (Figure 3.10.b) for cells 
treated with the GFP virus. This clearly demonstrates that the increase in 
CD38 expression in the CD38 negative primary CLL cells is due to the 
specific expression of the CD38 gene integrated into the genome (the 
provirus) following the addition of CD38 virus.
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F igure  3.9 C o m p arab le  am oun ts o f len tiv irus w ere 
p resen t in both  CD38 and  G F P  p rep a ra tio n s .
1/500,1/1000, 1/2500 and 1/5000 dilutions of the CD38 and GFP virus 
were prepared and placed into the wells of the The Retro-tek p24 
ELISA plate. The fluorescence of the tertiary streptavidin-peroxidase 
substrate was quantified at 450nm and the amount of p24 antigen was 
calculated as a mean of the two dilutions.
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F igure  3.10 CD38 w as no t expressed following the use of 
the  contro l G F P  len tiv irus.
lxlO6 CLL cells were treated with increasing amounts of CD38 and 
GFP virus and incubated at 37°C for 48 hours. The cells treated with 
the CD38 lentivirus express the antigen at high levels, where as the 
GFP virus treated cells do not express CD38. This is illustrated when 
plotting the percentage of cells expressing CD38 (a) and the MFI of 
the sample (b).
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3.4.8 CD38 gene expression in CLL cells by quantitative reverse 
transcription PCR (QRT-PCR)
Flow cytometry demonstrated that following transduction CD38 negative 
CLL cells expressed the CD38 antigen. To confirm these results QRT-PCR 
experiments were carried out to quantify the relative change in CD38 mRNA 
in transduced and untransduced samples. Figure 3.11 illustrates the QRT-PCR 
plot of a single sample following transduction. Using ABL expression as a 
house-keeping control gene, a 17,800 fold increase in the expression of 
mRNA encoding the CD38 gene was detected by QRT-PCR following the 
addition of CD38 lentivirus (Mean of 6 patient samples (SD±12,173)). A 7- 
fold increase in the gene expression of CD38 was detected in the GFP virus 
treated samples compared to the untreated control samples (Mean of 6 patient 
samples (SD±14)) (see Chapter 5.2).
3.4.9 Treating multiple patient samples with CD38 virus and control GFP 
virus
With many of the conditions required for maximum transduction 
optimised, further CD38 negative patient samples were infected to determine 
whether the high levels of CD38 transduction could be achieved in all of the 
samples tested. In total, 17 CD38 negative CLL samples (mean 3% SD±2%) 
were treated with the CD38 virus and the mean CD38 expression was 87% 
(SD±8.5%) (Figure 3.12). Seven patient samples from this cohort were also 
treated with GFP lentivirus to observe the effects of lentivirus on CLL cells. A 
mean of 8% (SD±6%) CD38 expression was observed in this cohort. P values 
were calculated from paired samples.
3.4.10 Stable CD38 expression in CLL cells
Following 48 hours incubation with lentivirus CD38 was expressed at 
high levels on the surface of CD38 negative CLL cells. To establish whether 
the expression of the antigen was stable over a longer period, the CLL cells 
were transduced and monitored for the expression of CD38 on the surface 
over a period of five days. Figure 3.13.a illustrates the stable expression of 
high levels of CD38 over the period of five days, compared to untreated 
controls, in a single patient sample (measured as the percentage of cells
91
Chapter 3 Genetic modification o f primary CLL cells
©
SQ.
•  3-
GFP Virus Uninfected
CD38 Virus
• 2
Cycles
Figure 3.11 CD38 w as highly expressed a t the level o f 
tran sc rip tio n  in C L L  cells illu stra ted  by qu an tita tiv e  
reverse tra n sc rip tio n  PC R .
Total RNA was extracted from virally treated CLL samples (MOI
3.2) and QRT-PCR was carried out to observe CD38 gene expression. 
The expression of mRNA encoding CD38 was determined relative to 
the ABL house keeping gene. A mean of 20,000 fold increase in the 
expression of CD38 was calculated in a single sample following the 
addition of CD38 lentivirus (compared to the untreated sample).
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Figure 3.12 CD38 w as expressed in m ultip le sam ples 
follow ing the add ition  o f CD38 len tiv irus.
17 CD38 negative patient CLL samples were treated with CD38 
lentivirus at an MOI of 3.2. There was a significant increase in the 
expression of CD38 on the surface of these samples compared to 
untreated and GFP virus treated samples (p<.0.001). The mean 
expression in the untreated sample was 3% (SD = 1.8)(n=17), the 
CD38 virus treated sample 87% (SD = 8.5)(n=17) and the GFP virus 
treated sample 8% (SD = 5.8)(n=7). There was no significant increase 
in the expression of CD38 in GFP treated samples compared to the 
untreated cells (p=0.2). (The student Mest was applied to paired 
samples).
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Figure 3.13 CD38 was expressed in CLL cells for up to 5 
days.
CLL cells were treated with CD38 lentivirus at an MOI of 3.2 and 
incubated at 37°C. A sample of the cells was phenotyped each day for 
5 days to observe CD38 expression. The number of cells transduced 
is determined from the percentage of cells expressing CD38 (a) and 
from the MFI (b).
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expressing CD38). Figure 3.13.b illustrates the MFI of the sample over the 
same period.
3.5 Discussion
The majority of the CLL cells in the peripheral circulation are in a non­
dividing state. In vitro, these cells are resistant to genetic modification through 
transfection of double or single stranded coding molecules or transduction of 
retroviral vectors. Various groups have evaluated such techniques and have 
reported contrasting results for the manipulation of gene expression in CLL 
cells. In 2007 Seiffert et al. reported a high level of transduction with the use 
of nucleofection of a plasmid vector encoding GFP, while in 2008 Van 
Bockstaele et al. succeeded in transfecting CLL cells using electroporation of 
in vitro transcribed mRNA (Seiffert et al., 2007, Van Bockstaele et al., 2008). 
Both groups reported high levels of cell viability as well as the inefficiency of 
other gene transfer techniques assessed. With this contrasting evidence in 
mind, all three methods of genetically modifying CLL cells were evaluated in 
this chapter.
Nucleofection of a plasmid vector incorporating a GFP-CD38 fusion gene 
resulted in transfection of 34.5% of the CLL sample. However, this was 
associated with a large amount of cell death and in order to recover a pure 
population of genetically modified cells they had to be physically sorted. This 
in turn, induced further cell death. Given that the aim of this project was to 
carry out functional studies on genetically modified cells, the requirement of 
large numbers of patient cells for nucleofection meant that patient samples 
were limited to those with high lymphocyte counts (Above 3x10 cells/ml). 
Also sorting the cells following nucleofection was time consuming and 
yielded a small number of genetically modified cells from which to extract 
genetic material for QRT-PCR and microarray investigations.
The second transfection method evaluated was electroporation of in vitro 
transcribed mRNA coding for GFP. Twenty four hours post electroporation 
the CLL cells were assessed for the expression of GFP using flow cytometry. 
No increase in fluorescence was observed in the sample following 
electroporation with increasing concentrations of IVTmRNA. Again a 
considerable amount of cell death occurred. In complete contrast to the results
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obtained by Van Bockstaele et al. in 2008, this method of gene transfer was 
unsuccessful in multiple experiments. Due to the success of the other 
techniques evaluated at the same time, further optimisation of this 
methodology was not carried out.
The use of a VSVG pseudotyped lentivirus in genetically modifying CLL 
cells has been attempted with varying success (Bovia et a l , 2003, Janssens et 
al., 2003, Serafim et al., 2004, Levy et al., Hazan-Halevy et al.). However, as 
an alternative to the transfection techniques, I decided to evaluate the 
lentiviral transduction method in our laboratory. Infection of Jurkat cells with 
a lentivirus housing the gene encoding GFP resulted in a dose-dependent 
increase in GFP expression in 100% of the cells treated. Levels of expression 
in CLL cells treated with GFP virus reached a maximum of 60% (Appendix 3) 
which is higher than previously reported (Van Bockstaele et a l , 2008, Frecha 
et a l , 2009). Following infection with lentivirus expressing CD38, up to 95% 
of the CLL cells treated were shown to express de novo CD38 with a mean 
transduction efficiency of 87% in 17 patient samples (Figure 3.12). The 
reason for such success using the pHR' SINcPPT SFFV-WPRE lentivirus is 
not clear. In a recent publication by Frecha et al. they compared the measles 
virus envelope glycoprotein to the VSVG envelope in the transduction of CLL 
cells (Frecha et a l , 2009). They suggested that both the viral envelope and the 
promoter used to drive the expression of the gene of interest were integral to 
the success of their lentiviral transduction system. In our experience 
pseudotyping the viral core with the VSVG envelope, which resulted in little 
transduction in their system, was highly successful. However, the SFFV 
promoter used in our lentiviral construct differed from the CMV promoter 
which they utilised. It seems likely that the combination of promoter and viral 
envelope used in our system facilitates the transduction process at multiple 
levels.
Generation of a lentivirus with the same viral back bone, but expressing a 
non-human reporter gene, was essential for two reasons: Firstly to ensure that 
the expression of CD38 was derived from the provirus incorporated into the 
host genome and not endogenous CD38 expression due to viral activation; and 
secondly as a control in subsequent experiments to distinguish the generic 
effects of the virus from the specific increase in CD38 expression on the CLL
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cell surface. The reporter gene utilised was derived from the Jelly fish 
(Aequorea Victoria) and expressed the green fluorescent protein which, 
following expression, can be observed in the transduced cells using a 
fluorescence microscope or within the FL1 channel of the flow cytometer 
(488nm laser line) (Xu et al., 1998). In order to constitute an accurate control, 
the GFP virus was added to the CLL cells in equal amounts to the CD38 virus. 
Both viruses were titrated on CLL cells to determine the number of viral 
particles present in one microlitre of each of the concentrated viral 
preparations. The results illustrated that there were comparative amounts of 
CD38 and GFP virus in each concentrate and therefore equal volumes of GFP 
virus could be used to infect CLL cell samples and provide an appropriate 
control in each of the experiments. This was confirmed by the use of an 
ELISA technique to detect soluble p24 protein, a product of the gag gene 
derived from the lentivirus. Comparative amounts of the p24 protein were 
detected in both viral preparations (Figure 3.9). The multiplicity of infection, 
which is the number of viral particles required to infect one cell, was also 
determined and employed when comparing individual virus preparations and 
scaling up the experiments to use large cell numbers. Following transduction 
of the CLL cells with the CD38 virus, flow cytometry was utilised to quantify 
the levels of CD38 expression over five days. Figure 3.13 illustrates that the 
expression of CD38 on CLL cells was stable over five days, determined by 
both the percentage of CLL cells expressing the antigen (Figure 3.13.a) and 
the mean fluorescence intensity (Figure 3.13.b).
Of the three methods of gene delivery evaluated the lentiviral 
transduction of CLL cells proved the most successful in generating large 
numbers of viable CD38 positive cells from a CD38 negative sample. This 
method caused substantially less cell death than the transfection techniques 
(discussed in chapter four) and eliminated the requirement for cell sorting or 
selection. A consistently high level of transduction was achieved in 17 patient 
samples treated (mean 87% SD±8.5%) providing a homogeneous background 
with which to perform further investigations.
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Chapter 4. CD38 ligation enhances the viability 
and proliferation of primary CLL cells
4.1 Introduction
The presence of CD38 on the surface of CLL cells confers a poor 
prognosis (Damle et al., 1999) but the biological rationale for this remains 
uncertain. Chapter three describes the development of a lentiviral vector 
system for inducing CD38 on the surface of CLL cells. This technology was 
utilised to investigate the role of CD38 in regulating the survival and 
proliferation of primary human CLL cells.
It is now presumed that due to the absence of specific signals from the 
tissue microenvironment, CLL cells do not survive for prolonged periods ex 
vivo (Bomstein et al., 2003). As they progress through the stages of apoptosis, 
CLL cells shrink and therefore increase in granularity prior to cellular 
fragmentation. With the use of flow cytometry, a population of apoptotic cells 
may be identified by observing changes in forward and side light scatter 
(Figure 4.1.a). An alternative, and more direct, means of assessing apoptosis 
involves the labelling of phosphatidylserine on the surface of the cells via 
binding of its ligand annexin V.
Annexin Vstaining
The cellular cytoplasmic membrane is made up of asymmetrically 
distributed phospholipids (Alberts et al 1994). Phosphatidylserine is normally 
located on the inner leaflet of the bilayer. However, during apoptosis a 
reduction in intra-cellular ATP results in the inability of a cell to retain 
phosphatidylserine on the inner membrane. Subsequently the molecule “flips” 
and is presented on the outside of the cell (Seigneuret and Devaux, 1984). 
Annexin V may be labelled with a fluorescent molecule which, when bound to 
phosphatidylserine on the outer membrane, can be detected using flow 
cytometry. The addition of propidium iodide to the cells within this assay 
identifies dead cells as well as those in a progressive apoptotic state 
(Steinkamp et al., 1999).
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Figure 4.1 C L L  cell su rv ival w as increased  following the 
add ition  o f len tiv irus.
(a) lx l 06 CLL cells were placed into liquid culture and incubated for 
48 hours with or without lentivirus. The CLL cell viability was 
assessed in untreated, CD38 virus treated and GFP treated samples, (b) 
Increasing amounts of CD38 virus were added to lx l0 6 CLL cells and 
CD38 expression was assessed by flow cytometry following 48 hours 
incubation, (c) Using forward and side scatter profiles the viability of 
the samples was assessed after 48 hours.
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4.2 CLL cell survival was enhanced over 48 hours following the addition 
of lentivirus
To investigate the effects of CD38 on the survival of CLL cells in vitro, 
CD38 negative CLL cells were transduced using CD38 virus and incubated in 
liquid culture for 48 hours to allow expression of the CD38 antigen. Cell 
viability was then assessed using forward and side scatter profiles obtained by 
flow cytometry. Viable cells were identified by the R1 gate (Figure 4.1.a). In 
the early stages of apoptosis the cells shrink. They show a reduction in 
forward light scatter, an increase in side light scatter and hence appear in the 
R2 gate. As the cell membrane disrupts in the latter stages of apoptosis the 
membrane blebs and finally fragments. The resultant cell debris is observed in 
the R3 gate (Figure 4.1 .a). Using this method the number of viable cells was 
calculated in untreated (Figure 4.1.a.i), CD38 virus (4.1.a.ii) and GFP virus 
(4.1 .a.iii) treated CLL samples by using the formula:
Viable cells = Rl/(R1+R2)xl00.
The percentage of viable cells was 66%, 78% and 76% in untreated, 
CD38 virus and GFP virus treated samples respectively (Figure 4.l.a). 
Increasing amounts of lentivirus were added to CLL cells from a single 
patient and CD38 expression was measured by flow cytometry (Figure 4.1.b). 
Subsequently cell viability was assessed by using the forward and side light 
scatter profiles. There was an increase in the number of viable cells following 
the addition of CD3 8-expressing lentivirus although this did not appear to be 
in a dose-dependent manner (Figure 4.1.c). A GFP-expressing lentivirus was 
also used to treat cells in multiple samples and an MOI of 3.2 was used for 
both the CD38 and the GFP virus. Figure 4.2 illustrates the viability of CLL 
cells from 21 untreated samples, 21 CD38 virus treated samples and 14 GFP 
virus treated samples. A mean of 63% ±15.6 (±SD) viable CLL cells were 
present following 48 hours incubation in the untreated sample. A mean of 
74% ±16.7 (±SD) viability was observed in the CD38 virus treated samples 
and 71% ±20.8 (±SD) in the GFP virus treated samples. The viability was 
significantly increased in the CD38 lentivirus treated samples
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Figure  4.2 C L L  cell v iability  w as increased in m ultiple 
v iru s trea ted  sam ples follow ing 48 hours in cu ltu re.
Multiple patient samples were isolated in liquid culture for 48 hours. 
The viability of the cells was assessed in untreated, CD38 virus treated 
and GFP virus treated samples using forward and side scatter. The 
student t-test was used to compare the viability between paired 
samples.
100 Uninfected
CD38 Virus
GFP VirusSt 60 •
53 41 20
Days Post Infection
Figure 4.3 C L L  cell v iab ility  w as increased  in v irus 
trea ted  sam ples assessed over 5 days in liquid  cu ltu re.
lxlO6 CLL cells from three patients were untreated, CD38 virus 
treated or GFP virus treated and incubated in liquid culture for 5 days. 
The viability of the cells was assessed using forward and side scatter at 
day 0, 1, 2, 3 and 5.
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compared to the untreated samples (P=0.01. (calculated from 21 paired 
samples)). There was no significant difference in the viability between 
untreated samples and cells treated with GFP virus (P=0.41. (14 paired 
samples)) or between CD38 treated and GFP treated samples (P=0.92. (14 
paired samples)). Therefore the addition of lentivirus seemed to have an effect 
on the survival of the CLL cells in liquid culture. The effect of CD38 
signalling may have been masked by such an effect.
4.3 CLL cell survival was enhanced over three days following the 
addition of lentivirus
The generic effects of the lentivirus on CLL cell viability over 48 hours 
made analyzing the role of CD38 in the modulation of cellular survival 
challenging. However, it did not negate the hypothesis that CD38 could 
increase CLL cell viability. To determine whether longer time points would 
establish if CD38 expression regulated viability, cells were incubated for up to 
five days and the viability was assessed. CLL cells were treated with CD38 
and GFP lentivirus (MOI 3.2) and incubated in liquid media. Using forward 
and side scatter, the viability of three patient samples was evaluated. Figure
4.3 shows a survival advantage for CLL cells treated with lentivirus over the 
first three days, though the difference in CLL cell viability was not significant 
(P=0.21 in untreated compared to GFP virus treated and P=0.2 in untreated 
compared to CD38 virus treated samples). Also the viability of the untreated 
and virus treated samples was not significantly different following five days in 
liquid culture (P=0.48 in untreated compared to GFP virus treated and P=0.42 
in untreated compared to CD38 virus treated samples).
4.4 Addition of lentivirus caused enhanced expression of 
phosphatidylserine on the CLL cell surface
Forward and side scatter profiles identify dying cells that decrease in size 
as they progress through programmed cell death. Annexin V staining can be 
used to detect phosphatidylserine on the surface of the cell providing an 
alternative means of assessing apoptosis. The annexin V investigation was 
carried out to further investigate the effects of CD38 on CLL viability. The 
vital dye propidium iodide was used in tandem with annexin V to discriminate
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between early and late stage apoptotic cells. Figure 4.4.a illustrates that 32% 
of the CLL cells were annexin V and PI positive in the untreated sample 
following 48 hours incubation. In virally treated samples however, it appears 
that a much larger portion of the CLL cells were annexin V positive with 93% 
of the cells treated with CD38 virus and 81% of the cells treated with GFP 
virus showing evidence of phosphatidylserine on their surface (Figure 4.4.a). 
The CLL cells were left in culture for five days and apoptosis/cell death was 
again assessed by annexin V/PI staining. In the untreated sample 61% of the 
cells were viable after 5 days (Figure 4.4.b). In contrast, the virally treated 
CLL cells were almost all annexin V/PI positive (97% and 96% in CD38 virus 
and GFP virus treated samples respectively) (Figure 4.4.b).
Forward and side scatter plots denote a large population of viable cells in 
lentivirally treated samples following 48 hours in liquid media. Conversely, 
annexin V/PI staining identified the presence of large numbers of apoptotic 
cells. Due to the conflicting evidence regarding the viability of the CLL cells 
further investigations were carried out to observe at which point, following 
the addition of lentivirus, the cells began to express phosphatidylserine on the 
surface. In a series of time course experiments the CLL cells were treated with 
CD38 and GFP virus and annexin V staining was assessed using flow 
cytometry. After one hour, the CLL cells were stained with annexin V/PI to 
detect the expression of phosphatidylserine on the surface. As expected, the 
untreated sample showed very little staining and only 6% of the freshly 
isolated CLL cells maintained in liquid media were annexin V/PI positive 
(Figure 4.5.a). After the same time period, 34% of the CLL cells treated with 
CD38 virus and 43% of those treated with the GFP control virus were annexin 
V/PI positive (Figure 4.5.a). Annexin V staining following two hours 
incubation identified an increase in the number of apoptotic cells in the 
untreated sample (a total of 13%) with much larger increases observed for the 
virus treated samples (49% in both CD38 and GFP virus treated samples) 
(Figure 4.5.b). CLL cells were incubated for an additional four and six hours 
following infection with lentivirus and subsequently analysed for annexin V 
and PI staining. Figure 4.6 summarises the proportion of the sample that was 
annexin V/PI positive at each of the time points in untreated and virus treated 
samples. The detection of phosphatidylserine on the cell surface occurred
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Figure  4.4 A large  popu lation  of the C L L  cells w ere 
annexin  V /PI positive a f te r  2 and  5 days incubation  with 
len tiv irus.
(a) lxlO6 CLL cells were treated with lentivirus and placed into liquid 
media for 48 hours. Viability was assessed in untreated, CD38 virus 
treated and GFP virus treated samples using annexin V/PI staining, (b) 
lxlO6 CLL cells were treated with lentivirus and placed into liquid 
media for 5 days. Viability was assessed in untreated, CD38 virus 
treated and GFP virus treated samples using annexin V/PI staining.
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Figure 4.5 A nnexin V positive C L L  cells w ere observed 
a fte r  1 and  2 ho u rs  incuba tion  w ith len tiv irus.
(a) lxlO6 CLL cells were incubated for 1 hour with lentivirus and 
CLL cell viability was assessed by annexin V/PI staining. The 
number of annexin V/PI positive cells was determined in untreated, 
CD38 virus and GFP virus treated samples, (b) lxlO6 CLL cells were 
incubated for 2 hours with lentivirus and CLL cell viability was 
assessed by annexin V/PI staining. The number of annexin V/PI 
positive cells was determined in untreated, CD38 virus and GFP virus 
treated samples.
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Figure  4.6 A nnexin V /PI sta in ing  identified a large 
n u m b er o f a p p a ren tly  apop to tic  cells 1 h o u r a fte r  the 
add ition  o f len tiv irus.
lxlO6 CLL cells were incubated for 6 hours with and without 
lentivirus. Samples from untreated, CD38 virus treated and GFP virus 
treated CLL preparations were stained for annexin V/PI at 0, 1, 2, 4 
and 6 hours.
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rapidly following the addition of lentivirus (within one hour). Given that this 
effect was observed with both the GFP-expressing virus and the CD38- 
expressing virus, it seems likely that it is a generic artefact induced by 
exposure to the virus and may be due to the interactions with the cell 
membrane rather than apoptosis induction at such early time points. There is 
no evidence suggesting that the VSVG pseudotyped virus has the ability to 
disrupt the cell membrane though a report by Benjouad et al illustrated the 
ability of the Tat protein to modify the permeability of the cell membrane and 
induce cell death in lymphocytes (Benjouad et al., 1993).
4.5 CLL cell morphology identified viable CLL cells following the 
addition of lentivirus
The evidence from the annexin V/PI investigation indicates that the virus 
treated cells were undergoing apoptosis. In contrast the forward and side 
scatter profiles, obtained from the same flow cytometry assays, identified a 
large viable population of cells 48 hours after treatment with lentivirus. To 
determine whether the CLL cells were undergoing apoptosis, untreated and 
virus treated CLL samples were cultured for 48 hours and then spread onto 
glass slides. They were then stained using the Giemsa dye and scrutinised 
under the microscope for evidence of apoptotic cell death. In the early stages 
of apoptosis the cell begins to shrink due to cleavage of lamins and actin 
filaments in the cytoskeleton (Fluckiger et a l , 1994). Chromatin in the 
nucleus is broken down and forms a tightly packed horse-shoe like structure. 
Blebbing of the cell membrane then occurs and small fragments of the cell 
break off to be engulfed and processed by macrophages (Fluckiger et al., 
1994). Figure 4.7.i and iv illustrate untreated CLL cells from a Giemsa stained 
CLL lymphocyte preparation. There was no evidence of cell shrinkage or of 
the latter stages of apoptosis. Figure 4.7.ii, iii, v and vi show CLL cells 
incubated with CD38 and GFP lentivirus. Again there was no evidence of cell 
shrinking or condensation of the chromatin. Figure 4.7.b.i illustrates a freshly 
stained blood smear from a patient with CLL and Figure 4.7.b.ii shows CLL 
cells undergoing apoptosis. In the latter there was an obvious reduction in the
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a i Untreated CD38 virus
f t
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Zeiss Axio microscope (x100)
Untreated CD38 virus
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*
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f t
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b.i and ii adapted from Fluckiger et a/., 1994
Figure 4.7 M orpho logy  o f u n trea ted  and  v irus trea ted  
C L L  cells follow ing 48 hou rs incubation .
(a) lxlO6 untreated (i and iv) CD38 virus treated (ii and v) and GFP 
virus treated CLL cells (iii and vi) were stained with Giemsa dye and 
analysed using a using a Zeiss Axio microscope (i-iii) or a Nikon 
DXM1200F Digital microscope (iv-vi). All images are at xlOO. (b) (i) 
Viable lymphocytes (ii) highlights the features of apoptotic 
lymphocytes. Both are adapted from: Fluckiger et al. (1994). (V, viable 
cells, A, cells undergoing apoptosis, showing chromatin condensation 
and nuclear fragmentation indicate apoptosis, G, ghost cells).
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size of the cells with darkly stained chromatin clumps within the degrading 
nucleus. Therefore, morphological analysis of the CLL cells under the 
microscope clearly illustrates that the CLL cells are not undergoing apoptosis 
following 48 hours incubation with lentivirus. This work contradicts the 
annexin V/PI assay data and adds weight to the assertion that 
phosphatidylserine is aberrantly exposed on the surface of CLL cells 
following exposure to lentivirus and is not associated with the induction of 
apoptosis.
4.6 CD38 was lost from the surface of lentivirus treated CLL samples 
following incubation in co-culture
Due to the effects of the lentivirus on the CLL cell the annexin V/PI 
staining method was deemed not suitable for assessing CLL cell viability in 
treated samples. Forward and side scatter data illustrated that there was no 
significant difference in the viability of the CLL cells following the addition 
of CD38 or GFP virus at an MOI of 3.2 (Figure 4.2). These cell populations 
were incubated in liquid media for 48 hours before assessing viability. Within 
the in vivo CLL cell microenvironment various cell stimuli exist which are 
known to enhance the survival of the CLL cells (Caligaris-Cappio, 2003). 
CD31 is a molecule which is present on many cell types including endothelial 
cells and has been described as the only known ligand for CD38 (Deaglio et 
al., 1996). It is possible that ligation of CD38 on the surface of the CLL cell 
may be required to induce CD38-mediated cell survival mechanisms. To 
further assess the role of CD38 in CLL cell survival, lentivirally transduced 
CLL cells were placed into co-culture with adherent fibroblasts expressing 
CD31. After 48 hours the CLL cells were removed from the co-culture and 
the percentage of apoptotic cells was determined using forward and side 
scatter. Sixty eight percent of the untransduced cells placed in liquid media 
were still viable after 48 hours (Figure 4.8.i). A sample of the same cells, 
which had been transduced using the CD38 virus, showed 87% viability over 
the same time period (Figure 4.8.ii). When co-cultured on control fibroblasts 
(NTL), CLL viability was enhanced in both the untransduced (93%) and 
CD38-transduced (92%) CLL samples (Figures 4.8.iii and iv respectively). 
Incubation with CD31-expressing fibroblasts further enhanced the CLL cell
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Figure  4.8 C o-cu ltu re  enhanced  the surv ival o f un trea ted  
and  CD38 tran sd u ced  C L L  cells.
lxlO6 CLL cells were placed into liquid media for 48 hours and the 
viability was assessed using forward and side scatter (i). Additional 
samples were placed into co-culture with (iii) NTL and (v) CD31- 
expressing co-cultures, lx l0 6 cells from the same patient were 
transduced using the CD38 virus and viability was assessed following 
48 hours incubation in (ii) liquid media (iv) NTL and (vi) CD31- 
expressing co-culture.
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viability. Untreated CLL cells showed 95% viability (Figure 4.8.v) and CD38- 
transduced cells 96% viability (Figure 4.8.vi).
Forward and side scatter profiles illustrated that an increased number of 
cells were viable following incubation with both NTL and CD31-expressing 
fibroblasts. The stable expression of CD38 on the surface following 
transduction is shown in Figure 3.12. These samples were maintained in 
liquid media for up to five days. To ensure that there was no loss of CD38 
expression following incubation of the transduced cells in co-culture the CLL 
cells were stained for surface CD38. Figure 4.9.i illustrates CD38 transduced 
CLL cells incubated in liquid media. Sixty seven percent of the transduced 
cells expressed the CD38 antigen. Following incubation in NTL (Figure 
4.9.iii) and CD31-expressing co-cultures (Figure 4.9.v) there was almost a 
complete loss of CD38 expression on the cell surface of the CLL cells. As a 
control, CLL cells from a CD38 positive patient were incubated for 48 hours 
in liquid media and under co-culture conditions. There was no loss of CD38 
expression from the CD38 positive cells following incubation in liquid culture 
(90% CD38 expression) (Figure 4.9.ii), NTL co-culture (92% CD38 
expression) (Figure 4.9.iv) or CD31-expressing co-culture (90% CD38) 
(Figure 4.9.vi). These data provide further evidence that the lentivirus had an 
effect on the CLL cell membrane which resulted in the shedding of CD38 
from the surface when the cells were physically removed from the co-culture. 
Alternatively, it may be that virus-induced ectopic expression of CD38 results 
in the aberrant insertion of CD38 in the membranes of CLL cells which 
destabilises the protein and facilities its loss from the cell surface following 
cell-cell contact.
4.7 Incubating untransduced CLL cells with CD31-expressing co-culture 
enhanced survival
Figure 4.9 illustrates the loss of the CD38 antigen from the surface of the 
transduced CLL cells following incubation with co-culture. It is possible that 
the concentrated virus disrupts the CLL cell membrane resulting in the loss of 
CD38 following co-culture. Addition of lentivirus also promoted changes in 
the cell membrane that made the assessment of cell viability impossible using 
the annexin V/PI assay. Therefore, to assess the effect of CD38 on CLL cell
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Figure 4.9 CD38 expression  w as lost from  transduced  
C L L  cells follow ing incubation  in co-culture.
lxlO6 CLL cells were transduced with CD38 virus and incubated in 
liquid media or co-culture for 48 hours. The cells were then removed 
and flow cytometry was used to assess CD38 expression on the surface 
of CLL cells incubated in (i) liquid media, (iii) NTL co-culture and (v) 
CD31-expressing co-culture. lxlO6 CLL cells from a CD38 positive 
sample were incubated under the same conditions. CD38 expression 
was determined in cells incubated in (ii) liquid media, (iv) NTL co­
culture and (vi) CD31 -expressing co-culture.
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survival, fresh patient samples expressing varying amounts of CD38 were 
incubated using co-culture conditions and annexin V/PI staining was carried 
out. Figure 4.10 illustrates the percentage of annexin V/PI positive CLL cells 
in a single sample following 48 hours in liquid media (Figure 4.10.i), NTL co­
culture (Figure 4.10.ii) and CD31-expressing co-culture (Figure 4.10.iii). The 
percentage of annexin V/PI positive cells was 63.0%, 11.2% and 10.5% 
respectively. A total of fifteen patient samples were incubated for 48 hours 
under liquid and co-culture conditions and viability was assessed. An increase 
in CLL cell viability was observed following incubation with the CD31- 
expressing fibroblasts compared to liquid media (P<0.001) and compared to 
NTL co-culture (P=0.008) (Figure 4.11).
4.8 CD38 expression did not correlate with CLL cell survival following 
incubation in co-culture
Incubation with CD31 -expressing co-culture enhanced the viability of the 
CLL cells. To determine whether CD38 played a role in this the constitutive 
CD38 expression was compared to the number of viable cells within the 
sample. For each patient the number of CD38 positive cells (percent) upon 
presentation was plotted against the number of annexin V/PI negative CLL 
cells (percent) incubated for 48 hours in CD31-expressing co-culture. Figure 
4.12 Illustrates that there was no correlation between the percentage of CD38 
expression and the viability of the sample (P=0.357). The data was analysed 
further and the difference between the viability of CLL samples incubated in 
CD31 -expressing co-culture and the viability of CLL cells incubated in NTL 
co-culture was plotted against their initial CD38 expression. Figure 4.13 
illustrates that there was a trend towards increased survival with increasing 
CD38 expression but the correlation was not significant from a total of fifteen 
patient samples investigated (P=0.2). There was also no significant correlation 
when the difference between the viability of CLL samples incubated in CD31- 
expressing co-culture and the viability of CLL cells incubated in liquid media 
was compared to initial CD38 expression (P=0.59).
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Figure  4.10 A nnexin  V /PI stain ing  illu stra ted  increased 
C L L  cell v iab ility  follow ing co-culture.
lxlO6 CLL cells were placed into culture and cell viability was 
assessed after 48 hours. Annexin V/PI staining was carried out on 
CLL cells incubated in (i) liquid media (ii) NTL co-culture and (iii) 
CD31-expressing co-culture.
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Figure 4.11 CLL cell viability was increased following 
incubation with CD31-expressing co-culture.
lxlO6 CLL cells were incubated in liquid media, NTL co-culture or 
CD31-expressing co-culture. Annexin V/PI staining was used to 
determine viability following 48 hours incubation. A total of 15 patient 
samples were assessed. A paired t-test was used to compare the 
viability between untreated and virus treated samples.
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Figure  4.12 T here  w as no co rre la tion  betw een C L L  cell 
v iab ility  and  CD38 expression .
The viability of each sample following 48 hours co-culture with 
CD31 expressing fibroblasts was compared to the native CD38 
expression (Percent) at day 0. The Spearman test was used to 
correlate the viability of the sample with CD38 expression.
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Figure  4.13 T h ere  w as a tren d  tow ards increased  C L L  
cell v iab ility  in sam ples expressing CD38 following 
incubation  w ith  C D 31-expressing  co-culture.
The difference between the viability of CLL samples incubated in 
CD31-expressing co-culture and the viability of CLL cells incubated 
in NTL co-culture was plotted against day 0 CD38 expression. The 
Spearman test was used to correlate the viability of the sample with 
CD38 expression.
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4.9 The proliferation of CLL cells was enhanced following incubation 
with CD31-expressing co-culture
Increased expression of CD38 occurs within the pseudofollicles of the 
lymph nodes. Within these sites there is an abundance of CD31 on the 
endothelial cells and increased levels of cytokines that promote cell survival 
and proliferation (Patten et al, 2008). These proliferation centres are thought 
to be the predominant location of CLL cell division (Herishanu et al., 2011). 
Whether CD38 signalling directly enhances the proliferation of the CLL cells 
within these regions is unknown. Bromodeoxyuridine (BrdU) added to 
proliferating cells is able to replace thymine during the process of DNA 
synthesis. Fluorescent antibodies against BrdU have been generated which 
can bind to the BrdU molecule incorporated within the newly synthesised 
DNA and can be detected by flow cytometry. When combined with PI 
staining for total DNA, a detailed representation of the cells’ position within 
the cell cycle can be obtained. CLL samples were placed into co-culture for 
32 hours. BrdU was then added and the sample was incubated in co-culture 
for a further 16 hours. The cells were fixed, permeabilised and incubated with 
anti-BrdU-FITC antibody. Propidium iodide was added before the cells were 
run on the flow cytometer. Figure 4.14 illustrates a 3-fold increase in BrdU/PI 
positive CLL cells following incubation with co-culture expressing CD31 
compared to cells incubated with the NTL co-culture in a single sample 
investigated. A sample of Jurkat cells was stained with BrdU and PI as a 
positive control.
An alternative means of identifying proliferating cells is to stain for the 
intracellular Ki-67 antigen. Ki-67 is a nuclear protein that is expressed in the 
cell during the cell cycle but is not present when the cell is in GO (Ross and 
Hall, 1995). CLL samples from twenty patients were incubated for up to five 
days in fibroblast co-culture expressing CD31 and the cells were stained for 
intracellular Ki-67. CLL cells co-cultured with NTL fibroblasts were used as a 
control. To further mimic the lymph node microenvironment, IL-2 was added 
to the co-culture media at a concentration of lOOIU/ml. This cytokine has 
been shown to result in inhibition of apoptosis in CLL cells and is secreted in 
the CLL microenvironment by T-cells (Decker et al., 2010). CD5/CD19 
positive CLL cells were fixed, permeabilised and stained using an anti-Ki-67-
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F igure  4.14 C L L  cells incubated  in CD31 co-culture 
show ed increased  B rdU  in co rp o ra tio n .
lxlO6 CLL cells were incubated in NTL or CD31-expressing co­
culture for 32 hours. lOpM BrdU was added and the sample was 
incubated for a further for 16 hours. The sample was then fixed and 
permeabilised before the addition of BrdU FITC antibody. Flow 
cytometry was used to determine the number of BrdU positive CLL 
cells following incubation with NTL and CD31-expressing co-culture. 
Jurkat cells were incubated in liquid culture for 5 hours with BrdU as a 
positive control.
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FITC antibody. Figure 4.15.i illustrates Ki-67 expression in the sample 
incubated for two days with NTL co-culture. There were a very small number 
of cells expressing Ki-67 (0.6%). Following incubation with CD31-expressing 
fibroblasts, more than five percent of the CLL cells were expressing Ki-67 
(Figure 4.15.ii). Figures 4.16.a, b and c illustrate the Ki-67 expression in 
twenty CLL patient samples following two and five days in co-culture. After 
two days the CLL sample incubated with the CD31-expressing co-culture 
showed a significant increase in the number of cells expressing Ki-67 
compared to the sample incubated with the NTL control fibroblasts 
(p=<0.001) (Figure 4.16.a. and b). However, there was no significant 
difference in the expression of Ki-67 between the CLL cells incubated for five 
days on CD31-expressing and NTL co-culture (p=0.097). This was probably 
due to the increase in Ki-67 expression in CLL cells incubated within the NTL 
co-culture at this time point (Figure 4.16.a and c).
4.10 Ki-67 expression correlated with increased expression of CD38
Increased Ki-67 expression was observed within 48 hours when co- 
culturing with CD31-expressing fibroblasts. The MFI values for Ki-67 
expression in CD31 co-culture were then correlated with constitutive CD38 
expression on day 0. Figure 4.17 illustrates that the increase in Ki-67 
following co-culture significantly correlated with the basal expression of 
CD38 on the surface of the CLL cells (R2=0.389, p<0.001). Ki-67 expression 
was then plotted for CD38 positive and negative CLL samples (cut-off 20%). 
There was a significant increase in Ki-67 observed in CD38 positive patient 
samples (P=0.003) (Figure 4.18).
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F igure  4.15 K i-67 expression w as increased in a C L L  
sam ple  follow ing 2 days incubation  w ith CD31- 
expressing  fib ro b la s t co-culture .
lxlO6 CLL cells were incubated with i) NTL and ii) CD31-expressing 
co-culture for 2 days. Flow cytometry was used to determine the Ki-67 
expression (Ki-67 FITC).
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Figure 4.16 Ki-67 expression was increased in CLL 
samples following 2 days incubation with CD31- 
expressing fibroblast co-culture.
lx l0 6 CLL cells were incubated with NTL and CD31-expressing co­
culture for 2 and 5 days. Flow cytometry was used to determine the 
Ki-67 expression in 20 CLL samples. A paired Mest was used to 
compare Ki-67 expression in the samples tested, (b) and (c) illustrate 
the Ki-67 expression at day 2 and 5 respectively. The paired samples 
within NTL and CD31-expressing co-culture are highlighted.
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Figure  4.17 A sign ifican t co rre la tion  w as observed 
betw een native CD 38 expression and  Ki-67 expression 
follow ing incubation  w ith  C D 31-expressing co-culture.
Ki-67 expression (MFI at 48 hours) was plotted against CD38 
expression (percent at day 0) for 20 patient samples. The Spearman 
test was used to correlate Ki-67 expression with CD38 expression.
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Figure  4.18 K i-67 expression w as significantly  increased 
in CD38 positive p a tien ts .
Ki-67 expression (MFI) was observed in CD38 negative (CD38 <20%) 
and CD38 positive (CD38>20%) patient samples. An unpaired /-test 
was used to compare Ki-67 expression in CD38 positive and negative 
samples.
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4.11 Discussion
CD38 is involved in cell signalling and has been shown to interact with 
the B-cell receptor and CD 19 in the induction of proliferation in CLL cells 
(Deaglio et al., 2003). Work by the same group illustrated a role for CD38 in 
the induction of the chemotactic regulator CXCR4 via signalling through the 
CD38/Zap-70 axis (Deaglio. et al., 2008). Following up this work, Vaisitti et 
al. described how CD38 signalling was able to enhance CLL cell homing to 
the lymph nodes through modulation of CXCR4 and CXCL12 (Vaisitti et al., 
2010a, Vaisitti et al., 2010b). In association with the integrin CD49d, CD38 
was also shown to induce the expression of other chemokines involved in cell 
migration including CCL3 and CCL4 (Zucchetto et al., 2009). Work by our 
own group has highlighted differences in gene expression between CD38 
positive and negative cells from the same patient and proposed a role for 
CD38 in angiogenesis through the induction of VEGF (Pepper et al., 2007). 
Investigations carried out by Damle et a l at around the same time illustrated 
that the CD38 positive sub-set expressed markers of proliferation (Ki-67) and 
survival (Bcl-2) (Damle et al., 2007). Even though a wealth of information 
highlighting the actions of CD38 in CLL has been presented over the past 
decade, a complete account of its role in the induction of survival and 
proliferation remains to be described. Following the successful transduction of 
CLL cells using the CD3 8-expressing lentivirus the effects of CD38 
expression on cell survival and proliferation were investigated.
Treating CLL samples with CD38 lentivirus increased the viability of the 
cells. However, this effect was also observed in samples treated with GFP 
lentivirus suggesting that the induction of survival was a generic consequence 
of the addition of concentrated lentivirus. Furthermore, the dose-dependent 
increase in the expression of CD38 observed following the addition of 
increasing amounts of CD38 virus did not correspond to an increase in CLL 
cell viability (Figure 4.1.c). The increased survival observed may have been 
due to an anti-apoptotic response from the cell. Following insult, the induction 
of protein stabilising chaperones (such as heat shock proteins) may occur to 
protect the cell from immediate death (Sedger and Ruby, 1994, Jaattela et al.,
1998). HSP-70 is highly up-regulated in lymphocytes following infection by 
the HIV-1 lentivirus (Iordanskiy et al., 2004) and HSP-90 has previously
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been shown to bind and stabilise Bcl-2 to enhance survival in primary cells 
and leukaemic cell lines (Dias et al., 2002). The innate immune response to 
viral infection is mediated through toll-like receptors on the cell surface 
(Xagorari and Chlichlia, 2008). Treatment of the cells with the lentivirus is 
likely to have induced activation and cell survival through toll-like receptor 
signalling (Gelman et al., 2004). Any subtle effects of CD38 on the viability 
of the cell might be masked by such processes.
Forward and side scatter from flow cytometric plots was used to 
determine apoptosis in the CLL samples. In addition CLL cells from untreated 
and virus treated preparations were stained with annexin V to observe the 
expression of surface phosphatidylserine and the PI dye was added to identify 
dead cells. These experiments suggested that a large proportion of the CLL 
cells were undergoing apoptosis following one hour incubation with 
lentivirus. However, forward and side scatter profiles did not suggest that this 
was the case. The HIV-1 derived lentiviral vector used in the transduction 
experiments was pseudotyped with the VSVG envelope which allows non­
specific binding of the virus to the cell membrane and entry into an extensive 
range of cell types (Farley et al., 2007). It seems possible that the interaction 
of concentrated virus with the fragile CLL cell membrane may have caused 
disruption to the lipid bilayer allowing the expression of phosphatidylserine 
on the cell surface. Even with an abundance of intracellular ATP 
(characteristic of a viable cell) such an effect would give the false impression 
that the cell was entering the early stages of programmed cell death.
To further assess the effects of the lentivirus, untreated and virus treated 
CLL cells were stained using the Giemsa dye and observed under the 
microscope at xlOO. Figure 4.7 illustrates that there were very few differences 
in CLL cells treated with either CD38 or GFP lentivirus compared to the 
untreated control. The absence of apoptotic features (which are highlighted in 
Figure 4.7.b.ii) suggests that the treated cells were viable and that the annexin 
V binding was not due to the induction of apoptosis, but to changes in the 
CLL cell following the addition of concentrated lentivirus.
Expressing CD38 on the surface did not have an effect on the viability of 
the CLL cell. To investigate whether ligating the CD38 antigen would result 
in increased cell survival, transduced samples were placed into CD31-
124
Chapter 4 CD38 ligation enhances the viability and proliferation ofprimary CLL cells
expressing co-cultures. Removal of the cells from co-culture caused a 
substantial loss of the CD38 antigen from the surface of the CLL cells. This 
was seen to occur in transduced cells incubated with both the NTL and the 
CD31 -expressing fibroblasts suggesting that it was not being caused by direct 
interaction between virus-induced CD38 and its cognate ligand CD31 (Figures 
4.9.iii and v). A CD38 positive patient sample was run in parallel to observe 
the effects of co-culture on native CD38 expression and there was no loss of 
the antigen following 48 hours incubation (Figure 4.9 ii, iv and vi). The ability 
of the lentivirus to induce changes in the CLL cell membrane was evidenced 
by the marked increase in annexin V staining. Such changes may also 
destabilise the ectopic insertion of CD38 into the CLL membranes and result 
in the loss of the CD38 antigen from the surface of the CLL cells following 
co-culture. The loss of CD38 on the surface of the CLL cells under these 
conditions made it impossible to assess the effect of CD38 on cell viability.
Investigating CLL cell viability following the induction of CD38 on the 
surface of the cell was challenging due to the effect of the lentivirus on the 
cell. Therefore, to determine whether CD38 has any effect on CLL cell 
viability, annexin V/PI staining was carried out on untransduced CLL samples 
with varying degrees of endogenous CD38 expression. There was a significant 
increase in cell survival following incubation with CD31-expressing co­
culture compared to NTL co-culture (P=0.008). These results suggest that 
stimulation of CD38 via its ligand CD31 enhances survival within the in vitro 
co-culture environment. The increased viability was then correlated with the 
basal CD38 expression (percent at day zero). There was no significant 
correlation between the cell viability and the CD38 expression in the 15 
samples investigated (P=0.357). This result does not rule out the possibility 
that CD38 is involved in inducing CLL survival. The CD31 expression on the 
surface of the co-culture may have exceeded that observed in vivo resulting in 
a marked increase in CD38 stimulation. It is possible that the threshold for 
CD38 signalling was reached in all samples regardless of the CD38 surface 
expression.
Until recently CLL was thought to be a disease of failed apoptosis; a 
slowly progressive disease, characterised by the accumulation of clonal 13- 
cells over a number of years (Caligaris-Cappio and Hamblin, 1999, Pepper et
125
Chapter 4 CD38 ligation enhances the viability and proliferation ofprimary CLL cells
al., 1999). This was shown not to be the case by in vivo heavy water 
experiments carried out by Messmer et al. who estimated that the turnover of 
the CLL cells was as high as 1% of the clone per day (Messmer et al., 2005). 
In this investigation the authors observed no correlation between the rate of 
proliferation and IGHV mutation status, CD38 or ZAP-70, though only 
nineteen patients were included in the study. In a subsequent study Callisano 
et al. described a link between proliferation and CD38 expression, 
highlighting an association between increased levels of the chemokine 
receptor CXCR4, lymphoid infiltration and CD38 positivity in a poor risk 
cohort (Calissano et al., 2009). To further examine whether CD38 has a role 
in the proliferation of CLL cells, CD31-expressing co-culture systems were 
set up to mimic the microenvironment and stimulate CD38 on the CLL cell 
surface. Incorporation of BrdU into dividing cells is an established method of 
assessing proliferation. Figure 4.14 illustrates an increase in BrdU 
incorporation into CLL cells incubated with CD31-expressing fibroblasts 
compared to the NTL control. A similar increase was observed when staining 
for the proliferation marker Ki-67 and a significant increase was observed in a 
cohort of twenty patient samples following stimulation of the CLL cells with 
CD31-expressing co-culture over a period of two days (P<0.001) (Figure 
4.16.a and b). Both the BrdU and Ki-67 staining methods illustrate an increase 
in the proliferation of CLL cells within CD31-expressing co-culture. This 
suggests that CD38 ligation results in downstream signals that induce 
proliferation in the CLL cells. Prior to incubation with co-culture each of the 
CLL samples was phenotyped for CD38 expression. The percentage CD38 
values were then plotted against Ki-67 MFI from samples incubated with 
CD31-expressing co-culture. Figure 4.17 illustrates that there was a 
significant correlation between the expression of CD38 and Ki-67 (R =0.389; 
P<0.001). Subsequent analysis identified a significant increase in Ki-67 
expression in CD38 positive patients compared to CD38 negative patients 
(Figure 4.18) (P=0.003). A recent publication by Khoudoleever et al. reported 
significantly higher Ki-67 expression in tissues from the lymph node and 
spleen compared to peripheral blood and bone marrow. They also describe a 
significant correlation between the expression of CD38 and Ki-67 in the bone 
marrow compartment (Khoudoleeva et al., 2011). Together these data provide
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convincing evidence that CD38 plays a role in the induction of proliferation in 
CLL cells following stimulation with CD31.
Incubation with CD31-expressing co-culture was shown to enhance CLL 
cell survival and proliferation. It must be noted that the CD31 ligand also has 
the ability to bind CD31 present on the lymphocyte surface in a homotypic 
interaction causing downstream signalling and changes in cell adhesion (Sun 
et al., 1996, Fawcett et al., 1995, Brown et al., 2002). In a recent publication, 
Poggi et al described how ligation of CD31 on the CLL cell surface resulted 
in cell activation through PI3K/Akt mediated NF-kB induction. The cells also 
exhibited increased survival following stimulation of CD31 with a CD31- 
agonist (Poggi et al., 2010). Of the twenty CLL samples phenotyped in this 
present study, seven were stained for surface CD31. No significant correlation 
was observed between CD31 expression (MFI) and Ki-67 expression (MFI) 
(R2=0.59, P=0.12) (Appendix 4.a).
The aim of this chapter was to investigate whether the expression of 
CD38 on the CLL cell surface had an effect on survival and proliferation. 
Interpreting the results from viability studies was challenging due to the 
effects of the lentivirus on the CLL cells. Such effects also confounded 
experiments carried out to stimulate CD38 with the use of CD31-expressing 
co-culture. Untreated CLL cells incubated in CD31-expressing co-cultures 
illustrated increased survival and proliferation compared to cells incubated in 
non-transduced co-culture. Within these samples the increased proliferation 
significantly correlated with CD38 expression. The underlying mechanisms 
by which CD38 signalling has an effect on CLL cell survival and proliferation 
is unknown. Further investigations are required to determine whether the 
induction of CD38 induces changes in gene expression that favour such 
events.
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Chapter 5. The genetic modification of CLL cells 
causes changes in gene expression
5.1 Introduction
Gene expression within CLL cells has been widely studied over the past 
decade. Early investigations illustrated that the gene expression profile of the 
CLL cell resembles that of a memory B-cell (Klein et al., 2001). Larger studies 
identified genes differentially expressed within good and poor prognostic groups 
(Rosenwald et al., 2001, Jelinek et al., 2003, Fait et al., 2005). In 2001, a study 
by Stratowa et al. was one of the first to show the differential expression of 
functional genes in CLL cells. The group illustrated an increase in the expression 
of genes coding for mediators of lymphocyte trafficking in patients with poor 
disease outcome. These included the cell adhesion molecules L-selectin and 
integrin-p2 and the cytokines IL-lp and IL-8 (Stratowa et al., 2001). A 
subsequent study illustrated an increased expression of genes involved in 
angiogenesis (angiopoietin 2) and oncogenesis (PIM2) in CD38+/Zap-70+ 
patients (Huttmann et al., 2006). In 2007, Pepper et a l illustrated that CD38 
positive and CD38 negative cells derived from the same (bi-modal) patient 
illustrated differences in gene expression (Pepper et al., 2007). The CD38 
positive cell subset showed increased expression of the potent angiogenic 
mediator VEGF. Increased expression of IL-ip and Mcl-1 was also observed in 
these cells presenting a biological rationale for the poor prognosis seen in CD38 
positive CLL. More recently a publication by Stamatopoulos et al illustrated a 
difference between the gene expression profiles of ZAP-70 positive and negative 
cells, the former expressing genes that enhanced the trans-endothelial migration 
of CLL cells (Stamatopoulos et al., 2009). In summary, gene expression 
profiling has proved a useful tool in identifying genes that are differentially 
expressed in good and poor prognostic groups of CLL patients. Genes with the 
potential to induce cell survival or disease progression have been identified 
which can be studied in more depth and exploited as targets for therapy.
In chapter three, a HIV-1 derived lentivirus was developed to induce the 
expression of CD38 in primary CD38 negative CLL cells. CD38 has been
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described as a signalling molecule in CLL (Deaglio et al., 2003, Morabito et al.,
2006), so the aim of this chapter was to determine whether there were any 
changes in gene expression following the induction of CD38 on the cell surface. 
QRT-PCR and microarray techniques were used to observe gene expression in 
untreated samples and CLL samples transduced using CD38 and GFP lentivirus.
5.2 CD38 mRNA was highly expressed in multiple CD38 virus treated 
samples
Flow cytometry illustrated that CD38 was highly expressed on the surface 
of CLL cells following the addition of CD38 lentivirus (Figure 3.12). Following 
treatment of six samples with CD38 or GFP virus QRT-PCR was carried out to 
quantify the expression of CD38. Figure 5.l.a illustrates the high expression of 
CD38 in six CD38 virus treated samples (Mean=17,800 relative fold increase, 
±12,173 (±SD)). In contrast, a relatively small increase in CD38 transcription 
was observed following the addition of GFP virus (Mean=7, ±14 (±SD)) (Figure 
5.l.b). The increase illustrated corresponds to the fold increase of CD38 mRNA 
compared to the expression of CD38 in the untreated sample and relative to the 
expression of the Abelson housekeeping gene (ABL). It should be noted that the 
large fold-change increase in CD38 expression was in part a product of the very 
low basal level of transcription of this gene in the CD38 negative samples 
chosen for genetic modification. This also explains why there was a 7-fold 
increase in CD38 transcription in the GFP virus treated cells.
For all QRT-PCR experiments the relative fold increase (RFI) was 
determined using the formula:
_  [-(Gene of interest ct -  ABL ct X) -  (Gene of interest ct -  ABL ct Y)] 
RFI — 2
Where ct = Crossing point of linear amplification 
X = Virus treated test sample 
Y = Untreated sample
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Figure  5.1 CD38 w as highly expressed in C L L  sam ples 
trea ted  w ith  (a) CD 38 v iru s  b u t not (b) G F P  virus.
(a) Six patient samples were treated with CD38 lentivirus at an MOI of
3.2 and left for 48 hours in liquid media. RNA was extracted from 
lxlO6 CLL cells and QRT-PCR was carried out to determine CD38 
expression, (b) Samples from the same six patients were treated with 
an equal amount of GFP virus and CD38 expression was determined.
| H  ■ CD38 Virus
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5.3 VEGF expression was increased following the addition of lentivirus
There are six VEGF isoforms which bind to at least two VEGF receptors to 
induce angiogenesis in local microvessels (Judith Harmey, 2004). The first 
described and the most potent isoform is VEGF-A (referred to as VEGF). VEGF 
has been shown to be up-regulated in CLL cells expressing the CD38 antigen 
(Pepper et al., 2007). To observe whether over-expression of CD38 would 
induce VEGF expression in CLL cells, CD38 negative patient samples were 
transduced and QRT-PCR was utilised to observe CD38 and VEGF gene 
expression. An MOI of 3.2 was used for both the CD38 and control GFP virus. 
Untreated, CD38 virus and GFP control virus treated samples were incubated for 
a period of two days to allow protein expression. Figure 5.2 illustrates VEGF 
gene expression in six virally treated samples relative to the expression in the 
untreated control (normalised to 1). VEGF expression was significantly 
increased in all of the CLL cells treated with the CD3 8-expressing virus. 
However, this was also the case in CLL cells treated with GFP virus. Three out 
of six of the samples tested showed a relative increase in VEGF transcription 
when transduced with the CD3 8-expressing lentivirus. However, the rate of 
transcription was variable and overall there was no significant difference in 
VEGF expression between CD38 virus and GFP virus treated samples (P =0.43).
5.4 Analysis of CLL cell supernatant using ELISA identified an increase in 
VEGF following transduction with lentivirus
VEGF is a soluble molecule which binds to at least two VEGF receptors on 
the cell surface. It is readily released from the cell and its actions can be 
autocrine or paracrine (Farahani et al., 2005, Till et al., 2005). VEGF gene 
expression was shown to be increased in both the CD38 and GFP lentivirally 
transduced samples. To observe whether VEGF protein was increased in the 
sample supernatant a VEGF-specific ELISA was carried out on six 
untransduced, CD38 virus treated and GFP virus treated samples. Figure 5.3 
illustrates the increase in VEGF protein in the supernatant of lentivirus treated 
samples. There was higher expression in the supernatant of CLL cells treated 
with CD38 virus compared to GFP virus, although this difference was not 
significant (P=0.645).
131
Chapter 5 The genetic modification o f  CLL cells causes changes in gene expression
oc.
60
s 50
CO 
0
CD ;g m o
>
_C0
0a:
40
30
2  20
10
0
CD38 Virus 
GFP Virus
Patient
Figure  5.2 V E G F  w as heterogeneously  over-expressed in 
CD38 and  G F P  len tiv iru s trea ted  sam ples.
RNA was extracted from lxlO6 CLL cells and QRT-PCR was carried 
out to determine VEGF expression in six virus treated patient 
samples.
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Untreated CD38 Virus GFP Virus
F igure  5.3 V E G F  pro tein  w as over-expressed in 
len tiv iru s trea te d  sam ples.
The supernatant from six untreated and lentivirus treated CLL 
samples was investigated for VEGF protein expression using an 
ELISA. A paired /-test was used to observe whether there was a 
significant difference in VEGF protein expression.
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5.5 VEGF gene expression increased in a dose dependent manner following 
the addition of increasing amounts of CD38 virus
In the above experiments an MOI of 3.2 was used to transduce over 80% of 
the CLL sample. The expression of VEGF was increased in the samples 
expressing CD38 but was also expressed in GFP treated samples (with the 
exception of sample six (Figure 5.2)). Addition of the lentivirus therefore 
seemed to have an effect on the induction of VEGF within the CLL sample. To 
further investigate whether the expression of CD38 had any effect on the 
induction of VEGF, increasing amounts of CD38 lentivirus were added to a 
CD38 negative CLL sample and VEGF and CD38 were measured by QRT-PCR. 
Equal amounts of GFP lentivirus were added to the CLL sample as a control. 
The addition of increasing amounts of CD38 lentivirus resulted in a dose- 
dependent increase in the expression of VEGF (Figure 5.4). Even though the 
induction of VEGF was also observed using increasing amounts of GFP virus, 
the levels of VEGF expression in the CD38 virus treated samples were much 
higher when an MOI of above 20 was used. This would suggest that the 
expression of CD38 on the surface of the CLL cells was associated with the 
induction of VEGF. Figure 5.5 plots the relative gene expression of VEGF and 
CD38. There was a significant correlation between the expression of VEGF and 
CD38 in the samples treated with increasing amounts of CD38 virus (R2=0.964) 
(PO.OOl).
5.6 IL-lfi and MCL1 expression were increased in CLL samples following 
transduction with lentivirus
IL-lp is a cytokine which is able to induce survival and proliferation in 
lymphocytes. This molecule was shown to be up-regulated in CD38 positive 
CLL cells compared to their CD38 negative counterparts (Pepper et al., 2007). 
IL-ip was measured in six untreated and virus treated samples using QRT-PCR. 
Figure 5.6 illustrates that IL-lp expression was increased in CLL samples 
treated with either CD38 or control GFP lentivirus compared to the untreated 
sample. The expression of IL-ip was heterogeneous following lentiviral 
transduction and there was no significant difference in IL-ip expression between 
samples treated with CD38 virus and those treated with GFP virus (P=0.76).
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Figure  5.4 V E G F  w as induced following the  addition  of 
increasing  am o u n ts  o f CD38 v irus.
Increasing amounts of CD38 or GFP lentivirus were added to CLL 
cells from a single patient and VEGF expression was determined by 
QRT-PCR.
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Figure  5.5 V E G F  expression co rre la ted  w ith CD38 
expression  in CD 38 v iru s  trea ted  sam ples.
Following the addition of increasing amounts of CD38 lentivirus 
VEGF expression was measured by QRT-PCR and plotted against 
CD38 expression. The Spearman test was used to determine any 
correlation between VEGF and CD38 expression.
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Figure  5.6 IL - ip  w as heterogeneously  over-expressed in 
six CD 38 an d  G F P  len tiv iru s trea ted  sam ples.
RNA was extracted from lxlO6 CLL cells and QRT-PCR was carried 
out to determine IL-ip expression in six virus treated patient samples.
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The anti-apoptotic BCL-2 family member Mcl-1 is over-expressed in CLL 
and is associated with resistance to therapy and a poor outcome (Hussain et al., 
2007). It has also been associated with other markers of aggressive disease 
including unmutated IGHV  genes, ZAP-70 and CD38 (Pepper et al., 2008). To 
assess whether the induction of CD38 resulted in up-regulation of MCL-1, six 
CLL samples were treated with CD38 and GFP virus and the gene expression of 
MCL-1 was determined by QRT-PCR. Figure 5.7 illustrates that the addition of 
either lentivirus induced an increase in MCL-1 expression in the six samples 
tested. This increase varied in each patient sample and only 1/6 samples tested 
showed increased MCL-1 transcription in cells treated with CD3 8-expressing 
lentivirus. Consequently, there was no significant difference in MCL1 
expression between samples treated with CD38 virus and those treated with GFP 
virus (P=0.42).
5.7 Microarray analysis revealed up-regulation of CD38 in CLL samples 
transduced with CD38 lentivirus
CLL cells expressing the CD38 antigen were shown to have a unique gene 
expression profile compared to their CD38 negative counterparts in bi-modal 
patients (Pepper et al., 2007). This profile favours angiogenesis and CLL cell 
survival and provides a rationale for the more aggressive nature of CD38 
positive CLL. Whether CD38 signalling is responsible for these changes in the 
gene expression profile is unknown. In an attempt to answer this question three 
untreated and virus treated samples were run on Affymetrix U133A GeneChips 
containing 23,500 gene sequences derived from the Genebank database. All of 
the data obtained from this gene array study were analysed using Genespring 
7.0. Figure 5.8 illustrates that CD38 was highly expressed in each of the samples 
treated with CD38 virus but not in untreated or GFP virus treated samples. Table
5.1 highlights the mean expression of CD38 in untreated and virus treated 
patient samples. The mean relative expression from three CD38 transduced 
samples was 8490 ±3606.9 (±SD) compared to 7.7 ±0.6 (±SD) and 8.5 ±6.8 
(±SD) in untreated and GFP virus treated samples respectively.
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Figure  5.7 M CL-1 w as heterogeneously  over-expressed 
in six CD 38 an d  G F P  len tiv iru s  trea ted  sam ples.
RNA was extracted from lx l0 6 CLL cells and QRT-PCR was carried 
out to determine MCL-1 expression in six virus treated patient 
samples.
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CD38 
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DND1 
SLC6A2
U ntrea ted  G F P  V irus  C D 38 Virus _
F igure  5.8 M ic ro a rra y  analysis illu stra ted  th a t CD38 
expression  w as increased  follow ing tran sduction  w ith 
CD38 len tiv irus.
5xl06 CLL cells were untreated or transduced using CD38 or GFP 
lentivirus and left for 48 hours at 37C. RNA was extracted and run on 
the Asymetrix U133A gene chip.
CD38 Untreated CD38 Virus GFP Virus
Relative
Increase
7.7 
±0.6 (SD) 
(n=3)
8490.1 
±3606.9 (SD) 
(n=3)
8.5 
±6.8 (SD) 
(n=3)
Table 5.1 CD 38 w as over-expressed  in sam ples expressing 
C D 38 b u t no t in con tro l sam ples.
The mean CD38 expression was calculated for the three untreated 
CD38 virus treated and GFP virus treated patient samples.
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5.8 Fifty five genes were up-regulated and seven down-regulated following 
the induction of CD38
QRT-PCR analysis revealed differential regulation of key genes implicated 
in the pathogenesis of CLL. Microarray data revealed 55 up-regulated genes and 
7 down-regulated genes when CD38 transduced samples were compared with 
untransduced and GFP treated samples. Figure 5.9 illustrates the differentially 
expressed genes within the CD38 virus treated samples.
5.9 Microarray analysis identified down-regulation of the gene encoding the 
DNA mismatch repair protein Msh6 in CLL cells following expression of 
CD38
The process of somatic hypermutation takes place in response to antigenic 
challenge and introduces point mutations into the V-region exons of 
immunoglobulin heavy chain genes. This process occurs within the germinal 
centres of the lymph nodes and culminates in the selection of B-cells that 
generate high affinity BCRs. Those cells with BCR displaying lower affinity to 
the antigen undergo clonal deletion (Li et al., 2004). SHM is initiated by the 
activation induced cytidine deaminase (AID) molecule and occurs in several 
kilobases of DNA around rearranged IGHV genes. AID deaminates cytosine to 
uracil which generates mutations of C and G nucleotides. In a secondary process 
the low fidelity DNA pol rj and the mismatch repair proteins Msh2 and Msh6 are 
involved in the generation of A and T mutations. Through investigations 
involving Msh3 and Msh6 knockout mice Martomo et a l showed that Msh6 (but 
not Msh3) was required for the process of somatic hypermutation to occur 
effectively (Martomo et al., 2004). The microarray identified a reduction in the 
expression of MSH6 in all three patient samples following the expression of 
CD38 (Figure 5.10). The mean values of MSH6 expression are illustrated in 
Table 5.2. A significant decrease in MSH6 was observed in CD38 transduced 
cells compared to GFP treated cells when the results from each of the gene 
probes were considered for all three patients (P=0.03). To investigate the 
expression of MSH6 further, QRT-PCR was carried out on two untreated and 
virus treated patient samples. Figure 5.11 illustrates that there was no difference 
in the expression of MSH6 in untreated and virus treated samples following the 
induction of CD38 on the CLL cell surface.
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0. 1 1 0 . 1 1 0 . 0 . ( 1  
U ntreated  G F P  Virus C D 3 8  Virus
F igure  5.10 M SH 6 w as dow n regulated  in CD38 
expressing  C L L  cells.
5xl06 CLL cells from three patients were untreated, treated with GFP 
virus or treated with CD38 virus. RNA was extracted from the 
samples after 48 hours incubation and run on the Affymetrix 
platform.
Untreated CD38 Virus GFP Virus
F igu re  5.11 Q R T -PC R  analysis illu stra ted  no difference 
in the  expression  o f M SH 6 following trea tm e n t w ith 
CD 38 o r  G F P  len tiv iru s .
5xl06 CLL cells from two patients were untreated, treated with GFP 
virus or treated with CD38 virus. RNA was extracted from the samples 
after 48 hours incubation and QRT-PCR was used to observe MSH6 
gene expression.
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PI P2 P3 PI P2 P3 PI P2 P3 Mean
Gene Probe ID Nig Ntg Nig
CD38
Virus
CD38
Virus
0038
Virus
GFP
Virus
GFP
Virus
GFP
Virus Nig
CD38
Virus
GFP
Virus P value
MSH6 211450 $j i 46.1 78.9 85.6 55.9193 70.1007 38.5074 97.7605 53.7089 89.4886 70.20 54.84 80.32 0.35
202911_«t 224.50 241.60 207,10 191.67 134.99 143.06 248.22 213.05 205.65 224.40 156.58 222.31 0,01
( 211449jt 5.10 1.30 6.90 8.62 4.38 7.48 6.90 0.45 7.16 4.10 6.83 4.84 0.20
Pvilut. All erobis 0.03
Table 5.2 The expression of MSH6 was decreased in three CD38 transduced patient samples.
Three CLL samples were untreated, treated with CD38 virus or GFP virus. RNA was extracted and run on the 
Affymetrix gene chip.
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5.10 Discussion
Gene expression studies in CLL have identified gene profile signatures of 
poor risk disease and implicated mechanisms such as adhesion and migration in 
the pathogenesis of this disease (Stratowa et al., 2001, Deaglio and Malavasi, 
2009). Recent work from our group identified over-expression of molecules 
involved in angiogenesis and apoptosis in CD38 positive cells (Pepper et al.,
2007). Until now, such investigations have highlighted differences between 
CD38 positive and CD38 negative cells and, with the exception of the bi-modal 
study, were carried out on a heterogeneous genetic background (i.e. inter-patient 
analysis). The aim of this chapter was to observe whether ectopic expression of 
the CD38 molecule directly contributes to changes in genotype in the absence of 
any other changes within the cell. To achieve this, a method was developed 
using a lentiviral vector to induce CD38 expression on the surface of CD38 
negative cells. Following transduction, RNA was extracted and QRT-PCR and 
microarray analysis were carried out to determine the expression of key 
molecules which may play a role in the pathogenesis of CLL.
Gene expression analysis revealed that CD38 was markedly induced in all 
of the samples treated with the CD38 expressing lentivirus (Figure 5.1.a). 
Although the addition of the GFP virus induced a small increase in CD38 
expression (seven fold) in the sample, it was apparent that the virus had a 
profound effect on the expression of other genes. VEGF, IL-lp and MCL1 were 
all up-regulated in the six patient samples investigated by QRT-PCR. However, 
in these experiments there was little difference between the increase in gene 
expression observed following the addition of CD38 or GFP virus. Microarray 
analysis also revealed substantial alterations in gene expression in all three 
samples investigated following the addition of the GFP lentivirus. In chapter 
four the viability of the CLL sample increases in response to the addition of 
CD38 or GFP virus. The results from microarray analysis suggest that the effect 
of the virus on the cells is promoted, at least in part, at the level of transcription. 
Whether these changes are caused by aberrant signalling from the disruption of 
signalling molecules in the cell, or due to genetic changes following integration 
of the provirus is unknown. In 2002 Schroder et a l showed that the HIV-1 
provirus integrates into transcriptionally active sites following infection 
(Schroder et al., 2002). More recently Ciuffi et a l illustrated that HIV-1
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preferentially targets DNA transcription units in non-dividing cells (Ciuffi et al., 
2006). This work suggests that integration of the provirus may indeed disrupt the 
gene expression within the infected cell. The concentrated lentivirus used in 
these experiments may have integrated into many different regions of the host 
DNA causing an array of changes in gene expression.
Both QRT-PCR and microarray investigations illustrated a large amount of 
heterogeneity between the patient samples tested. Figure 5.1.a shows that the 
expression of CD38 following the addition of equal amounts of CD38 lentivirus 
varied greatly between the six samples. This variation was also observed when 
determining the expression of VEGF, IL-lp and MCL1. Individual patients are 
known to have different responses to in vivo and in vitro stimuli (Alvarez-Mon 
et al., 1993, Cutrona et al., 2008). Such heterogeneity in response to the addition 
of lentivirus is therefore not unexpected. The microarray analysis of three patient 
samples also generated a large amount o f discordant data due to heterogeneity 
within the gene expression. In this context, attempts to determine patterns of 
gene expression using small numbers of patient samples were very challenging 
in CLL. The over (or under) expression of genes involved in the pathogenesis of 
the disease may not occur in all patients and studying large cohorts may be 
required to uncover such aberrant gene expression.
The global expression of 23,500 genes was analysed following transduction 
and those up-regulated or down-regulated in the CD38 transduced samples, 
compared to the untreated and GFP virus treated controls, are highlighted in 
Figure 5.9. This analysis revealed the down-regulation of MSH6 in CD38 virus 
treated samples. The Msh6 protein is involved in the generation of somatic 
hypermutation following antigen stimulation of B-cells. The mutation status of 
the CLL clone is highly significant in CLL as unmutated cases have a 
particularly poor prognosis. CD38 positivity correlates with the presence of 
unmutated IGHV genes in CLL although a link between the two has never been 
established. The DNA mismatch repair protein Msh6 has been shown to be 
deregulated in other cancers including hereditary non-polyposis colorectal 
cancer and endometrial and colonic cancers (Wagner et al., 2001, Wijnen et al.,
1999). The results obtained from the microarray analysis carried out in this 
chapter suggest a link between the expression of CD38 and down-regulation of 
MSH6. If CD38 signalling influences the mutation status of the clone then this
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pathway would be an important therapeutic target in CLL. This phenomenon 
would also provide insight into the origin of the CLL cell and add to the debate 
over whether CLL is a single disease or one of either pre or post-germinal centre 
origin (Hamblin et al., 1999, Damle et al., 1999, Hamblin, 2002). Conversely 
the AID molecule has been shown to be associated with unmutated IGHV genes 
and is up-regulated in poor prognosis CLL particularly within the lymph node 
proliferation centres (McCarthy et al., 2003, Hancer et al., 2011). AID has the 
capacity to induce class switch recombination (Muramatsu et al., 2000) and 
unpublished work by Professor Chiorazzi’s group suggests that this molecule 
may maintain mistargeted mutational activity and induce intraclonal diversity 
and CLL progression in the CD38 positive CLL cell fraction (Calissano et al., 
2009). The microarray data illustrate a significant decrease in MSH6 in all three 
patient samples following transduction with the CD38 virus (P=0.03). However, 
subsequent analysis utilising QRT-PCR on two CD38 transduced samples failed 
to show a similar pattern of expression. The low number of samples investigated 
together with the heterogeneity of the disease may have caused the discrepancy 
observed. The literature suggests that the ABL gene may be over-expressed in 
CLL. (Lin et al., 2006, Allen et al., 2011) Therefore, its use as a house-keeping 
gene in these experiments may have confounded attempts to show differences in 
the expression of the genes under investigation. Finally a lack of probe 
specificity for various isoforms of the gene or a variation in hybridisation 
conditions may have yielded erroneous results from the microarray 
investigations carried out (Kothapalli et al., 2002).
An MOI of 3.2 was used to transduce each of the samples. Further 
investigations looked at how the expression of CD38 related to that of VEGF in 
a single sample. Following the addition of increasing amounts of CD38 
lentivirus VEGF expression was increased in a dose-dependent manner. No such 
increase was observed using the GFP lentivirus. Within this experiment the 
amount of lentivirus used to treat the samples was increased to a maximum MOI 
of 28. The evidence suggests that there may be a threshold of CD38 signalling 
required for the induction of VEGF in these cells. A highly significant 
correlation was observed when comparing VEGF expression to CD38 
expression (rather than the viral MOI) (P<0.001) (Figure 5.5). These results
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indicate a potential role for CD38 signalling in the induction of VEGF although 
high levels of CD38 were required to observe any correlation.
Although the system utilised was able to induce large amounts of CD38 on 
the surface, the antigen lacked any form of exogenous stimulation. It is quite 
feasible that CD38 signalling requires more than just the mere presence of CD38 
on the surface of the cell and that in the initial experiments carried out the 
threshold for the effects of CD38 signalling to occur were not reached. By 
increasing the expression of CD38 by manipulating the MOI of the virus VEGF 
was induced; an effect that was not due solely to the addition of lentivirus since 
the GFP virus failed to recapitulate these effects.
Investigating gene expression in CLL samples following the induction of 
CD38 on the cell surface supported data already published and gave insight into 
the aberrant expression of novel genes with biological relevance. Heterogeneity 
was observed following the investigation of multiple patient samples and there 
was some discordance between results obtained using QRT-PCR and 
microarray. The novel part of this work was to induce changes in gene 
expression following the expression of CD38 on the surface of CLL cells which 
were originally CD38 negative. Therefore unlike any other study before it, this 
work identifies the changes in gene expression which occurred specifically in 
response to CD38 expression.
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Chapter 6. Incubation with CD31-expressing co­
culture causes phenotypic changes in CLL cells
6.1 Introduction
The aim of this chapter was to design a set of experiments, using multi­
colour flow cytometry, to investigate the effects of CD38 ligation on the 
phenotype of the CLL cell. The expression of CD5, CD 19, CD38, CD49d, 
C D llc, CD103 and CD138 were analysed on the cell surface and Zap-70 and 
Ki-67 within the cells using three antibody panels (Table 6.1). Stimulation of 
CD38 was achieved with the use of a CD31-expressing fibroblast co-culture 
system and CLL cells were incubated in NTL co-culture as a control. To further 
simulate the CLL microenvironment and enhance cell survival over a period of 
five days in co-culture, IL-2 was added at a concentration of lOOIU/ml. CLL 
cells were sampled from the co-culture at day two and day five and multi-colour 
flow cytometry was carried out using a Beckman Coulter Cyan cytometer. The 
analysis of key surface and intracellular molecules was carried out on CD5+ and 
CD 19+ cells present within the lymphocyte gate (Figure 6.1). The MFI values of 
paired samples were compared for twenty patient samples displaying a range of 
constitutive CD38 expression on their cell surface.
6.2 CD5 was down-regulated on the CLL cell surface following co-culture
CD5 was one of the first markers described on the surface of the CLL B-cell 
(Matutes et al., 1994). This molecule is expressed on B la lymphocytes in the 
peripheral blood of normal individuals. These cells are thought to be derived 
from B-cell precursors which have been exposed to self-antigen. The B1 
repertoire therefore tends to be autoreactive and it is believed that CD5 
suppresses BCR signalling in these cells to limit autoreactivity but allow them to 
react to potent BCR stimuli such as mucosal pathogens (Berland and Wortis, 
2002). In keeping with this notion, CLL cells are generally anergic with 
defective BCR signalling (Muzio et a l, 2008). The presence of CD5 on the 
surface of the cell may contribute to this unresponsiveness and suggests that the 
CLL B-cell may be generated in response to auto-antigen. The initial expression
148
Chapter 6_ Incubation with CD31 -expressing co-culture causes phenotypic changes in CLL cells
Panel 1 Fluorochrome Emission
CD5 ECD 613
CD19 AF750 750
CD38 PE-Cy7 785
CD49d FITC 520
Panel 2 Fluorochrome Emission
CD5 ECD 613
CD19 PB 452
Zap-70 AF647 647
Ki-67 FITC 520
Panel 3 Fluorochrome Emission
CD5 ECD 613
CD19 AF750 750
CD11c PE-Cy7 785
CD103 FITC 520
CD138 PB 452
Table 6.1 F lu o rescen t an tib o d y  panels used to 
c h a ra c te rise  C L L  cells.
Three different combinations of fluorescent antibodies were designed 
to stain surface and intra-cellular antigens in CLL cells.
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of CD 5 following collection (day zero) was compared to samples incubated in 
NTL and CD31 expressing co-culture for two and five days. Figure 6.2 
illustrates that CD5 was down regulated on the surface of CLL cells incubated 
within both NTL and CD31-expressing co-culture after five days compared to 
day zero (P=0.01 and P=0.02 respectively). There was no significant difference 
in CD5 expression between CLL cells incubated in NTL and CD31-expressing 
fibroblasts after two or five days (P=0.15 and P=0.22 respectively).
6.3 CD19 expression was increased in CLL cells following two and five days 
incubation with CD31-expressing co-culture
CD 19 is present on the surface of B-cells from an early stage in their 
development and is only lost following differentiation of the cell into an 
antibody secreting plasma cell (de Rie et al., 1989). The trans-membrane 
molecule is essential for efficient BCR signalling and forms lipid raft complexes 
with other surface molecules such as CD81 and CD21 (Sato et al., 1997). 
Following BCR cross linking the CD 19/BCR complex is internalized resulting 
in down-stream signalling and cell activation (Pesando et al., 1989, Buhl and 
Cambier, 1999). CD 19 is generally expressed on the surface of CLL cells in 
lower quantities than that expressed on the surface of normal B-cells (Ginaldi et 
al., 1998). Although BCR signalling is perturbed in CLL, an increase in the 
levels of CD 19 may allow signalling to occur and promote survival or 
proliferation of the clone. CD 19 expression was assessed in twenty patient 
samples at day zero and following two and five days incubation with NTL or 
CD31 -expressing co-culture. There was no significant difference in the 
expression of CD 19 on the surface of CLL cells incubated for two or five days in 
NTL co-culture (Figure 6.3). In contrast, there was a significant increase in 
CD 19 expression on the surface of CLL cells incubated for two and five days in 
CD31-expressing co-culture (P=0.0003 and P=0.0004 respectively). 
Subsequently the expression of CD 19 was compared between samples incubated 
in NTL and CD31-expressing co-cultures. There was a significant increase in the 
expression of CD 19 in CLL samples following two days incubation with CD31- 
expressing co-culture when compared to cells incubated with NTL co-culture 
(P=0.01) (Figure 6.3); this was even more pronounced after five days 
(P=0.0002).
151
Chapter 6_ Incubation with CD31 -expressing co-culture causes phenotypic changes in CLL cells
P=0.01
u.
s
1 0
O
O
1000-
800-
600-
400*
200'
0-
i X
■ ■mfm
P=0.01
±A
A
A ▼
♦♦♦♦
•  •
- 4 ---------- 1—
Day 0 NTL CD31 NTL CD31 
Day 2 Day 5
Figure 6.2 CD5 expression was decreased following five 
days in co-culture.
lx l0 6 CLL cells were placed into co-culture with NTL or CD31- 
expressing fibroblasts. Surface CD5 was measured by flow cytometry 
on day 0, 2 and day 5 (CD5-ECD) and the MFI value was plotted for 
each CLL sample. CD 19 positive CLL lymphocytes were identified by 
surface staining and forward and side scatter. A paired f-test was used 
to compare CD5 expression.
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Figure 6.3 An increase in CD19 expression was observed 
following incubation with CD31 expressing co-culture.
lxlO6 CLL cells were placed into co-culture with NTL or CD31- 
expressing fibroblasts. Surface CD 19 was measured by flow 
cytometry on day 0, 2 and day 5 (CD 19- Alexafluor 750) and the MFI 
value was plotted for each CLL sample (a) CD5 positive CLL 
lymphocytes were identified by surface staining and forward and side 
scatter. A paired /-test was used to compare CD 19 expression, (b) and 
(c) illustrate the CD 19 expression at day 2 and 5 respectively. The 
paired samples within NTL and CD31-expressing co-culture are 
highlighted.
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6.4 CD38 expression was increased in CLL cells following five days 
incubation with CD31-expressing co-culture
Studies of serial patient samples suggest that the CD38 glycoprotein is 
stably expressed on the surface of peripheral blood CLL B-cells (D'Arena et al., 
2002). Its expression within the lymph node or bone marrow has been more 
difficult to assess due to the challenge of obtaining such tissues. However, in 
2004, Jasic et al. showed increased expression of CD38 on the surface of CLL 
cells within the lymph nodes compared to peripheral blood and bone marrow 
(Jaksic et al., 2004). Subsequently Lin et al. illustrated increased levels of CD38 
on the CLL cell surface in the bone marrow compartment compared to 
peripheral blood (Lin et al., 2008). Evidence by Pepper et al suggests that the 
expression of CD38 is transient (Pepper et al., 2007), a theory that was 
supported by Calissano et al. (2009). Microenvironmental niches within 
lymphoid tissues may provide the sites for rapid CD38 up-regulation and 
shedding following cell activation. Higher expression of CD38 on the CLL cell 
surface may promote down-stream effects such as survival and proliferation 
(Patten et a l, 2008). To investigate whether CD38 was up-regulated following 
stimulation in co-culture the CLL cells were incubated within NTL and CD31- 
expressing fibroblasts. A significant increase in CD38 expression was observed 
following two days in NTL or CD31-expressing co-culture (P=0.01 and P=0.01 
respectively) (Figure 6.4). There was also an increase in CD38 expression 
following five days in CD31 -expressing co-culture (P=0.01). Following five 
days incubation there was a significant increase in CD38 expression on the 
surface of CLL cells incubated with CD31-expressing co-culture compared to 
cells incubated with NTL co-culture (P=0.01).
6.5 CD49d expression was increased in CLL cells following co-culture
CD49d is the a4 subunit of the a4plintegrin and is expressed on the surface 
of CLL B-cells. Increased expression of this antigen has been associated with a 
poorer prognosis in CLL (Eksioglu-Demiralp et al., 1996, Gattei et al., 2008). 
Molecules involved in cell migration have been widely studied in CLL due to 
enhanced lymph node and bone marrow infiltration (Burger et al., 1999, Ocana 
et al., 2007). These sites are thought to act as centres of enhanced activation and
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Figure 6.4 An increase in CD38 expression was observed 
following incubation in CD31 expressing co-culture.
lxlO6 CLL cells were placed into co-culture with NTL or CD31 
expressing fibroblasts. Surface CD38 was measured by flow cytometry 
on day 0, 2 and day 5 (CD38-PC-7) and the MFI value was plotted for 
each CLL sample (a) CD5+/CD19+ CLL lymphocytes were identified 
by surface staining and forward and side scatter. A paired /-test was 
used to compare CD38 expression, (b) illustrates the CD38 expression 
at day 5. The paired samples within NTL and CD31-expressing co­
culture are highlighted.
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proliferation in CLL (Jaksic et al., 2010). Increased expression of CD49d has 
been associated with up-regulation of CD38 and other chemokines such as 
CCL3 and CCL4 (Pittner et al., 2005, Zucchetto et al., 2009). Whether 
stimulation of CD38 results in increased expression of CD49d is unknown. CLL 
cells from twenty patients were stained for surface CD49d at day zero and 
following two and five days in co-culture. CD49d was up-regulated on the CLL 
cell surface following two days in NTL and CD31 -expressing co-culture 
(P=0.0001 and 0.0003 respectively) (Figure 6.5). The levels of CD49d were also 
significantly increased following five days in NTL and CD31-expressing co­
culture (P=0.0001 and 0.0001 respectively). However there was no significant 
difference in CD49d expression on the surface of CLL cells following two or 
five days co-culture with CD31-expressing fibroblasts compared to cells 
incubated with NTL co-culture (P=0.88 and P=0.1 respectively).
6.6 Zap-70 expression was increased in CLL cells following two days in 
CD31-expressing co-culture
Expression of Zap-70 is associated with a poor prognosis in CLL (Wiestner 
et al., 2003). The molecule has been shown to be closely associated with BCR 
signalling (Chen et al., 2008) and correlates with other poor prognostic markers 
such as CD38 and unmutated IGHV in CLL. (Hamblin et al., 2002, Cruse et al., 
2007, Rassenti et al., 2008, Crespo et al., 2003, Rassenti et al., 2004, Wiestner et 
al., 2003). Zap-70 was also reported to play a role in the up-regulation of the 
chemokine receptor CXCR4 on the surface of CLL cells (Ticchioni et al., 2002) 
and CD38 and Zap-70 positive cells illustrate enhanced migration when 
investigated in vitro (Deaglio et a l, 2007). To determine whether stimulation of 
CD38 had an effect on Zap-70 expression, intracellular Zap-70 was assessed in 
CLL cells at day zero and following two and five days co-culture with NTL and 
CD31-expressing fibroblasts. The CLL cells were stained for CD5 and CD 19 
before being fixed and permeabilised and then stained for Zap-70. There was a 
significant increase in Zap-70 expression after two days in NTL and CD31- 
expressing co-culture (P=0.003 and 0.0003 respectively) (Figure 6.6). Zap-70 
was also significantly increased following five days co-culture in NTL and 
CD31-expressing co-culture (P0.0001 and 0.0001 respectively). A significant
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Figure 6.5 An increase in CD49d expression was observed 
following co-culture.
lxlO6 CLL cells were placed into co-culture with NTL or CD31- 
expressing fibroblasts. Surface CD5 was measured by flow cytometry on 
day 0, 2 and day 5 (CD49d-FITC) and the MFI value was plotted for each 
CLL sample. CD5 +/CD19 + CLL lymphocytes were identified by surface 
staining and forward and side scatter. A paired /-test was used to compare 
CD49d expression.
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Figure 6.6 An increase in Zap-70 expression was 
observed following incubation with CD31-expressing co­
culture.
lxlO6 CLL cells were placed into co-culture with NTL or CD31- 
expressing fibroblasts. Surface CD5 was measured by flow cytometry 
on day 0, 2 and day 5 (Zap-70- Alexafluor-687) and the MFI value was 
plotted for each CLL sample (a) CD5+/CD19+ CLL lymphocytes were 
identified by surface staining and forward and side scatter. A paired t- 
test was used to compare Zap-70 expression, (b) illustrates the Zap-70 
expression at day 2. The paired samples within NTL and CD31- 
expressing co-culture are highlighted.
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increase in the expression of Zap-70 was observed in the CLL cells following 
two days co-culture with CD31 -expressing fibroblasts compared to 
cells incubated with NTL fibroblasts (PO.OOOl) (Figure 6.6). Following five 
days in co-culture there was no significant difference in the expression of Zap- 
70 between the CLL cells incubated in CD31 -expressing and NTL co-culture 
(P=0.08).
6.7 The increase in intracellular Zap-70 expression following incubation 
with CD31-expressing co-culture significantly correlated with constitutive 
CD38 expression
Incubation of CLL cells for two days in CD31-expressing co-culture 
resulted in up-regulation of intracellular Zap-70 when compared to cells 
incubated in NTL co-culture for the same period. To investigate whether there 
was a relationship between Zap-70 and CD38, Zap-70 expression (MFI) at day 
two was plotted against the expression of surface CD38 (percentage of positive 
cells) at day zero. There was a significant correlation between Zap-70 MFI and 
CD38 expression as illustrated in Figure 6.7 (^=0.54, PO.OOOl). Subsequently 
the Zap-70 MFI values for CD38 negative and CD38 positive patient samples 
were compared (<20% versus >20%). There was a significantly higher 
expression of Zap-70 in CD38 positive samples following two days in CD31- 
expressing co-culture (Figure 6.8) (P=0.03).
6.8 There was no change in C D llc  expression on the surface of CLL cells 
following co-culture
In normal B-cells, exposure to antigen results in the selection of a highly 
specific cell which proliferates and differentiates into a memory B-cell or plasma 
cell population (Carter, 2006). In order to determine whether the co-culturing of 
CLL cells caused such changes, the sample was investigated for markers of 
differentiation. C D llc  is an integrin expressed at low levels on the surface of 
CLL cells. It is found in much higher levels on the surface of the malignant cells 
in Hairy cell leukaemia, B-PLL and less so in NHL (Marotta et al., 2000). 
Increased expression of CD1 lc following co-culture would indicate that the cell 
was undergoing phenotypic changes consistent with differentiation. C D llc  was 
therefore measured following co-culture of the CLL cells to observe whether
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Day 0 CD38 expression (percent) was plotted against day 2 Zap-70 
expression (MFI) for 20 patient samples following incubation with 
CD31-expressing co-culture. The Spearman test was employed to 
assess the correlation.
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Figure  6.8 C D 38 positive pa tien ts  expressed h igher 
levels o f Z ap-70  th a n  CD 38 negative patien ts.
Patients were separated into CD38 negative and CD38 positive 
groups (cut off 20%) and the mean Zap-70 expression was 
determined. An unpaired r-test was used to determine whether there 
was a significant difference in Zap-70 expression between the two 
groups.
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such changes were occurring. Figure 6.9 Illustrates that there was no significant 
difference in the expression of C D llc  following two or five days in NTL 
(P=0.27 and P=0.36 respectively) or CD31-expressing co-culture (P=0.18 and 
P=0.36 respectively). There was also no significant difference in the expression 
of C D llc  when CLL cells incubated with NTL co-culture were compared to 
those with CD31-expressing co-culture at day 2 and day 5 (P=0.8 and P=0.95 
respectively).
6.9 An increase in CD 103 expression was observed on the surface of CLL 
cells following five days in co-culture
CD 103 (Integrin a  E) is a member of the integrin family and is usually 
present on the surface of CD8 positive T-cells as a receptor for the epithelial 
cell-specific ligand E-cadherin (Hadley et al., 1997). The integrin is expressed at 
high levels in Hairy cell leukaemia but not in CLL (Del Giudice et al., 2004). 
The expression of this surface molecule was determined in six CLL samples at 
day two and day five. A significant increase in CD 103 expression was observed 
following five days in NTL and CD31 -expressing co-culture (P=0.005 and 0.004 
respectively) (Figure 6.10). No significant difference was observed in the 
expression of CD 103 between CLL cells incubated with NTL and CD31- 
expressing co-culture following two or five days incubation (P=0.64 and P=0.7 
respectively).
6.10 There was no change in CD 138 expression on the surface of CLL cells 
following co-culture
CD 138 (Syndecan 1) is a transmembrane heperan sulphate proteoglycan 
which mediates cell-cell and cell-matrix adhesion (Mali et al., 1990). Protolytic 
cleavage of the molecule following translation generates a soluble form which 
has been shown to induce tissue invasion in breast cancer cells (Nikolova et a l, 
2009). Within the haematopoietic system CD 138 is expressed at high levels on 
plasma cells and is a marker of B-cell differentialtion (Chilosi et al., 1999). To 
determine whether the CLL cells in culture were differentiating in to plasma 
cells samples were stained for CD138. Figure 6.11 illustrates that there was no 
significant difference in the expression of CD138 following two or five days in 
NTL (P=0.45 and P=0.15 respectively) or CD31-expressing co-culture (P=0.12
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Figure 6.9 There was no change in C D llc expression 
following co-culture.
lxlO6 CLL cells were placed into co-culture with NTL or CD31- 
expressing fibroblasts. Surface C D llc  was measured by flow 
cytometry on day 0, 2 and day 5 (CDllc-PC-7) and the MFI value 
was plotted for each CLL sample (n=6). CD5+/CD19+ CLL 
lymphocytes were identified by surface staining and forward and side 
scatter. A paired t-test was used to compare C D llc expression.
162
Chapter 6_ Incubation with CD31 -expressing co-culture causes phenotypic changes in CLL cells
P<0.0001
P<0.000116-1
♦  ♦12-
LL
5
COoT"
Q
O
DayO NTL CD31 NTL CD31
Day 2 Day 5
Figure 6.10 An increase in the expression of CD103 was 
observed following co-culture.
lxlO6 CLL cells were placed into co-culture with NTL or CD31- 
expressing fibroblasts. Surface CD 103 was measured by flow 
cytometry on day 0 2 and day 5 (CD103-FITC) and the MFI value 
was plotted for each CLL sample (n=6). CD5+/CD19+ CLL 
lymphocytes were identified by surface staining and forward and side 
scatter. A paired /-test was used to compare CD 103 expression.
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Figure 6.11 There was no change in CD138 expression 
following co-culture.
lx l0 6 CLL cells were placed into co-culture with NTL or CD31- 
expressing fibroblasts. Surface CD 138 was measured by flow 
cytometry on day 0, 2 and day 5 (CD138-PB) and the MFI value was 
plotted for each CLL sample (n=21). CD5+/CD19+ CLL
lymphocytes were identified by surface staining and forward and side 
scatter. A paired t-test was used to compare CD138 expression.
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and P—0.64 respectively). There was also no significant difference in the 
expression of CD138 when CLL cells incubated with NTL 
co-culture were compared to those with CD31-expressing co-culture at day 2 
and day 5 (P=0.62 and P=0.34 respectively).
6.11 Discussion
The aim of this chapter was to investigate the expression of key molecules 
on the CLL cell surface following ligation of CD38 with its in vivo ligand CD31, 
expressed on fibroblast co-culture. Multi-colour flow cytometry was employed 
and the phenotype of twenty patient samples was determined at day zero and 
following two and five days in co-culture.
Four important observations were made from these experiments. The first 
was that there were significant changes in CLL cell immunophenotype following 
incubation with co-culture. CLL cells up-regulated CD 19, CD38, CD49d, Zap- 
70, and CD 103 and down-regulated CD5 following two or five days in either 
NTL or CD31-expressing co-culture compared to day zero expression. In 
contrast, there was no significant change in C D llc  or CD 138 expression when 
the CLL cells were placed into the same co-culture conditions. These results 
highlight the effect of the co-culture system on the CLL cells. The co-culture 
fibroblasts are likely to express molecules on their surface and release cytokines 
which induce changes within the CLL cells. Such experiments highlight the 
requirement for the control NTL co-culture in these experiments.
The second observation was the change in the expression of proteins 
following incubation with CD31-expressing co-culture compared to those 
incubated with the control NTL co-culture. There was no significant difference 
in CD5 or CD49d expression between CLL cells incubated with NTL and 
CD31-expressing co-culture (Figure 6.2). However, CD 19 and Zap-70 were 
significantly up-regulated after two days and CD 19 and CD38 after five days co­
culture with CD31-expressing fibroblasts (Table 6.2). All three molecules have 
been shown to be involved in BCR signalling (Lund et al., 1996, Cherukuri et 
al., 2001, Gobessi et al., 2007). Such signalling is known to induce proliferation 
in CLL cells and is therefore likely to be mechanistically linked to the clonal 
expansion of this disease (Herishanu et al., 2011). The recent report by 
Herishanu et a l identified the lymph node as a site of CLL cell activation.
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Day 2 Day 5
Marker Dav 0 NTL CD31 P value NTL CD31 P value
No difference CDS 314 (±204) 301 (±170) 280(±148) 0.15 213 (±135) 227 (±137) 0.22
CD49<1 19 (±15) 26 (±15) 26 (±15) 0.88 32 (±14) 29 (±15) 0.11
Increased CD19 239 (±72) 288 (±108) 334(±118) 0.01 275 (±119) 355 (±154) 0.0002
expression CD38 38 (±22) 62 (±53) 76 (±74) 0.08 60 (±77) 83 (±85) 0.01
Zap-70 5<=l. 8 (±3) 10 (±5) <0.0001 11 (±6) 12 (±7) 0.08
Differentiation C D llc 8 (±3) 10 (±4) 10 (±4) 0.81 7 (±2) 7 (±2) 0.95
marker CD103 4(±1) 7 (±3) 7 (±2) 0.66 11 (±3) 11 (±3) 0.71
CD138 19 (±5) 20 (±4) 20 (44) 0.62 20 (±4) 19 (±4) 0.34
Table 6.2 C L L  cell expression of key surface and in trace llu lar molecules.
Flow cytometry was utilised to observe the expression of key molecules on the surface and within the CLL cells of twenty 
patients. The mean MFI values (± the standard deviation) were calculated at day zero and following 2 or 5 days co-culture 
with NTL or CD31-expressing fibroblasts. The P values were calculated from the difference in protein expression (MFI) in 
CLL cells incubated with NTL co-culture compared to that of CLL cells incubated with CD31-expressing co-culture.
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In their experiments they used gene expression profiling to illustrate the over­
expression of genes involved in BCR signalling and NF-kB activation in CLL 
cells taken from the lymph node. Additionally, they highlighted the up- 
regulation of E2F and c-MYC target genes that induce proliferation in the cell. 
Supporting evidence for this enhanced proliferation was illustrated in the form of 
an increase in the expression of the cell cycle protein Ki-67 (Herishanu et al., 
2011). The phenotyping data from this chapter illustrate that molecules involved 
in BCR signalling are also induced following stimulation of CD38 on the surface 
of the CLL cell. This data is in keeping with that published by Herishanu et al. 
(2011) and suggests that our CD31 co-culture model, to some extent, simulates 
the in vivo environment when stimulating CLL cells and that CD38 is involved 
in the induction of molecules involved in BCR signalling and proliferation in 
CLL cells.
The third observation was made when comparing protein expression with 
the constitutive CD38 expression. The expression of Zap-70, within CLL cells 
incubated with CD31-expressing co-culture, significantly correlated with the 
initial CD38 expression of the sample at day zero (Figure 6.7). Zap-70 
expression was also significantly higher in CD38 positive patient samples 
compared to CD38 negative patient samples (Figure 6.8). The presence of both 
CD38 and Zap-70 confer a poor prognosis in CLL and recent studies have 
illustrated that there is around 70% concordance in the expression of these 
molecules (Schroers et al., 2005, D'Arena et al., 2007, Gachard et al., 2008). In 
2007 Deaglio et a l showed that these two molecules are functionally linked and 
that Zap-70 is required for CD38 signalling to occur (Deaglio et al., 2007). With 
this in mind it is reasonable to surmise that CD38 plays a role in the up- 
regulation of Zap-70 in an attempt to increase the effects of CD38 or BCR 
signalling and induce CLL cell activation.
The final observation was made when the CLL cells were stained for CD1 lc 
CD 103 and CD 138 which are markers of differentiated B-cells. Following two 
days in co-culture there were no significant increases in CD llc, CD 103 or 
CD138 (Figures 6.9 and 6.10). However, co-culture for five days resulted in a 
significant increase in the expression of CD 103 on the surface of CLL cells 
incubated within both CD31-expressing and NTL co-culture (Figure 6.10). Any 
differences in protein expression observed following this period should be
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considered carefully as the CLL cells appeared to have undergone changes 
consistent with differentiation. However, there was no significant difference in 
the expression of C D llc, CD 103 or CD 138 between CLL cells incubated with 
NTL or CD31 -expressing fibroblasts suggesting that the increase in CD 103 was 
not specifically induced by the CD31-CD38 cognate interaction (Table 6.2). The 
lack of increased expression of CDllc  and CD 138 coupled with the low MFI 
values for all three molecules raise doubts about the biological significance of 
the increased expression of CD 103 in these co-cultures. This supports the view 
that these co-culture conditions are not inducing plasmacytoid differentiation in 
the CLL cells.
It has become apparent that, to understand the mechanisms behind the 
development of CLL, the cells need to be studied under the conditions provided 
by the in vivo microenvironment. In the absence of primary tissue, this niche has 
been simulated in vitro by the use of ligand expressing adherent co-cultures. In 
two previous studies, primary tissue has been available which has allowed the 
identification of a highly active proliferation centre, rich in immunomodulatory 
cells (such as T-cells and dendritic cells) and cytokines (such as IL-2 and IL-4) 
involved in B-cell activation (Patten et al., 2008, Herishanu et al., 2011). In this 
section CD31 -expressing fibroblasts were used to mimic the microenvironment 
and specifically induce CD38 stimulation on the surface of the CLL cell. 
Phenotypic changes were observed which favoured BCR signalling and 
proliferation. The results provide rationale for subsequent investigations which 
inhibit the actions of CD38 in this stimulatory environment. Similar 
investigations, where CLL cells have been targeted with a specific drug in the 
presence of co-culture, have yielded important findings. In a study by Vogler et 
al potent inhibitors of Bcl-2 and Bcl-xL were shown to selectively kill CLL cells 
in liquid media. When placed into CD40L-bearing co-culture however, the 
effectiveness of the drug decreased by 1000 fold and it failed to induce apoptosis 
(Vogler et al., 2009). In summary the use of co-cultures to mimic the CLL 
microenvironment has proved to be an important part of uncovering the true 
nature of the disease. It has enabled us to observe the actions of individual 
stimuli and given insight into the effect of therapeutic agents within the in vivo 
environment. Developments within this area will surely unveil more important 
mechanisms of cell survival and proliferation within the CLL cell.
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Chapter 7. Final Discussion
7.1 Discussion
In this study, I applied a range of techniques to enhance our knowledge of 
the role that CD38 plays in the pathogenesis of CLL. Induction of CD38 on the 
CLL cell surface using lentiviral gene transduction identified changes in gene 
expression which may contribute to and enhance disease progression. This work 
also highlighted the challenges involved in using a lentiviral knock-in system 
and led to the design of experiments utilising CD31-expressing co-cultures to 
stimulate CD38 on the CLL cell surface. Importantly, the CD31-expressing co­
culture system induced survival, proliferation and changes in the phenotype of 
the CLL cells which favour enhanced B-cell receptor signalling. The novel 
findings within this project have provided direction for future work and 
highlighted the potential of CD38 as a therapeutic target in CLL.
The forced expression of CD38 in CLL cells utilising a lentivirus was 
achieved with great success. All of the CLL samples treated showed a large 
increase in CD38 expression and changes in gene expression were observed. The 
pro-angiogenic VEGF molecule has been implicated in the pathogenesis of 
many malignancies and it has been shown to be over-expressed in CLL (Chen et 
al., 2000, Kay et al., 2002, Pepper et al., 2007). In this study the induction of 
high levels of CD38 on the CLL cell surface resulted in increased expression of 
VEGF. This suggests that VEGF may be transcriptionally regulated by CD38 
signalling; a novel and potentially important finding.
The DNA mismatch repair molecule Msh6 has never been implicated in the 
pathogenesis of CLL, but was found to be down regulated following induction of 
CD38. This is especially interesting considering the importance of the IGHV 
mutation status of the CLL clone and the recent focus on the AID molecule 
(Palacios et al., 2010, Hancer et al., 2011), which is closely linked to the Msh 
family in the generation of somatic hypermutation. Further investigations are 
required to determine whether CD38 plays a direct or indirect role in regulating 
the expression of Msh6.
As previously discussed, genetically modifying leukocytes using lentiviral 
vectors can alter cells independently of transgene expression (Chapters 4 and 5).
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Three major challenges were highlighted from these investigations. The first was 
the effect of adding concentrated lentivirus to the CLL cells. Molecular analysis 
revealed that the addition of both CD38 and GFP vims caused considerable 
changes in gene expression within CLL cells. This made analysing the effects of 
the ‘ectopic’ introduction of CD38 difficult. Following lentiviral infection, the 
induction of toll-like receptor signalling and integration of the provirus into 
transcriptionally active sites may alter gene expression within transduced cells 
(Schroder et al., 2002, Gelman et al., 2004, Ciuffi et al., 2006). Given that the 
GFP-expressing vims also had an effect on the expression of molecules on the 
CLL cell surface, it seems plausible that the viral envelope may trigger the 
activation of the toll-like receptor pathway. It is clear that the vims induces 
major changes in the cytoplasmic membrane of CLL cells and at least transiently 
induced the exposure of phosphatidylserine. However, these changes in 
membrane asymmetry were not associated with apoptosis induction. Further 
studies are required to determine whether the effect is specific to CLL cells or is 
a general consequence of exposure to this particular lentivims. A further 
conundrum following successful introduction of the CD3 8-expressing lentivims 
was the apparent stripping of the CD38 molecule from the surface of CLL cells 
following co-culture. It seems possible that the vims-induced perturbations in 
the CLL cytoplasmic membranes is responsible for this effect since it was not 
observed in native CD38 positive cells cultured under identical conditions.
Gene expression analysis revealed a great deal of heterogeneity between the 
patient samples tested. CLL is renowned for its heterogeneity between patients 
and the investigation of large patient cohorts are often required to identify 
pathogenic mediators of this disease (Rodriguez et al., 2007). Also the simple 
expression of CD38 was not enough to induce its signalling cascade and there 
was a requirement for CD38 stimulation to drive this process. Previous studies 
illustrating signalling through CD38 have utilised various stimuli (including 
agonistic antibodies, CD31 and anti-IgM) to induce the down-stream effects of 
CD38 signalling (Lund et al., 1996, Deaglio et al., 2005, Vaisitti et a l , 2010). 
Such observations led to the decision to use CD31-expressing co-cultures to 
ligate CD38 on the CLL cell surface.
In the absence of a single genetic transformation event or the identification 
of a single antigen or molecule responsible for driving proliferation, CLL is
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thought to be a disease whose maintenance and progression are controlled by a 
multitude of factors (Caligaris-Cappio, 2003). External stimuli which result in 
cellular activation and proliferation of the CLL clone are thought to reside in 
microenvironmental niches within the lymph nodes and bone marrow of the 
patient (Caligaris-Cappio, 2003, Friedberg, 2011). It has become apparent that if 
the underlying mechanisms of this disease are to be deciphered, and novel 
therapies devised, then in vitro systems must be developed which mimic the 
CLL cell microenvironment. In this study, CD38 was stimulated by incubating 
the CLL cells with CD31 -expressing co-culture. Comparing these CLL samples 
to matched samples in liquid media or control co-culture (mouse fibroblasts not 
expressing human CD31) illustrated changes in cell survival, proliferation and 
the phenotype of the cells that was specifically induced by CD38. Three 
prominent studies used similar in vitro co-culture models to illustrate that CD38 
signalling results in increased homing to lymph nodes, BCR signalling, survival 
and proliferation in CLL cells (Lund et al., 1996, Deaglio et al., 2005, Poggi et 
al., 2010). Similar investigations have utilised CD40 ligand-expressing co­
cultures to induce significant changes in gene and protein expression in CLL 
cells (Schattner, 2000, Willimott et al., 2007, Gricks et al., 2004). It is now clear 
that a large number of different microenvironmental stimuli enhance the survival 
and proliferation of the CLL clone in vivo (Calissano et al., 2009). Investigating 
the molecules which stimulate the CLL cells within this niche, so that this 
environment may be closely simulated in vitro, will be integral in determining 
the pathogenesis of CLL and in devising more successful therapeutic strategies.
An important aspect from the work carried out in this thesis (and by others) 
is the ability of the CLL cell to react to in vitro stimuli. Substantial modifications 
in gene expression were observed within the CLL cells following treatment with 
lentivirus. Also the phenotype of the CLL cells changed following two days 
incubation in co-culture with CD31-expressing or NTL fibroblasts. If the cells 
behave in such a manner in vivo within the microenvironmental niches, then the 
CLL cell should be perceived not as an anergic cell, reluctant to undergo 
apoptosis, but as an active cell which responds rapidly and effectively to external 
stimuli.
Chapter four highlights the induction of proliferation in CLL cells incubated 
with CD31-expressing co-culture. More specifically, expression of the cell cycle
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antigen Ki-67 was induced and correlated with increased CD38 expression. In 
vivo heavy water experiments by Messmer et al. in 2005 clearly illustrated that 
the CLL clone was proliferating at a much higher rate than previously thought 
(Messmer et a l, 2005). This work was complemented by Calissano et al who 
used the same technique to illustrate increased proliferation in the CD38 positive 
cellular sub-set (Calissano et al., 2009). Following this work many groups have 
tried to uncover the mechanisms behind the induction of proliferation. In 2007 
Damle et al. identified CD38 positive CLL cells as an actively proliferating sub­
set (Damle et al., 2007). They illustrated increased Ki-67, Zap-70 and human 
telomerase reverse transcriptase within CD38 positive clones. In 2010 Deaglio et 
al reported the induction of proliferation following ligation of CD38 on the 
surface of the CLL cell. In their experiments they identified CD31 as an integral 
part of the signalling axis and suggested that it plays a key role in stimulating the 
proliferation of CLL cells within the lymph node microenvironment (Deaglio et 
al., 2010). Taken together these data strongly suggest that CD38 signalling plays 
a role in the induction of CLL cell proliferation. The evidence presented in 
chapter four shows that CD38 ligation induces Ki-67 expression. Extending this 
study using a molecule to block the CD38-CD31 interaction would confirm 
whether CD38 signalling was directly responsible for the induction of Ki-67.
CLL cells incubated with CD31-expressing co-cultures illustrated a 
significant increase in cell survival. This is in keeping with previously published 
data by Zuchetto et a l who observed that CD38+/CD49d+ CLL cells showed 
increased survival compared to their CD38-/CD49d- counterparts, following 
stimulation with VCAM-1 (Zucchetto et al., 2009). Furthermore, in 2010 
Buggins et al. illustrated the up-regulation of pro-survival molecules, including 
Bcl-2 and Mcl-1, following incubation with endothelial co-cultures (Buggins et 
al., 2010). In their experiments the up-regulation of these molecules was shown 
to be preceded by DNA binding of the NF-kB sub-unit Rel A. These 
investigations also highlighted the induction of molecules involved in 
lymphocyte migration including CCL3, CCL4 and CD49d. Both the lymph node 
and bone marrow environments harbour pro-survival stimuli for lymphocytes 
and CLL cells expressing pro-migratory molecules are more likely to enter these 
sites. In 2010 Poggi et a l  illustrated increased survival in CLL cells placed into 
CD31-expressing co-culture through the induction of Bcl-2 and Bcl-xL (Poggi et
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al., 2010). The CLL cell survival described in chapter four was in keeping with 
the data reported by Poggi et a l though neither study was able to demonstrate a 
correlation between CD38 expression and CLL cell survival. Immunohisto- 
chemistry has illustrated that CD31 is expressed on the surface of immune cells 
including T-cells and dendritic cells within the lymph node microenvironment 
(Patten et al., 2008). Additionally CD31/CD38 interactions and their role in the 
pathogenesis of other malignancies have been described in the bone marrow 
compartment (Gallay et al., 2007). Enhanced CD38 signalling within these 
regions may therefore promote the survival of the CLL cell.
CD31 has the ability to ligate other CD31 molecules in a homotypic fashion 
on the cell surface. CD31 is present on the surface of CLL cells and contrasting 
evidence exists as to whether this molecule plays a role in the pathogenesis of 
CLL (Ibrahim et a l, 2003, Mainou-Fowler et a l, 2008, Poggi et al., 2010). In 
this project the increased expression of surface and intracellular molecules did 
not correlate with constitutive CD31 expression on the CLL cells (Appendix 4.a- 
e). Furthermore, previous studies have illustrated similar findings following the 
use of agonistic antibodies specific for CD38 and CD31-expressing co-cultures 
(Deaglio et al., 2003, Deaglio et a l,  2010). Both the induction of the signalling 
molecule Zap-70 and the cell cycle marker Ki-67 correlated with constitutive 
CD38 expression suggesting that the effects were indeed due to CD38 
signalling. Further experiments using a CD38 blocking antibody could be carried 
out to confirm these findings.
In this study, CD 19, CD38 and Zap-70 were up-regulated following 
stimulation of CD38 using the CD31-expressing co-culture system. CD 19 and 
CD38 associate with co-accessory molecules such as CD81, CD21 and the B- 
cell receptor on the cell surface to mediate B-cell signalling (Fujimoto et al., 
1998, Deaglio et al., 2003). The formation of such raft complexes results in the 
activation of Akt and Erk pathways and in a tertiary pathway calcium is released 
from intracellular stores and NF-kB is translocated to the nucleus (Guo et al., 
2000). In 2007, investigations by Deaglio et al illustrated the induction of 
calcium release and increased survival in CLL cells following stimulation of 
CD38 with an agonistic antibody (Deaglio et al., 2007). In their report they 
highlighted the requirement of accessory molecules, such as CD 19, for effective 
CD38 signalling. In chapter six, both CD38 and CD 19 were up regulated on the
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CLL cell surface following co-culture with CD31-expressing fibroblasts. 
According to the literature this would promote signalling via CD38 and the BCR 
and induce CLL cell activation. NF-kB is over-expressed in CLL (Cuni et al., 
2004) and induces the expression of anti-apoptotic mediators such as Mcl-1 and 
Bcl-2 (Zaninoni et al., 2003, Petlickovski et al., 2005). In 2008, Hewamana et 
al. showed that CD38 expression did not correlate with NF-kB DNA binding in 
CLL (Hewamana et al., 2008). The cells analysed in this study had not 
undergone any stimulation and it would be interesting to extend these 
investigations by stimulating CD38 on the surface using the CD31-expressing 
co-culture. Zap-70 was induced in CLL cells following two days in CD31- 
expressing co-culture. Additionally, its expression significantly correlated with 
the native expression of CD38 at day zero (PO.OOOl). The association between 
CD38 and Zap-70 has been previously documented in the pathogenesis of CLL 
(Deaglio et al, 2008), but this is the first time that CD38 signalling has been 
shown to up-regulate this tyrosine kinase. The induction of Zap-70 is also likely 
to enhance BCR mediated CLL cell activation and promote the survival and 
proliferation of the clone.
The results from this study support the use of molecules which inhibit CD38 
in the treatment of CLL. Daratumumab is such a molecule under investigation in 
the laboratory to treat a number of haematological malignancies including CLL 
and Multiple Myeloma. A report by de Weers et al. described effective antibody 
and complement-mediated killing even in the presence of bone marrow stromal 
cells (de Weers et al., 2011). They illustrated the potent effect of the antibody in 
vivo where low doses inhibited tumour growth in their xenograft mouse model. 
In a parallel study, the same group have shown enhanced antibody mediated 
cytotoxicity when daratumumab was used in combination with lenolidamide 
(van der Veer et al., 2011). The side effects of using anti-CD38 monoclonal 
antibodies in vivo have not been extensively investigated and initial concerns are 
centred around the fact that CD38 is expressed on a wide range of cell types 
including lymphoid, myeloid epithelial, eye and brain cells (Tai and Anderson, 
2011, Mizuguchi et al., 1995, Horenstein et al., 2009). A series of reports in the 
1990s discussed the potential effects of CD38 chimeric molecules for the 
treatment of Multiple Myeloma (Stevenson et al., 1991, Goldmacher et al., 
1994, Vooijs et al., 1995). Antibody mediated tumour toxicity was reported with
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little side effects (Stevenson et al., 1991). Concerns were raised regarding the 
induction of anaphylactic shock following the use of an immunotoxic anti-CD38 
antibody conjugated to blocked ricin, though the response by Goldmacher 
mentions that seven patients receiving the treatment showed no haematologic or 
organ toxicity (Vooijs et al., 1995). Additionally, in 2002 Marchetti et al 
reported the impairment of pancreatic cell function following treatment with 
CD38 monoclonal antibodies (Marchetti et al., 2002). Whether CD38 can be 
safely targeted in the treatment of haematological malignancies requires further 
investigation and the design of molecules which inhibit specific regions of the 
molecule may prove advantageous and limit systemic side effects.
7.2 Summary and conclusions
The experiments carried out were aimed at determining the role of CD38 
following the genetic modification of CD38 negative CLL cells and through 
stimulation of surface CD38 with the use of co-cultures. The overall hypothesis 
was that CD38 was able to signal in CLL and cause changes in gene expression 
which favoured CLL cell survival and proliferation. Using the two models 
described the hypothesis was broken down into three parts to investigate CLL 
cell survival and proliferation, gene expression and changes in phenotype. The 
profound effect of adding concentrated lentivims to the cells was apparent as 
was the heterogeneity in the response of individual patient samples to viral 
treatment and other external stimuli (e.g. CD31 -expressing co-culture). 
However, with the use of appropriate controls, differences were observed 
between transduced and untransduced CLL cells and between those stimulated 
with CD31 and unstimulated samples. The increased expression of key 
molecules was illustrated by microarray studies and the co-culture experiments 
denoted increased survival and proliferation and changes in cell surface and 
intracellular markers. This work extends our knowledge of CD38 signalling 
events in CLL and provides direction for future investigations.
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7.3 Future investigations
Recent findings in CLL have highlighted the role that the microenvironment 
plays in promoting the survival and proliferation of CLL cells (Vogler et al., 
2009, Poggi et al., 2010, Herishanu et al., 2011). Incubating CLL cells in vitro, 
without stimuli, results in rapid cell death, a feature contrary to the nature of the 
CLL cell in vivo. The experiments carried out in this project using co-culture 
highlight the importance of simulating the CLL microenvironment by providing 
stimulation via molecules which are present within the malignant proliferation 
centres. Hence, an important objective of the Cardiff CLL research group has 
been to develop in vitro co-culture systems which will mimic the CLL 
microenvironment. With the use of such systems the biology of the CLL cell 
may be observed whilst in its most active state. Additional experiments are 
already underway looking at phosphorylation events in CLL cells following co­
culture with CD31-expressing fibroblasts. Any such events will further elucidate 
the effects of CD38 signalling in CLL and give valuable insight into the 
pathways initiated following stimulation of this molecule.
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2.1 List of Materials and laboratory equipment
2.1.1 General reagents
Material Source Code
Phosphate buffered saline tablets Oxoid BR0014G
1.5ml Eppendorf tubes Fisher FB74031
0.5ml tubes Starstedt 72-699
1.5ml Cryo-storage tubes Fisher 10-500-26
15ml tubes Greiner 188271
50ml tubes Coming 430291
Haz Tabs (Chlorine for 
decontamination of waste)
Guest Medical H8801
Ficoll lymphoprep Axis-Shield Lys-3773
T175 Large tissue culture flasks Nunc. Thermo Sci 178883
T75 Small tissue culture flasks Greiner 658175
6-well plates Nunc. Thermo Sci 140675
12-well plates Greiner 665180
48-well plates Nunc. Thermo Sci 150687
5ml Pipettes Coming 4487
10ml Pipettes Coming 4101
25ml Pipettes Coming 4251
Test tubes (Flow cytometry) BD Falcon 352054
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2.1.2 Cell culture
2.1.2.1 Eukaryotic cell culture
Material Source Code
Dulbecco’s modified Eagle’s 
Media (DMEM)
Gibco (Invitrogen) 41965
Roswell Park Memorial 
Institute Media 1640(RPMI)
Gibco(Invitrogen) 31870
Foetal Calf Serum (FCS) Gibco(Invitrogen) 12319018
Penicillin (5,000 
U/ml)/Streptomycin 
(5,000ug/ml)
Gibco(Invitrogen) 15140148
Sodium Pyruvate Gibco(Invitrogen) 11360070
0.5% Trypsin EDTA Gibco(Invitrogen) 25300
L-glutamine X I00 (200uM) Gibco(Invitrogen) 25030
Interleukin 2 Tecin RO-23-6019
2.1.2.2 Prokaryotic cell culture
Material Source Code
Bacto-Tryptone Fisher Scientific DF0123173
Bacto-Yeast extract Oxoid X589B
Sodium Chloride 0.17M Sigma S9888
Agar Fisher Scientific S70213A
Ampicillin lOOmg/ml Sigma A5354
Glycerol Sigma T1503
Competent E-coli DH5a Invitrogen 18258-012
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2.1.3 Co-culture and cell lines
Cell line Application Source (Kindly donated by)
Jurkat Transduction/Controls Professor Martin Rowe
CD31/NTL Co-culture Professor Silvia Deaglio
CD40L Co-culture Dr Aneela Majid
293T Virus packaging Professor Gavin Wilkinson
2.1.4 Molecular Biology reagents
Material Source Code
Trizol Reagent Invitrogen 15596-026
RNase A Sigma R6513
Chloroform Fisher C2984
Ethanol Fisher NC9602322
Agarose Fisher BP1356500
Ethidium Bromide Invitrogen 15585011
NEB Buffer 1 New England Biolabs B7001S
2 B7002S
3 B7003S
4 B7004L
Xhol (25,000U) NEB R0146L
Kpnl(25,000U) NEB R0142L
Notl(25,000U) NEB R0189L
BSA NEB B9001S
Shrimp alkaline Fermentas EF0511
phosphatase
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2.1.5 Plasmids
Plasmid Gene encoded Application Source
HR' SINcPPT 
SFFV-X-WPRE 
(SXW)
(HIV LTR incorporated 
backbone construct)
Lentivirus 1
Lenti-SEW Green fluorescent protein Lentivirus 2
Lenti-S38W Human CD38 Lentivirus Generated in 
house
pA8.91* HIV gag, pol & rev Lentivirus *
pMD2G* VSV-G envelope protein Lentivirus *
pEGFP-Cl GFP-CD38 fusion Nucleofection 3
pEGFP-1 GFP Nucleofection 4
pGEM4Z-
EGFPA64bis
GFP Electroporation 5
* Accessory plasmid
1 - Dr.R.J.Matthews. Department of Infection, Immunity and Biochemistry, University 
of Wales, Cardiff.
2 - Dr. W.Qasim and Professor A.J.Thrasher Institute of Child Health, London. High- 
Level Transduction and Gene Expression in Hematopoietic Repopulating Cells Using a 
Human Imunodeficiency Virus Type 1-Based Lentiviral Vector Containing an Internal 
Spleen Focus Forming Virus Promoter. Christophe Demaison, Kathryn Parsley, Gaby 
Brouns, Michaela Scherr, Karin Battmer, Christine Kinnon, Manuel Grez, Adrian J. 
Thrasher. Human Gene Therapy. May 2002, 13(7): 803-813.
3 - Dr.S.Deaglio. Laboratory of Immunogenetics, Department of Genetics, Biology, and 
Biochemistry and Centro di Ricerca in Medicina Sperimentale, University of Torino 
Medical School, Torino, Italy.
4 - AMAXA Biosystems, MD, USA,
5 - F.Van Bockstaele. Department of Clinical Chemistry, Microbiology and 
Immunology, Ghent University, Ghent, Belgium. Efficient gene transfer in CLL by 
mRNA electroporation. Leukaemia, 2008 Feb;22(2):323-9.
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2.1.6 Antibodies
Antibody Species Fluorochrome Company Code
CD19 M~H RPE-Cy5 Dako C7066
CD19 M~H APC Invitrogen MHCD1905
CD19 M~H Alexafluor750 Beckman Coulter A78838
CD19 M~H Pacific Blue Dako PB985
CD38 M~H RPE Invitrogen MHCD3804
CD38 M~H PC7 Beckman Coulter A54189
Zap-70 M~H Alexafluor 488 Caltag MHZap-7020
Zap-70 M~H Alexafluor 647 Beckman Coulter A24071
CD5 M~H ECD Beckman Coulter A33096
C D llc M~H PC7 Beckman Coulter A80249
CD 103 M~H FITC Beckman Coulter IM1856U
CD138 M~H PE Beckman Coulter A54190
CD138 M~H Per-CP-Cy5 Beckton Dickinson BD341087
VEGF M~H 1° Santa Cruz SC7269
Akt 1 M~H PE Santa Cruz SC5298
IL-1B R~H 1° Santa Cruz SC7884
VEGFR2 M~H APC R&D FAB357A
Flk-1 M~H 1° Santa Cruz SC6251
Mcl-1 M~H 1° Santa Cruz SC12756
CD31 G~M 2° (PE) Southern Biotech 1070-1 IS
Ki-67 FITC Dako F7268
CD40 R~M 2° (FITC) Dako F0313
CD49d M~H FITC Serotec MCA2503F
M = Mouse, R = Rabbit, G = Goat, H = Human, ~ = Anti. 1°= 
Primary antibody, 2°= Secondary antibody
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2.1.7 Primers (Primers were purchased from Eurogentec)
Primer Sequence (‘5 -  ‘3)
ABL F CGGCTCTCGGAGGAGACGTAGA
R CCCAACCTTTTCGTTGCACTGT
CD38 F ATGCTTTCAAGGGTGCATTT
R TTTTACTGCGGGATCCATTG
ZAP-70 F AAGAACTTTGTGCACCGTGA
R TTCATCTTCTTGTAGGGCTTCTG
MCL1 F AAAAGCAAGTGGCAAGAGGA
R TTAATGAATTCGGCGGGTAA
VEGFA F TCAGGACATTGCTGTGCTTT
R TGGTTTCAATGGTGTGAGGA
Ki-67 F CAAAAGGATTCCCTCAGCAA
R TTTGTGCCTTCACTTCCACA
CD31 F TATTTTCCAAGCCCGAACTG
R TGGGCATCATAAGAAATCCTG
CD49d F AGATGCAGGATCGGAAAGAA
R GCCCCCATCACAATTAAATC
IL-lp F TGGCAGAAAGGGAACAGAAA
R ACTTCTTGCCCCCTTTGAAT
MSH6 F ATTGCATTTGGCCGTTATTC
R CAATGGCGATCATCTGAAAA
218
Appendix
2.1.8 Molecular Biology Kits
Kit Application Source Code
QIAGEN DNA 
Maxi
DNA isolation QIAGEN 13362
QIAGEN QIAquick PCR
purification
QIAGEN 28104
QIAGEN gel 
Extraction
Agarose gel 
extraction
QIAGEN 28704
Calcium Phosphate Transfection Sigma MB-315
Sybr Green QPCR Roche 03 515 869 001
Big Dye 3.1 Sequencing ABI 4337455
Human B-cell 
Nucleofection kit
Nucleofection AMAXA VP A 1001
T7 Message machine Electroporation Ambion AM 1340
RT-Kit (200 
reactions)
Reverse
transcription
Applied Biosystems 4374966
2.1.9 Cell biology and biochemistry
Kit Application Source Code
VEGF ELISA Protein
quantification
Bender Medsystems BMS277
P24 ELISA Quantification 
of lentivirus
Retro-tek 8001111
Annexin V Apoptosis assay Bender Med systems BMS500FI/300ce
Fix & perm kit Fix and perm Caltag GAS-002-1
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2.1.10 Instruments
2.1.10.1 General
Material Source Model
Orbital shaker Sanyo Orbisafe
NanoDrop-1000
(Spectrophotometer)
Thermo Scientific V 3.7
Ultracentrifuge Beckman Coulter Optima L-100XP
Nucleofector AMAXA AAD-1001
Electroporator BioRad 165-2100
Thermal cycler GeneAmp 9600
Irradiator Nordion Int Gammacell 1000 Elite
Laser microscope Leica DM1L
Sorval centrifuge Sorval Evolution RC
Large Centrifuge Heraeus Megafuge 1.0
Mini centrifuge Heraeus Biofuse fresco
Light cycler Roche 2.0
Cytospin Thermo Shandon Cyto 4
2.1.10.2 Cytometers and analysis software
The Beckman Coulter Calibur, Beckman Coulter Cyan, and Accuri 
C6 cytometers were used in flow cytometry experiments. Cellquest Pro 
software was utilised to acquire data on the FacsCalibur cytometer and 
Summit 4.0 software was employed to acquire data on the Cyan and 
analyse the data from both Beckman Coulter cytometers. The CFlow plus 
software package was used for acquiring and analysing the data from the 
Accuri C6 cytometer.
220
Appendix
2.1.11 Additional software tools
Software Application Source
Vector NTI Plasmid design Invitrogen
Prism 4 Graphs and statistical analysis Graphpad
OligoPerfect Primer design Invitrogen
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A ppend ix  2
Accessory plasmids for the generation of lentivirus
hCMV
gpt ______
gag
Sv40
ORI
Amp
p8 91 Thesis
12150 bp
a) pA8.91 encoding gag and pol
AmpR promoter
Ampicillin CMV immearly promotei 
CMV promoter
pBR322 origin
pMD2.G Thesis
vsv-G
b) pMD2G encoding the VSVG envelope protein 
A ppend ix  3
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GFP expression in CLL cells
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A ppendix  4
CLL cell expression of key molecules following 2 or 5 days incubation 
with CD31 expressing co-culture. Correlation with constitutive CD31 
expression at day zero.
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Figure 4.a No significant correlation was observed between CD31 
and day 2 Ki-67 expression (n=7). The Spearman test was used to 
assess the correlation (P=0.11).
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Figure 4.b No significant correlation was observed between CD31 
and day 2 Zap-70 expression (n=7). The Spearman test was used to 
assess the correlation (P=0.5).
224
Appendix
80 
70 
_  60 
^  50
S' 40
S 30 
°  20 
10 
0
0 1000 2000 3000 4000 5000
CD31 (MFI)
Figure 4.c No significant correlation was observed between CD31 and 
day 5 CD38 expression (n=7). The Spearman test was used to assess 
the correlation (P=0.6).
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Figure 4.d No significant correlation was observed between CD31 
and day 2 CD19 expression (n=7)(P=0.12). The Spearman test was 
used to assess the correlation (P=0.7).
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Figure 4.e No significant correlation was observed between CD31 and 
day 5 CD19 expression (n=7). The Spearman test was used to assess 
the correlation (P=0.6).
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ABSTRACT
Studies of the role of individual genes in chronic lymphocytic 
leukemia (CLL) have been hampered by the inability to consis- 
tendy transfect primary tumor cells. Here, w e describe a high­
ly efficient method of genetically modifying primary CLL cells 
using a VSVG pseudotyped lentiviral vector. We transduced 
CD38 negative CLL cells with a lentiviral vector encoding 
CD38 which caused increased surface CD38 expression in all 
the samples tested (n=17) with no evidence of plasmacytoid 
differentiation. The mean percentage of positive cells express­
ing CD38 was 87%±8.5% and the mean cell viability 
74%±17%. This high level of transduction of all the CLL cell 
samples tested demonstrates the utility of this technique which 
should prove applicable for the introduction and analysis of
other genes in these non-dividing cells.
Key words: chronic lymphocytic leukemia, primary tumor 
cells, CD38 negative.
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Introduction
Chronic lymphocytic leukemia (CLL) is a heterogeneous 
disease ranging from a stable condition requiring no therapy 
to a progressive disease refractory to treatment. One impor­
tant molecule associated with this disease is CD38: the 
expression of the CD38 antigen on the surface of clonal B cells 
is associated with a poor prognosis and reduced overall sur­
vival in patients with CLL.1'6 The expression of CD38 defines 
an altered pattern of gene expression including increased lev­
els of anti-apoptotic, pro-inflammatory, signaling and pro- 
angiogenic molecules.7,8 However, these experiments were 
performed by comparing cells from different patients, w ith  
heterogeneous genetic backgrounds, and other studies depend 
on correlations in expression. These comparative experiments 
demonstrated a technical limitation of our ability to genetical­
ly modify CLL cells to alter CD38 expression.
To date, CLL cells have been difficult to genetically modify. 
The cells do not grow in liquid culture and most methods of 
manipulation result in the modification of a subset of cells and 
often cause substantial cell death. To address this problem, w e  
developed a method of genetically modifying CLL cells using 
lentiviruses. This allowed us to increase CD38 expression in all 
the patient samples tested (n=17) with high transduction effi­
ciency and viability. Using this approach, we now have the 
opportunity to determine whether CD38 can directly alter gene 
expression in primary CLL cells and influence cell survival, 
migration and proliferation.
Design and Methods
Lymphocyte separation
Following informed consent, peripheral blood samples from CLL 
patients with low expression of CD38 were separated using Ficoll- 
Hypaque (Sigma, Poole, UK), washed in PBS and counted. Patients were 
diagnosed using morphological and immunophenotyping criteria and 
were treatment free for at least three months prior to their analysis.
Generation of lentivirus
A cDNA corresponding to CD38 (Accession NM_001775) or the first 
233 amino acids of rat CD29 was cloned into the pHR' SINcPPT SFFV- 
WPRE vector. Transgene expression was under the control of the SFFV 
promoter.10 The GFP virus, driven by the same promoter, has been pre­
viously described.10 The vector plasmids (pLentiSEW, pLentiSCD38W 
or pLentiSrCD2AW), together with the gag-pol plasmid (pA8.91) and 
the VSVG envelope encoding plasmid (pMD2-G), were amplified in 
bacteria and purified with the Endofree Maxiprep Kit (Qiagen). The 
transfer vector (13pg), pA8.91 (lOpg) and pMD2-G (6 pg) was mixed
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Lentivirus infection of CLL cells
with 1.5 mL of CaCl (0.25M) (Sigma Poole, UK). This was added to 
1.5 mL of 2X HEPES (Sigma Poole, UK) while bubbling. The solution 
was left for 20 min to allow a precipitate to form. This was then 
added to a large flask (175 cm2) of 293T cells (approximately 60% 
confluent) containing 20 mL of Dulbecco’s Modified Essential Media 
(DMEM) with 10% fetal calf serum, 100 units/mL penicillin, 100 
|xg/mL streptomycin and 2 mM glutamine.11 After 48h, at 37°C, in 
5% CO2, the supernatant was removed and centrifuged at 1,700 g 
for 10 min to pellet any cell debris, followed by ultracentrifugation 
at 121,603 g for two hours to concentrate the virus. The pellet, con­
taining concentrated virus, was re-suspended in DMEM, (Invitrogen, 
Paisley, UK) without supplements and stored at -80°C.
Lentiviral infection of chronic lymphocytic leukemia cells
Primary CLL cells were added to DMEM cell culture media with 
supplements (10% FCS, 100 units/mL penicillin, 100 pg/mL strepto­
mycin, 2 mM glutamine). Concentrated viral supernatant was added 
to the culture media. The cells were then incubated at 37°C, in 5% 
CO2. Expression of CD38 and other molecules were typically mon­
itored after 48 h. No feeder cells or cytokines were added to the cul­
tures.
Titration of lentivirus
The lentivirus was titrated using CLL cells. Five hundred thousand 
CLL cells were placed in 1 mL of DMEM cell culture media with 
10% FCS, 100 units/mL penicillin, 100 pg/mL streptomycin, 2mM 
glutamine. Volumes of viral supernatant, ranging from lpL to 128 
pL, were added. After 48 h, gene expression was monitored and the 
number of infectious virus particles per microliter was estimated by 
determining the percentage of cells infected in the linear portion of 
the curve. In some cases, the amount of the lentiviral protein, p24, 
was determined by ELISA (Helvetica Health Care Sari, Switzerland).
Flow cytometry
The following antibodies were used for immunophenotypic 
analysis: anti-CD19PE-Cy5 from DACO (C7066), anti-CD38RPE 
from Caltag (MHCD 3804-4) and anti-CD2FITC from Santa Cruz 
Biotechnology (sc-53036). Expression was measured using a Becton 
Dickinson FACSCalibur.12
Results and Discussion
Lentiviral technology represents a powerful method of 
genetically modifying quiescent cells.13 Three decisions 
underpinned the development of this protocol. Firsdy, we 
chose to use a viral backbone where transgene expression 
was driven by the spleen focus forming virus promoter. The 
CMV promoter has been shown to be ineffective in some 
quiescent lymphocytes.14 Secondly, w e focused on CD38 as 
a candidate molecule that is important for CLL prognosis.15 
Finally, CD38 is a cell surface marker, detected using flow  
cytometry, so the effectiveness of the genetic modification 
could be easily monitored. The virus generated to express 
CD38 was compared to two other viruses: a virus contain­
ing the genetic material for GFP and a vims containing the 
genetic material for truncated rat CD2.
All three viruses were capable of expressing their trans­
gene in primary human CLL cells following lentiviral infec­
tion (Figure 1 A). The highest level of expression was detect­
ed for CD38. We investigated CD38 expression in the CD19 
positive population infected with both the CD38 vims and 
the GFP vims. A dramatic increase in CD38 was observed 
following infection with the CD38 vims (Figure IB). This 
contrasted with a small increase in CD38 expression follow­
ing infection with the GFP-expressing vims (Figure IB).
Figure 2A and B show  CD38 expression following 
increasing multiplicity of infections (MOI) of both the CD38 
and the GFP lentivimses. A dose response was observed 
depending on the amount of CD38 vims used. This dose 
response was apparent for both the percentage of cells that 
were CD38 positive (Figure 2A) and the mean fluorescent 
intensity for CD38 expression (Figure 2B). It was, therefore, 
possible to select a dose of lentivirus which would allow the 
expression of physiological levels of CD38 on the surface of 
the CLL cells. Importandy, the expression from the CD38 
vims at an MOI of one, was higher than the expression of 
CD38 seen following infection with the GFP vims, even 
with an MOI above ten. The number of viral particles, 
determined by BLISA, in both preparations was compara-
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Figure 1. Su ccessfu l 
transduction of CLL cells  
with lentivirus. (A) 
Treatment of CLL cells  
with lentivirus containing 
th e gen etic  co d es  for 
CD38 (I), GFP (II), and a 
truncated rat CD2 (iii) 
resulted in high levels of 
transduction (87%, 70%  
and 43%, respectively). 
(B) CLL cells from a CD38 
negative patient (i) were 
infected with a CD38 
lentivirus and 94% trans­
duction was achieved (ii). 
Infection with a GFP con­
trol lentivirus saw  a 9.7%  
increase in CD38 expres­
sion (iii).
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ble. CD38 mRNA expression, measured by quantitative 
PCR, was higher in CD38 virus treated samples than in 
untreated or GFP virus treated samples (Online Suppl­
ementary Figure S1). The expression of CD38 was sustained 
over five days (Figure 2C and D).
Given the heterogeneity of CLL, w e investigated the 
changes in CD38 expression following viral infection in 
multiple patient samples. A high percentage of cells 
expressing CD38 was observed in all patient samples treat­
ed with the CD38 lentivirus (Figure 3A; n=17, mean per­
centage of positive cells (±SD) was 87% ±8.5%). To inves­
tigate the effect of lentivirus on cell differentiation, we ana­
lyzed the cells following treatment with lentivirus and 
observed no major changes in CLL cell morphology (Figure 
3B), and only observed a small increase in the expression of 
CD138, which is highly expressed in antibody-secreting 
plasmacytoid cells (data not shown). Thus, w e demonstrated 
reproducible transduction of primary CLL cells to manipu-
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Figure 2. Expression of CD38 on virally Infected CLL cells. A dose  
dependent increase In CD38 expression w as observed in both the  
number of cells expressing CD38 (A) and in the MFI (B) of sam ­
ples following treatm ent with CD38 virus (diamonds). No such 
increase is observed following the addition of a com parable 
amount of GFP virus (squares). Following transduction a high level 
of CD38 expression was observed on th e surface of CLL cells fol­
lowing 2 4  h incubation. This level w as sustained over a period of 
five days as measured by the percentage of cells expressing the  
CD38 antigen (C) and by the MFI (D) of the sam ple.
Figure 3. Expression of CD38 in multiple patient sam ples. (A) The 
m ean expression of CD38 in the untreated sam ples was 3±1.8%  
(n -1 7 ). Following treatment with CD38 virus a m ean of 87±8.5%  
(n -1 7 )  of CLL cells expressed the CD38 antigen. A mean of 8±5.8%  
CD38 expression (n -7 ) was observed in sam ples treated with con­
trol GFP virus. (B) Morphology of untreated and lentivirus treated  
CLL cells following 4 8  h Incubation. Pictures were taken using a 
Zeiss Axio microscope equipped with a digital camera following 
Giemsa staining (xlOO magnification).
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late the expression of CD38 without causing cell differenti­
ation. Here, w e describe a lentiviral technique which is able 
to transduce CLL cells to a level greater than previously 
described. In tw o studies, no GFP was detected when driv­
en by a CMV promoter16,17 using VSVG coated lentivirus, 
which suggests that our use of the SFFV promoter allows 
higher levels of expression in CLL cells. Given the impor­
tance of promoters, using B-cell specific18 or other gene 
expression units19 may be useful. A report, published since 
submission, has demonstrated gene expression in CLL cells 
using lentivirus incorporating measles virus glycoproteins, 
H and F, on their surface.16 This allowed genetic modifica­
tion of a subset of cells (20-45% of cells). In contrast, our 
data shows a change in the whole population of CLL cells 
rather than a subset and a technique for CD38 which  
allows genetic modification of an average of 87% of cells. 
This high level of expression means there is no need for cell 
sorting for further studies. Our data also shows that CD38 
can be detected at a higher level than GFP (despite the 
amount of virus used, MFI of GFP infected cells is shown in 
the Online Supplementary Figure 2) or CD2, which may be 
due to the human origin of CD38.
The next step in our study is to characterize the function­
al effects o f CD38 in CLL cells. Our initial experiments indi­
cate that CD38 has a subde effect on the survival of CD38
negative cells when expressed alone from the lentivirus. 
Our analysis of gene expression shows that CD38 is highly 
up-regulated at the mRNA level (data not shown) but analysis 
of expression patterns is confounded by the heterogeneous 
nature of CLL patient samples. Our immunophenotypic 
analysis shows that CD 19 expression is not altered and the 
levels of CD 138 (data not shown) do not indicate differentia­
tion of the CLL cells. However, an analysis of other cell sur­
face markers and of the effects of ligating CD38 are current­
ly underway.
In conclusion, this report describes the successful genetic 
modification of primary CLL cells to generate a CD38 posi­
tive population from a CD38 negative population. This 
method has been successful on all the samples w e have test­
ed to date and does not require any other treatment of the 
cells.
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